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ABSTRACT 
Galectins are galactoside-binding proteins that are expressed by various types of 
human cells. Recent studies have shown that the levels of circulating galectins are 
significantly higher in the bloodstream of cancer patients and promote cancer cell 
adhesion and aggregation by interaction with the cancer-associated mucin protein 
MUC1.  However, previous studies have also shown that circulating galectins have 
MUC1-independent actions in metastasis promotion. This thesis further explores 
these MUC-1 independent actions. The studies reported here show that galectin-2, 3,  
-4 and -8, whose serum concentrations are all increased in cancer patients, induce 
secretion of various cytokines from endothelial cells in vitro and in vivo: (G-CSF, GM-
CSF, IL-6 and sICAM-1 by galectin-3; G-CSF, IL-6 and GROα/CXCL1 by galectin-2; G-CSF, 
IL-6, GROα/CXCL1 and MCP-1/CCL2 by galectin-4 and -8). The secretion of these 
cytokines autocrinely/paracrinely enhances the endothelial expression of cell surface 
adhesion molecules, causing adhesion of cancer cells to the blood vascular 
endothelium. The galectin-induced secretion of cytokines is also shown to promote 
endothelial cell migration and tubule formation in angiogenesis. Intravenous 
introduction of a pathological galectin concentration into nude mice resulted in 
significant increase of circulating cytokine concentrations within 24 or 48 hours. 
Higher serum levels of these galectins correlated with higher serum levels of these 
cytokines in colon and breast cancer patients. Thus the increased circulation of 
galectins in the bloodstream of cancer patients promotes secretion from the blood 
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vascular endothelium of metastasis-promoting cytokines that enhance circulating 
cancer cell adhesion and angiogenesis. These MUC1-independent actions of 
circulating galectins likely make an important contribution to the metastasis-
promoting action of circulating galectins. Targeting the actions of circulating galectins 
in cancer patients therefore represents a promising therapeutic strategy to reduce 
metastasis and improve survival. 
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ABBREVIATIONS 
ACF    aberrant crypt foci 
AGE    advanced glycation end-products 
Akt    Protein Kinase B (PKB) 
AP-1    activator protein 1 
APC    adenomatous polyposis coli 
BBE    Bacteroides Bile Esculin 
BCL2    B-cell lymphoma 2 
BER    base-excision repair 
bFGF    basic fibroblast growth factor 
BRAF    v-raf murine sarcoma viral oncogene homolog B 
BSA    Bovine serum albumin 
CAMs    cell adhesion molecules 
CCL2    Chemokine (C-C motif) ligand 2 (MCP-1) 
CCL5    Chemokine (C-C motif) ligand 5 (RANTES) 
CCL20    Chemokine (C-C motif) ligand 20 (LARC) 
CCR    C-C motif receptor 
CM    conditioned medium 
CRDs    Carbohydrate recognition-binding domains 
CXCL1    Chemokine (C-X-C motif) ligand 1 (GROα) 
CXCL12   the stromal cell-derived factor 1 (SDF-1) 
CXCR2    interleukin 8 receptor, beta (IL8RB) 
DCC    Deleted in Colorectal Carcinoma gene 
DMEM    Dulbecco’s modified Eagle’s medium 
DMSO    dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
ECL    enhanced chemiluminescence 
ECM    extracellular matrix components 
EDTA    ethylenediaminetetraacetic acid 
EGM    endothelial growth media 
ELISA    enzyme-linked immunosorbent assay 
ELR    Glutamic acid-leucine-arginine 
ERK    extracellular signal-regulated kinases 
FAP    familial adenomatous polyposis 
Fas    CD95 
FCS    fetal calf serum 
G-CSF    Granulocyte colony-stimulating factor 
GlcNAc   N-acetylglucosamine 
GM-CSF   Granulocyte-macrophage colony-stimulating factor 
GPCRs    G protein coupled receptors 
GROα    Chemokine (C-X-C motif) ligand 1 (CXCL1) 
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GTP    Guanosine-5’-triphosphate 
H-RAS    GTPase H-Ras (transforming protein p21) 
hEGF    human Epidermal Growth Factor 
HMVEC-Ls   human micro vascular lung endothelial cells 
HNPCC    hereditary nonpolyposis colorectal cancer 
HUVEC    human umbilical vein endothelial cells 
ICAM-1   intercellular adhesion molecule-1 
IFN    interferon 
IRF-1    interferon regulatory factor 1 
IGF-1    insulin-like growth factor 1 
IL-6    interleukin 6 
JAK    Janus kinase 
K-RAS GTPase K-Ras (V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog) 
KSHV    Kaposi’s sarcoma-associated herpesvirus 
LAMP    Lysosomal-associated membrane protein 
LARC    Chemokine (C-C motif) ligand 20 (CCL20) 
LFA-1    leukocyte function-associated antigen-1 
Mac-1    macrophage adhesion ligand-1 
MAPK    mitogen-activated protein kinases 
MCP-1    Chemokine (C-C motif) ligand 2 (CCL2) 
MEK    mitogen-activated protein kinase 
MGAT5   beta1, 6N-acetylglucosaminyltransferase V 
MMP    matrix metalloproteinase 
MMR    mismatch repair 
N-CAM    neural cell adhesion molecule (CD56) 
N-RAS    neuroblastoma RAS viral oncogene homolog 
NER    nucleotide-excision repair 
NF-Kappa B   nuclear factor Kappa B 
NHEJ    non-homologous end joining 
NIH    National Institute of Health 
NK    natural killer cell 
NWAG    Asp-Trp-Gly-Arg amino acid sequence 
PAGE    Polyacrylamide gel electrophoresis 
PBMC    peripheral blood mononuclear cells 
PCD    programmed cell death 
PCTA-1    prostate carcinoma tumour antigen-1 
PGE2    prostaglandin E2 
PI    propidium iodide 
PI-3    phosphatidylinositide 3-kinase 
Poly-HEMA   poly-2-hydroxyethyl methacrylate 
PTEN    Phosphatase and tensin homolog 
RAF-1    Raf proto-oncogene serine/threonine-protein kinase 
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RANTES   Chemokine (C-C motif) ligand 5 (CCL5) 
SDF-1    the stromal cell-derived factor 1 (CXCL12) 
SDS    sodium dodecyl sulphate 
STAT    Signal Transducers and Activators of Transcription 
TCR    T cell receptor 
TEMED   Tetramethylethylenediamine 
TF Thomsen-Friedenreich oncofetal carbohydrate antigen 
(N-acetyl-D-galectosamine linked to protein) 
Tn    GalNAc-α 
TNF-α    tumor necrosis factor-alpha 
TNM the TNM Classification of Malignant Tumor (Tumor, 
Lymph Nodes, Metastasis) 
UV    Ultraviolet light 
VEGF    Vascular endothelial growth factor 
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CHAPTER 1 Introduction 
1.1 Cancer Epidemiology 
In 2010, cancer caused 157,250 deaths in the UK, 28% of the total (Office for 
National Statistics)(1). Cancer mortality is higher in males (31%) than in females 
(26%). Up to 1,660,290 newly diagnosed cancer cases can be expected in 2013 in the 
USA, and nearly 1,600 people per day will die because of cancer(2). 
Over seventy-five percent of cancer deaths occur in people more than sixty-five 
years old, and more than half of the cases are in people seventy-five and over. In the 
UK, cancers of lung, bowel, breast and prostate caused nearly half of cancer related 
deaths with lung cancer, which in 2010 caused around 34,900 deaths, the leading 
cancer cause of death (3). 
The cost of cancer is enormous. In 2010, the amount spent on cancer treatment 
was 9.4 million pounds in the UK, and this number is expected to reach 15.3 million 
pounds by the year 2021, which is an increase of 62% (4). According to the American 
National Institute of Health (NIH), the overall cost of cancer in the USA in 2008 was 
201.5 billion dollars(2). 
The overall cancer mortality is decreasing despite small increases in incidence. 
Better survival rates have resulted from earlier diagnosis and improved treatments. 
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1.2 Cancer Biology 
1.2.1 Genetics 
At the molecular level, cancer is caused by mutations in DNA, in which process 
oncogenes, tumor suppressor genes and DNA repair are all involved. Cancer 
development generally requires mutations in multiple genes.  
An oncogene is a gene that has the potential to cause cancer if mutated or over-
expressed. In cancer cells, oncogenes may be inappropriately activated or 
abnormally expressed. The mutation of oncogenes enables the cells to undergo 
uncontrollable proliferation and survive, avoiding programmed cell death (apoptosis) 
(5). The mutation of oncogenes can result from chromosomal abnormality or single 
point intragenic mutations causing alterations of residues crucial to regulating the 
activity of the gene product. It is not necessary for both alleles of an oncogene to 
undergo a somatic mutation to cause an effect, such as proliferation of the cells. 
Since 1970, dozens of oncogenes have been reported and characterized. The 
mutation of BRAF (v-raf murine sarcoma viral oncogene homolog B) is a particularly 
commonly observed oncogene mutation. In cancer, valine at codon 599 may be 
replaced by a glutamate. The glutamate replacement simulates the structure of a 
phosphate group so that BRAF functions as a continuously activated enzyme, 
without requiring activation signals (6). Knowledge of oncogene changes in cancer 
has been used in cancer drug development to target the oncogene-encoded proteins 
(7-9). 
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Tumor suppressor genes function as a protection against cancer development. 
Cancer development will usually only occur once a tumor suppressor gene has 
mutated with resultant loss of function. The inactivation of the tumor suppressor 
gene could be caused by missense mutation at essential functional residues, or a 
deletion or an insertion that changes the gene sequence, resulting either in a 
truncated protein or epigenetic silencing. Tumor suppressor genes behave, unlike 
oncogenes, according to the “two-hit hypothesis”, which means that changes of both 
maternal and paternal alleles have to be mutated to have an effect, not just one (10, 
11). On occasion though, a tumor suppressor gene may exhibit “haplo-insufficiency”, 
in which the presence of only one dysfunctional allele may be sufficient to allow 
cancer development (12). Some of these effects of either oncogenes or tumor 
suppressor genes may be mediated indirectly via effects such as altered nutrient 
provision or angiogenesis formation (13).  
DNA repair is a process by which a cell seeks out the structural damage 
affecting DNA molecules and exerts a targeted fix. Structural damage to DNA is 
remarkably common. For each cell, up to one million molecular lesions may happen 
daily because of defective steps in the metabolism or external stimuli such as UV 
light or irradiation (14). These lesions may have harmful effects on transcriptional 
ability and can also cause changes in the cellular genome that persist into daughter 
cells after mitosis. It is crucial for a cell to keep its genomic integrity. The rate of DNA 
repair can be affected by internal causes such as cell type or cell age, or external 
causes such as nutrition supply or environmental stimulation (15). DNA repair 
inefficiency can directly contribute to cancer progression. The consequence of the 
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frequency of DNA damage and its incomplete repair is that humans would all 
eventually develop cancer if we lived long enough (16).  
It has been shown that mutations in BRCA1 and BRCA2 genes, which play 
important roles in the DNA repair process through non-homologous end-joining 
(NHEJ) and homologous recombination, are strongly associated with the morbidity of 
breast cancer (17). In addition, epigenetic alterations in DNA repair genes, with 
consequent reduced production of DNA repair proteins, can also be important in the 
initiation of cancer (18-20). DNA repair failure in turn will also increase chances for a 
mutation affecting a tumor suppressor gene or oncogene (21).  
In the process of chemotherapy and radiotherapy, which are the most common 
medical methods used in modern cancer treatment, the damage to cancer caused by 
therapies is aimed to be beyond the level that cells manage to repair, resulting in cell 
death. The therapies target cells undergoing rapid division and this provides some 
selectivity for cancer cells over healthy cells. However, it is inevitable that healthy 
cells with rapidly dividing abilities are damaged as well, such as stem cells in the 
bone marrow. These cells are crucial for patients’ recovery after cancer therapies. 
Greater understanding of DNA damage and repair thus will improve our knowledge 
about cancer development as well as the chances of better targeted treatment and 
recovery (22). 
Tumor stability genes, if mutated, contribute to cancer development via a 
different mechanism. In normal physiological conditions, stability genes, including 
mismatch repair gene (MMR), nucleotide-excision repair gene (NER) and base-
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excision repair gene (BER), work by repairing small mistakes in the DNA molecules 
due to internal and external (mutagenic) causes (23). 
The process of genetic changes typically occurring during cancer development is 
illustrated in Fig. 1.1. This process is not speedy, and may take up to 20 years to get 
from a normal cell to a malignant tumor. The reason it takes that long is because it 
requires a series of mutations to occur sequentially in the same stem cell population. 
In a patient who has a defective mismatch repair system it often takes a much 
shorter period of time, which is why patients with Hereditary Non-polyposis colon 
cancer develop cancer at an earlier age. 
 
Fig. 1.1: Genetic Changes Associated with Colorectal Tumourigenesis (Adapted from Kinzler 
et al (24))(Permission acquired from Cell, License Number: 3345580509357) 
In the above pathway, colorectal tumourigenesis starts with mutations of Adenomatous 
polyposis coli (APC) gene, followed by mutations of a series of other genes. Patients with familial 
adenomatous polyposis (FAP) develop numerous dysplastic aberrant crypt foci (ACF) leading to 
the formation of early adenomas. The oncogene GTPase K-Ras is activated after only one genetic 
event. Mutations affecting one or more of Deleted in Colorectal Carcinoma (DCC) gene, SMAD 
family member 4 (DPC4) gene or Mothers against decapentaplegic homolog 2 (JV18-1) genes on 
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chromosome 18q21 typically occur during progression to late adenoma with mutation of p53 a 
common late event. The tumors from patients with hereditary nonpolyposis colorectal 
cancer (HNPCC) undergo similar (25), but not identical (26) steps of mutations. MMR deficiency 
speeds up this process.  
 
1.2.2 Biology / Physiology 
1.2.2.1 Apoptosis 
Cells die by one of two processes – apoptosis or necrosis. Necrosis happens 
when a cell is injured by an external insult that could be toxic, physical injury, 
infection or insufficient blood supply. Necrosis usually leads to inflammation. On the 
contrary, as programmed cell death, apoptosis follows a controllable, predictable 
routine (27). In response to apoptosis-triggering signals, caspases are activated and 
DNases secreted to destroy the DNA in the nucleus of the cell. The resulting 
apoptotic bodies are then devoured by phagocytic cells such as macrophages. 
Apoptosis avoids the damage that necrosis would cause (28) and plays an essential 
roles in metabolism. Fifty to seventy billion cells die each day via apoptosis in the 
adult human (29). Apoptotic cells demonstrate blebbing, cellular shrinkage, nuclear 
fragmentation, chromatin condensation, and chromosomal DNA fragmentation (30-
32).  
Increased apoptosis may lead to atrophy, while significantly reduced apoptosis 
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may lead to uncontrolled cell proliferation. One of the characteristics of cancer is a 
failure of apoptosis resulting in relative immortality of the cell line although a large 
percentage of cell loss from tumours is nevertheless still due to apoptosis (30). 
Mutations of some oncogenes interfere with apoptosis, promoting tumor formation 
or metastasis. Alternatively, mutations of oncogenes may promote apoptosis, 
forming competitive mechanisms that affect tumour development. The study of bal-
2 oncogene established the role that apoptosis contributes to neoplasia. Bal-2 
mutation inhibits apoptosis (33-35) as well as promoting lymphoproliferation and c-
Myc-induced lymphomagenesis (34, 36). Fifteen B-cell lymphoma protein 2 (bcl-2) 
family member proteins have been identified to date, some have been proven to 
promote apoptosis while others have been proven to prevent apoptosis (37). 
Mutations of the tumor suppressor gene p53 are widely involved in many 
human cancers, and often correlate with poor prognosis (38). Elevated level of p53 
found in a myeloid leukemia cell line was strongly associated with apoptosis(39) and 
Injection of exogenous p53 into nude mice provided direct evidence that p53 could 
participate in apoptosis (40, 41). Many other mutations which can disrupt apoptosis 
are related to cancer, including Fas receptor/CD95 (42) or phosphoinositide 3-kinase 
(PI-3) which are activated by Ras and can be influenced by the Phosphatase and 
tensin homolog (PTEN) tumor suppressor (43, 44).  
In spontaneously regressing tumours, the apoptosis rate has often been found 
to be clearly elevated. A similar situation is found when tumour cells respond to 
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cytotoxic anticancer agents (32). Thus apoptosis is an important target in cancer 
treatment. 
 
1.2.2.2 Angiogenesis 
Angiogenesis means creation of new blood vessels. In the normal physiological 
state, angiogenesis facilitates important functions including embryonic development, 
repair of wounds and formation of the placenta during pregnancy. 
In pathological conditions such as cancer, tumour-induced angiogenesis is 
indispensable for tumour development, extravasation and metastatic site formation. 
A tumour whose mass is larger than 0.125 mm2 is too large to obtain nutrition and 
dispose of waste by simple diffusion mechanisms. So angiogenesis plays an essential 
role in remodelling the vascular tree and forming new capillaries to satisfy the new 
needs of the growing cancer (45). It has been suggested that primary tumours 
without angiogenesis may remain in equilibrium with a balance of cellular 
proliferation and apoptosis (46). 
Angiogenesis also contributes to the process by which cancer cells enter into the 
blood circulation. Histological and ultra-structural analyses of tumour vessels have 
shown their unique properties compared to normal vessels, which include 
differences in cellular and basement membrane composition as well as permeability. 
The integrity of tumor vessels is significantly worse and easier for cancer cells to 
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penetrate. In addition, tumour cells induce secretion of various growth factors such 
as bFGF and VEGF, which accelerate the process of new capillary growth into the 
primary tumor site (47-49). 
Angiogenesis is also necessary for metastasis. The newly formed capillaries 
supply oxygen and nutrients in order to support metastatic tumor expansion and 
angiogenesis can be considered as a rate-limiting element in the metastasis process 
(50-52). Angiogenesis under normal conditions as well as in cancer shares similarities 
in mechanism. 
 
1.2.2.3 Immunology 
There is typically a “battle” between the development of a cancer and its attack 
by the immune system. The process of tumor immunogenicity can be divided into 
three stages: elimination, equilibrium and escape (53). 
The first stage, elimination, happens when cancer cells draw the attention of the 
innate immune system often via cytokine release. Immune cells such as natural killer 
T cells, natural killer (NK) cells, dendritic cells and macrophages are recruited to the 
tumor environment. 
 IFN-gamma, newly synthesized by natural killer T cells and/or NK cells, directly 
induces tumor cell death as well as inhibiting new blood vessel formation by inducing 
secretion of chemokines CXCL9, CXCL10 and CXCL11, which also lead to tumor cell 
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death. The cell fragments produced are then ingested and eliminated by dendritic 
cells. The chemokines produced in this way may stimulate cytokine secretion in 
several parallel mechanisms and recruit more immune cells by chemotaxis. 
Macrophages and NK cells stimulate each other in a positive feedback loop, in which 
IFN-gamma and IL-12 as well as reactive oxygen and nitrogen intermediates are 
induced to promote tumor cell death through apoptosis. Tumor-related dendritic 
cells in the lymph nodes modify the behaviour of Th1 cells, which subsequently 
induce the development of CD8+ T cells. In turn, CD4+ and CD8 + T cells are 
transferred to the tumor environment, along with cytolytic T lymphocytes, thus 
potentially eliminating the remaining tumor cells. 
If the above processes fail to clean up the tumor cells completely, the effect of 
lymphocytes and IFN-gamma may cause mutations which are usually unstable. In 
the equilibrium phase, the cells gradually obtain resistance to the human immune 
system. Cells that successfully acquire resistance enter the escape phase, in which 
they continue to grow uncontrollably (54, 55). 
Various infiltrating immune cells are involved in cancer immunity and can be 
found in and around tumours of different kinds in different sites. (Fig. 1.2). 
Macrophages, mast cells, granulocytes and myeloid derived suppressor cells (MDSCs) 
are found in most cases infiltrating or surrounding the tumor environment both in 
the centre and at the diffusion edge of the tumor. 
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 Fig. 1.2: Cancer immunity. (Adapted from Fridman et al) (56) (Permission acquired from 
Nature Review Cancer, License Number: 3344701138304) 
Showing the cell types that may potentially interact with and attack the developing cancer 
 
In cancer patients, immune responses (both innate and adaptive immune 
reactions) seem usually to be dysfunctional (57, 58). Local tumour immune escape or 
tumour-induced immune suppression as well as an inflammatory microenvironment 
are often observed. There is increasing evidence that inflammation contributes to 
the development of cancer and cancer also promotes the generation of an 
inflammatory microenvironment (59). As Trinchieri (60) stated, “the class of 
inflammation and immunity that is responsible for tumour initiation and early 
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progression is likely also to be the same class that makes the immune system unable 
to destroy the tumours successfully”. Malignant tumours can utilise local 
mechanisms within their microenvironment to prevent the activation of 
immunological effector functions, thereby protecting the tumour from a potential 
immune attack (61, 62).  
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 1.3 Cancer Metastasis 
1.3.1 General 
Metastasis is the main cause of cancer-associated mortality. Metastasis results 
from a series of sequential, interrelated steps, which involve a number of cell-cell 
and cell-extracellular matrix interactions (63). These include cellular transformation 
and growth of the original neoplasm, followed by extensive vascularisation as a 
consequence of angiogenesis when the primary tumour mass exceeds 2mm in 
diameter (64), detachment of the cancer cells and invasion into the circulation 
system (65), survival in the circulation, aggregation of single tumour cells to allow 
embolus formation, adhesion to the capillary endothelial cells (66), and eventually 
extravasation and proliferation at a secondary site. To continue growing, the micro-
metastasis has to develop a vascular network (64), to allow adequate nutrition and 
oxygenation and this also allows more cancer cells to invade blood vessels (67, 68) 
(Fig. 1.3). A successful metastasis depends on completion of each step, so each of 
these steps is rate-determining (67, 68). 
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 Fig. 1.3: The main steps in the formation of a metastasis. (Adapted from Fidler et al (63)) 
(Permission acquired from Nature Review Cancer, License Number: 3345580762453) 
a) Cellular cancerization and development. At the initial stage of cancer formation, the 
nutrients required for growth can still be supplied by simple diffusion. b) capillary proliferation in 
the tumor is essential if its size is to exceed 1–2 mm3 (64). The microenvironment contributes to 
angiogenesis by synthesis and secretion of angiogenic factors (64). c) continuous tumor growth 
results in invasion of nearby host stroma (65) through thin-walled venules, such as lymphatic 
channels (69, 70). d) Tumor cells detached from the primary tumor enter into blood circulation. 
Most tumor cells in the circulation are then eliminated but others may adhere to either capillary 
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endothelial cells or subendothelial basement membrane (66). e) After successful adherence at a 
distant site, extravasation occurs f) Subsequent proliferation, invasion and angiogenesis occur to 
support the metastasis (64) the cells from metastatic sites may enter the circulating system again 
to produce additional metastasis (63, 68). 
 
The concept that formation of metastasis depends not only on the selected 
cancerous cells (the ‘seeds’), but also relates to the microenvironments that 
metastatic site would be formed in (the ‘soil’) was first suggested in 1889 by the 
English surgeon Stephen Paget (71). This theory suggests that the process of tumour 
cells spreading to remote sites depends on the interaction of the cancer cells with 
homeostatic factors and with the host cells. The host cells involved include 
endothelial cells, epithelial cells, fibroblasts and infiltrating leukocytes.  
Phenotypic and functional heterogeneity of cancer cells result from frequent 
genetic changes during cancer development, which in turn promote cancer 
metastasis by promoting proliferation, adhesion, angiogenesis and invasion (68, 72). 
It has been shown that 24hours after injection of tumor cells into the blood 
circulation of nude mice, 0.1% of the tumour cells remained alive and 0.01% of these 
cells survived and gave rise to metastasis (73). A “successful” tumor cell was capable 
of going through steps including invasion, survival in the circulation, susceptibility to 
immune system attack and subsequent forming metastasis site. The process of 
metastasis is selective for cells that succeed in all of the steps in metastasis, instead 
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of just a few (74). To survive all of these steps requires an apparent evolution of the 
cancer cells, which may cause heterogeneity within a single neoplasm. Many 
tumours are apparently heterogeneous, with numerous subpopulations of cells. This 
biological diversity, which provides different biological characteristics, including 
metastatic potential, could be derived of a series of gradual changes during the 
formation of neoplasm from a benign tumour. In other words, during neoplasia 
cancer cells gradually gain permanent, irreversible qualitative alterations in their 
characteristics. (75). 
The development of experimental pathology brought scientists new knowledge 
of factors responsible for the formation of metastasis. By observing labelled cancer 
cells injected into nude mice, it was found that metastasis usually forms in not all but 
only some organs. It was also observed that, in the organs affected, the tumour cells 
were stuck in the capillaries while, in the sites where metastasis rarely occurred, 
circulating cells were mainly staying in arterioles (76). This provided a clue that the 
direction of metastasis may depend greatly on mechanical factors. 
Experiments in which the relationship of blood supply and metastasis formation 
site were investigated have shown variable correlation. Thus a metastasis experiment 
using syngeneic mice indicated that although mechanical arrest does contribute to 
the metastasis, circulating tumor cells growing into secondary sites were also under 
the influence of specific organ cells (77). Comparison of carcinoma metastases in the 
livers and lungs of rabbits, showed that more and larger liver metastases were 
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observed, which was similar to that which happens in humans (78). Thus it seems 
that a given type of cancer cells would be attracted to specific organs. Furthermore, 
both cancerous cells and host cells adjust their behaviours in this microenvironment, 
such as altering cell-surface receptor expression or growth factor secretion (79, 80).  
Thus both mechanical and organ-specific mechanisms contribute to the 
formation of a metastasis. Therefore, therapy for metastasis should be not only 
focused on the cancer cells themselves, but also against the homeostatic factors that 
contribute to the microenvironment.  
Through the development of metastatic research, the ‘seed’ has now been 
defined as a progenitor, and the ‘soil’ has been defined as the host factors and 
microenvironment. Over more than 120 years of scrutiny and critical analysis, this 
‘seed and soil’ hypothesis has become the prevailing viewpoint for the mechanisms 
behind metastasis. 
 
1.3.2 Cell-cell Homotypic Aggregation 
As mentioned above, in the seed and soil hypothesis, cancer cell heterotypic 
adhesion to blood vessel endothelium and tumour cell homotypic aggregation are 
two coordinated but essential parts in the metastatic process. It has been shown  
that in the metastasis of breast and prostate carcinoma, cancer cells form multi-
cellular homotypic aggregates before they first attach to the endothelium in vitro and 
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in vivo [32]. Cancer cells selected in vitro with enhanced homotypic aggregation 
kinetics were shown to have a higher chance to induce metastasis compared to 
control cells [33-35]. Aggregated cells also showed higher viability in the blood 
circulation in rats [23, 24]. Injection of pre-treated DHD/K12/TRb colon cancer cell 
aggregates into syngeneic BS IX rats produced more than four times the amount of 
liver metastasis than that of single cancer cells in suspension [25]. 
It has also been demonstrated that the small vasculature is the place where 
cancer cells aggregates can arrest efficiently and more easily form metastasis [36]. 
Aggregation of cells increases their ability to resist anoikis (suspension-induced 
apoptosis) [37]. Anoikis is a special type of apoptosis that occurs to free floating cells 
in the blood circulation in the absence of cell-cell and cell-matrix interactions [38]. 
This is considered to be a vital mechanism for removing circulating tumour cells in 
the body [39]. Thus the formation of tumour cell aggregates represents an important 
step in the development of metastasis [40]. 
 
1.3.3 Adhesion to Endothelial cells 
Metastasis is an organ-preferential process which involves the action of a 
variety of cell surface adhesion molecules (81, 82). For example, the regional lymph 
nodes, bone marrow, lung and liver are the commoner metastasis organs for breast 
cancer. There have been three possible mechanisms proposed in the past to explain 
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the organ-specific manner of cancer metastasis: circulation patterns, mechanical 
trapping and cell adhesion. 
After cancer cells have invaded from the primary tumour into the blood or 
lymphatic circulation the direction and connection of lymphatic or venous drainage 
becomes a significant factor determining the site of metastasis however metastasis 
site does not always correspond to the predicted downstream site (63). Patients with 
different primary tumours were analysed to find out the relationship between 
relative blood supply and metastasis formation in a given organ. This showed that 
the preferred metastasis organs of breast cancer were the lungs, bones, liver and 
brain, with no relation to the circulatory connections to the breast. Intravenous 
injection of melanoma cells had also shown that, although the number of tumour 
cells reaching all organs are approximately even, metastasis only occurs in the lungs 
and ovaries, but not in the kidneys (83). Therefore, circulation patterns alone cannot 
explain the mechanism behind the formation of metastasis. 
The mechanical trapping hypothesis suggested that the relative size of the 
tumour cells and tumour cell clusters play a key role in the initial site of tumour 
arrest (84). By acting as micro-emboli, cancer cell aggregates produce more 
metastases than single cell populations (85-87). However, it has also been observed 
that colon carcinoma cells preferentially adhere to the endothelium on the surface of 
lung and liver capillaries, although the diameters of the micro-vessels involved were 
larger than the adherent tumour cells (88). This indicates that other factors, besides 
31 
 
mechanical trapping, play a key role in the organ-specific metastasis of all types of 
cancers. 
Another possible factor is the site-specifity of different cell adhesion 
mechanisms which involve cell adhesion molecules such as integrins, lectins and 
their ligands (89-91). In a recent study of breast cancer, 344 primary breast tumours 
of lymph node-negative patients were classified into different molecular subtypes 
according to the ‘intrinsic’ gene list describing the subtypes, in which Luminal A 
subtype was abundant in bone relapse but absent in lung relapse. Focal adhesion 
was found to be up-regulated in the luminal A subtype but down-regulated in lung 
relapse (92), which indicates that molecular subtypes cause preferential metastasis 
at different sites and that the rate of metastasis in the lung is reduced as a 
consequence of down-regulation of local adhesion molecules. Although the exact 
adhesion molecules involved in cancer cell adhesion to endothelial cells are still 
unclear, several families of adhesion molecules, including cell adhesion molecules 
(CAMs) (93) are believed to be involved.  
 
1.3.4 Cytokines in Cancer Metastasis 
1.3.4.1 General 
Cytokines are a collection of proteins, peptide or glycoproteins secreted by 
various cells in the human body. They serve fundamental functions involving 
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regulation of hormones and mediation of signalling in the inflammatory responses 
(94). 
Most cytokines are relatively small, usually less than 20 kDa. The secretion of 
cytokines is typically autocrine or paracrine, but not endocrine, and is usually 
induced as a response to various stimuli at the transcriptional or translational level. 
The production of cytokines is typically transient and their constitutive production is 
seldom observed. Each cytokine binds to its specific cell surface receptor to perform 
its function, which may include gene expression alterations in the target cells. 
Cytokines serve a variety of functions including cell proliferation and cell 
differentiation and serve a particularly important physiological role in the regulation 
of haematopoietic cells (94-96). 
The concepts of cytokines, growth factors and hormones overlap. The term 
cytokines was first used when associated with haematopoietic cells and the immune 
system. It was later realized that the some of the cytokines also contribute to cell and 
tissue development in other systems and to metabolism. The term “cytokine” can 
also be used interchangeably with the term “growth factor”. They share similarities 
and can act as messengers and mediators for the basic physiological functions. 
However, whilst some of the cytokines such as G-CSF and GM-CSF promote 
proliferation, others may have an inhibitory effect. Another unique characteristic is 
that cytokines with structurally dissimilarity can perform remarkably similar effects 
on different cells, and individual cytokines may perform widely different functions 
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(97). 
Although growth factors, cytokines and hormones are very similar to each other, 
the production of growth factors is persistent and less tightly regulated and their 
major actions are usually targeted on non-haematopoietic cells. For classical 
hormones, the hormone is produced by specialised cells, such as insulin, which is 
produced by pancreas beta cells. Nevertheless, cytokines, growth factors and 
hormones can all function as extracellular signalling molecules. Thus receptors for 
certain cytokines and hormones (IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, GM-CSF, G-CSF, 
erythropoietin, prolactin and growth hormone) share similarities in structural 
features (98-104). They also share several components in their signal transduction 
pathways. 
Chemokines form a subgroup of cytokines with the special property of 
chemotaxis. Responsive cells nearby can be attracted by chemokines following a 
signal of gradually increasing chemokine concentration to move to the sites of 
infection and inflammation. More than 45 chemokines are currently known. They 
serve fundamental functions in normal metabolism as well as in cancer. 
Based on the position of the first two cysteine residues in their structure, the 
chemokines can be classified into four groups. The CC chemokine or β-chemokine 
proteins have 27 members which in structure have two adjacent cysteines near their 
amino terminus. Their major functions include chemotaxis of monocytes, NK cells 
and dendritic cells. The CXC chemokines or α-chemokines contains two N-terminal 
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cysteines separated by one other amino acid. Seventeen members of this family can 
be subcategorized into two groups based on the presence of absence of a glutamic 
acid-leucine-arginine (ELR) motif. ELR positive CXC chemokines, in which an ELR motif 
is adjacent to the first cysteine of CXC motif, induce the migration of neutrophils by 
interaction with chemokine receptors CXCR1 and CXCR2. The ELR negative CXC 
chemokines mainly have their effects on lymphocytes receptors, such as CXCL13. The 
C chemokines or γ chemokines only have one N-terminal cysteine and one cysteine 
downstream. The CXC3C chemokines or d-chemokines have three amino acids 
between two cysteines. Only one CX3C chemokine has been discovered - CX3CL1, or 
fractalkine, which is secreted and then tethered to adhesion molecules on the cell 
surface. 
Chemokines perform their functions by interaction with specific G protein-
coupled receptors containing seven transmembrane domains. Chemokines bind to 
and activate two or more cognate receptors, which is a unique property in the 
cytokine family. With their chemotaxis properties, chemokines have complex 
biological effects in pathological conditions, including cancer. In cancerous conditions 
the production and expression of chemokines is frequently abnormal. The signalling 
pathway through chemokine receptors is often altered as well for chemokines 
binding to an altered extracellular domain of the chemokine receptor may 
subsequently lead to a cascade of intracellular events (105). Thus chemokines 
contribute to primary tumor initiation, proliferation and survival, the regulation of 
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angiogenesis as well as cell adhesion, invasion and migration in the process of 
metastasis. 
 
1.3.4.2 Cytokines and Tumour Infiltration 
Tumor-derived chemokines induce chemotaxis of leukocytes, such as T cells, 
dendritic cells, mast cells and monocytes/macrophages to the tumour 
microenvironment. Although immune cells may attack the tumour their presence 
may also promote tumour growth, angiogenesis and metastasis. For example, 
tumour-associated macrophages may promote tumor cell proliferation by releasing 
growth factors such as epidermal growth factor, or mediate angiogenesis by 
producing angiogenic mediators such as VEGF and bFGF (106). Tumor associated 
macrophages can also promote metastasis by modifying immunosuppression from 
the host by secretion of IL-10 and prostaglandin E2(PGE2), which are both potent 
immune regulators (107).  
Expressed and secreted by most tumour cell lines, CCL2 (MCP-1) is believed to 
have a strong link to specific monocyte/macrophage recruitment, and has been 
shown to play a role in breast, ovarian, bladder, and lung cancer (105, 108, 109). The 
tumor associated macrophages in turn produce CCL2 in the microenvironment, 
forming an amplification loop for their recruitment (110). In bladder and breast 
cancer, CCL2 expression levels correlate with tumour stage and grade and are 
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therefore considered a marker of tumour aggressiveness (111, 112). Similar 
recruitment effects have also been observed with CCL8 (MCP-2) and CCL7 (MCP-3) 
(113).  
Accumulating research indicates that CCL5 (RANTES) produced by tumor cells 
and stromal cells promotes metastasis. CCL5 plays a role in infiltration of 
macrophages and T cells by binding to receptors C-C motif receptor 1 and 5 (CCR1 
and CCR5) on the cell surface. CCL5 acts as a prognostic marker in breast carcinoma. 
In the murine model, the presence of high intensity CCR5 binding protein Met-CCL5 
dramatically inhibits CCL5 induced tumor formation, causing decreased size of 
established tumours (114).  
 
1.3.4.3 Cytokines and Neoplastic Transformation 
Chemokines secreted by tumour cells attract leukocytes into their environment, 
which respond to their ligands and activate cytokine receptors expressed on the 
tumour cells, thus promoting tumor survival and proliferation by triggering a manner 
and site specific signalling cascade. 
Cytokine-induced proliferation of tumour cells is particularly well characterised 
in Kaposi’s sarcoma. The Kaposi’s sarcoma herpes virus encodes a human G-protein 
coupled receptor, KSHV-GPCR, which shares high similarities with the structure of 
human CXCR2 (115). Overexpression of KSHV-GPCR in haematopoietic cells induces 
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increased proliferation and angiogenesis in mice (116). This phenomenon is due to 
KSHV-GRCR binding to CXCL8 and CXCL1, triggering a constitutive signal, which 
induces transcription via multiple transcription factors including activator protein 1 
(AP-1) and nuclear factor Kappa B (NF Kappa B). In this way, virally-mediated 
chemokine/chemokine receptor expression promotes tumourigenesis by propagation 
of Kaposi’s sarcoma. A point mutation of CXCR2 can also induce constitutive 
signalling in the absence of CXC chemokines, as an alternative process leading to 
neoplastic transformation (117).  
 
1.3.4.4 Cytokines and Tumour Growth 
There is accumulating evidence that cytokines may directly promote growth and 
survival in various tumours. 
The expression of IL-8 has been shown to be associated with growth of several 
types of cancer, including pancreatic cancer, gastric cancer, melanoma, Hodgkin’s 
disease, breast cancer, cervical cancer and prostate cancer (118). It was found that in 
melanoma cells, IL-8 and GROα (CXCL1) are constitutively secreted and in turn 
enhance the proliferation of melanoma cells (119). Use of anti-sense 
oligonucleotides or neutralising IL-8 antibodies to inhibit IL-8 results in decreased 
melanoma cell proliferation in vitro (120). CXCR1 and CXCR2 are two receptors which 
IL-8 binds with high affinity and are both expressed on neutrophils. Neutralisation of 
38 
 
these two receptors in melanoma inhibits proliferation, indicating that they play an 
important role in tumour growth (121, 122). Also, the expression levels of CXCR1 and 
CXCR2 are found to correlate with invasion of melanoma (123). In other studies, 
neutralisation of GROα but not IL-8 inhibited the proliferation of melanoma cells, 
suggesting that cytokines may utilise different ligands to induce their effects in 
melanoma cells (124). 
GROα, IL-8 and LARC (CCL20) have all been shown to promote growth of 
pancreatic tumour cell lines (125). By using xenograft models, it has been shown that 
the level of IL-8 correlates with pancreatic tumour cell severity and metastatic 
potential (126, 127). When PANC-1 cells are treated with IL-8, it is observed that IL-8 
induces their invasion through Matrigel by inducing secretion of matrix 
metalloproteinase-2 (MMP2), which leads to matrix degradation (128). In ovarian 
cancer, tumor cells are found that are not only active for GROα, but also show high 
proliferation when stimulated by Stromal cell-derived factor 1 (SDF-1 or CXCL12) 
(129). Some prostate cancer cell lines produce IL-8 constitutively, which correlates 
with their growth in vivo (130). However, levels of both GROα and IL-8 are higher in 
diffuse compared with intestinal type gastric carcinoma, suggesting that cytokines 
induce tumor cell proliferation via complex mechanisms (131). 
 
1.3.4.5 Cytokines and Angiogenesis 
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CXC chemokines regulate angiogenesis and can thus promote cancer metastasis. 
The extent by which CXC chemokines induce angiogenesis depends upon the 
presence or absence of the ELR (Glu-Leu-Arg) motif, which is a potent promoter of 
angiogenesis at each chemokine’s NH2 terminus (ELR+) (132). In corneal 
neovascularisation experiments, chemokines with ELR motifs were shown to be able 
to chemo attract endothelial cells to the tumourigenesis site and promoted 
angiogenesis (133, 134). On the other hand, CXC chemokines without the ELR motif 
were angiostatic (132). ELR+ chemokine-induced angiogenesis could be inhibited by 
the presence of ELR- chemokines (135-137), while similar effects were observed 
when ELR+ chemokines were substituted with other pro-angiogenic mediators such 
as bFGF (132). When the ELR motif was added to the ELR- chemokine CXCL9 by 
transfection, the product behaved as an angiogenic factor both in vitro and in vivo, 
indicating that CXC chemokines with/without ELR motif play an essential role in 
mediating angiogenic activity. 
Angiogenesis induced by CXC chemokines is mediated through chemokine 
receptors on the endothelial cell surface (138, 139). Binding of CXCR2 and CXCR4 are 
pro-angiogenic, while binding to CXCR3 usually has angiostatic functions. All ELR-
positive CXC chemokines binding receptor CXCR2 show pro-angiogenic properties, 
while ELR-negative chemokines CXCL9 and CXCL10 binding CXCR3 are angiostatic. 
These observations are important for understanding the mechanism by which 
chemokines contribute to angiogenesis, and the importance of the ELR 
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sequences(140). 
 
1.3.4.6 Cytokines and Tumour Cell Invasion and Metastasis 
Cytokines interact with tumour cells stimulating the secretion of matrix 
degradation enzymes such as matrix metalloproteinases (MMPs) and 
serine/cysteine proteinases. These enzymes, in turn, help tumour cells detach from 
primary tumours, invade through the basement membrane and the extracellular 
matrix. Moreover, cytokine secretion by tumor cells may induce chemotaxis of 
mononuclear phagocytic cells. These may release additional cytokines and enzymes, 
forming an amplification loop that further promotes tumor cell invasion. 
IL-8 can induce secretion of matrix metalloproteinases MMP-2 and MMP-9 from 
various tumor cell lines (141-144) to mediate the proteolysis of basement 
membranes. The presence of IL-8 in the culture medium of human pancreatic cancer 
cell line PANC-1 induced elevated level of MMP-2 in the supernatant as well as 
increased ability for PANC-1 migrate through Matrigel (141). IL-8 was also shown to 
be able to regulate MMP-2 activity in human melanoma cells (142). By using cDNA 
for IL-8 to transfect SB-2 melanoma cells, which produce small amounts of IL-8 in 
normal conditions, it was observed that MMP-2 levels and collagenase activity were 
up-regulated, and more cancer cells migrated through Matrigel. Additionally, the 
concentration of IL-8 was found to correlate with MMP-9 expression in human 
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prostate cancer cells both in vitro and in vivo (143). 
Further studies have confirmed that chemokines enhance tumor cell invasion by 
interaction with cell surface molecules of the extracellular matrix, including integrins. 
Integrins are transmembrane proteins that function as adhesion molecules to 
mediate cell-cell and cell-matrix interactions. After treatment of ovarian cancer cells 
with SDF-1, the cell surface β1-integrin has been shown to be increased, leading to 
enhanced cancer cell adhesion to the extracellular matrix (145). In pancreatic tumor 
cells, SDF-1 has also been shown to induce enhanced tumor cell migration by a 
similar mechanism (146). SDF-1 interacted with the localized chemokine receptor 
CXCR4, induced an increase in the expression of β1-integrin, and subsequently 
induced increased adhesion of B16 murine melanoma cells to endothelial cells (147). 
This effect could be inhibited by the presence of anti-β1-integrin and anti-CXCR4 
antibodies in the culture medium of murine B16 cells which reduced cancer cells 
adhesion to endothelial cells in vitro and prevented murine lung metastasis in vivo. In 
samples from breast cancer patients high concentrations of SDF-1 were observed in 
the popular sites of metastasis i.e. lymph nodes, lung, liver and bone marrow. On the 
other hand, low concentrations of SDF-1 were seen in organs such as brain, kidney 
and skin, which are rare sites for breast cancer.  
Compared to breast cancer metastasis, the distribution of melanoma cells 
follows a similar appearance only with the difference that they metastasis to the skin 
as well. This difference may due to the fact that on melanoma cells, not only 
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receptors CXCR4 and CCR7 were expressed like that on the breast cancer cells, but 
also high levels of CCR10 were expressed, whose interaction with skin specific 
homeostatic cytokine CCL27 (ESkine) promotes metastasis (148). 
 
1.3.4.7 Cytokine Interaction Network in Cancer Metastasis 
1.3.4.7.1 Synergistic and Antagonistic Interaction 
By using recombinant DNA techniques, the actions performed by each cytokine 
have been assessed. This has provided a lot of valuable information but at some 
distance from the real situation as most information was derived from the analysis of 
in vitro systems. Cytokines may exhibit pleiotropy and redundancy in vivo which is 
difficult to imitate in vitro, and cytokines could be easily diluted or inhibited by the 
microenvironment they are in, especially in the presence of their activators or 
inhibitors (149). However, in natural conditions a cell almost always encounters an 
environment in which various cytokines and biological active agents are included. 
These cytokines will perform a special action based on conditions in the current 
environment, so that, cells with different number and/or kind of cytokines at a time 
behave distinctively. One typical example of the synergistic action of cytokines is 
seen between TNF and IFN-γ. IFN-γ enhances cytotoxic effect of TNF on tumor cells 
(150, 151), potentiates production of CSF-1 and G-CSF from monocytes or 
lymphocytes (152), accelerates the differentiation of human myeloid cell lines (153), 
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promotes antiviral activity (154), and induces nitric oxide production in murine 
macrophages (155). TNF and IFN-γ partially target similar genes in target cells (156, 
157). TNF and IFN-γ can both induce the transcription factor interferon regulatory 
factor 1 (IRF-1) (158-160), yet the pathways they work in are distinct (161). In HT29 
colon carcinoma cell lines, a single cytokine TNFα or IFN-γ does not seem to induce 
alterations in cell viability even at high concentrations. Once these two cytokines 
existed in the same cell environment, a rapid and significant cytotoxic effect was 
observed, leading to cell death due to enhanced apoptosis (162, 163). Interestingly, 
not only can two cytokines together produce more effects than the sum of that from 
each cytokine (definition of a synergistic effect), but sometimes a cocktail of 
cytokines could induce significantly different qualities as well. 
Antagonistic interactions may also occur amongst cytokines. IFNs, considered as 
growth-inhibitory, may have a mutually antagonistic effect when in the presence of 
growth stimulatory cytokines or growth factor in many types of cells (164). 
Recognition of the synergistic and antagonistic interactions of cytokines helps to 
understand the complexities of their actions in the organism in physiological and 
pathological conditions. 
 
1.3.4.7.2 Stimulatory and Inhibitory Actions of Cytokines on 
Cytokine Production 
44 
 
Cytokines also have the ability to stimulate or inhibit the secretion of other 
cytokines. Thus, one cytokine secreted may induce secretion of several other 
cytokines, which perform their functions, leading to a biological response. This 
indirect action was demonstrated by the mitogenic action of IL-1 in murine 
thymocytes. IL-1 stimulates the production of IL-2 which then stimulates  thymocytes 
proliferation (165). IL-1 and IL-2 can in turn both stimulate the production of IL-6 
(166), GM-CSF (167), and chemokines (168) in various types of cells. 
There is also evidence of secretion inhibitory actions between cytokines. Many 
immunosuppressive and anti-inflammatory actions of TGF-β are related to its ability 
to suppress cytokine secretion in T cells and mononuclear phagocytes (169). The 
extensive redundancy and pleiotropic actions of cytokines makes it often difficult to 
predict how a certain cytokine works in the complex biological system to produce its 
ultimate effect. 
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1.4 Galectins and their Roles in Cancer 
1.4.1 General 
Galectins are members of a family of lectins with specific binding to β β-
galactoside-containing carbohydrates and glycoconjugates (170). Fifteen members of 
the galectin family have been identified in mammals. 
All galectins share major sequence similarity in at least one conserved 
carbohydrate-binding site, or CRD (carbohydrate recognition domain) of around 130 
amino acids (171). This domain folds to form a slightly bent β-sandwich with a groove 
on the concave side that forms the binding site. The binding site is long enough to 
contain a linear tetra-saccharide and it can be divided into sub-sites A to E which 
have their own specificity. Sub-site C has the specific affinity for the β-galactosides 
across the whole family, while other sub-sites provide the variable specificity for 
larger saccharides (172, 173). 
After being synthesised on cytosolic ribosomes, galectins are translocated to the 
nucleus or outside the cells (174, 175) but all of the galectin members lack signal 
sequences required for the classical protein secretion pathway. 
The galectins are believed to have a very old origin, as there are many galectin-
like sequences in the genomes of creatures with long history, such as fungi, protists, 
and prokaryotes. 
The secretion of galectins is a general phenomenon for various cell types in the 
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human body, including fibroblasts, ovary cells, epithelial cells, endothelial cells, 
dendritic cells, macrophages, bone marrow cells, T cells and B cells. Some galectins 
are widely distributed whilst others are mainly focused on only a few cell types (176). 
Based on their structural differences, galectins have been classified into three 
categories: (i) Prototype galectins (galectin-1, -2, -5, -7, -10, -11, -13, -14 and -15), 
which contain only one CRD in the structure. They exist as monomers or homodimers 
in a non-covalent form; (ii) the chimera galectin (galectin-3), containing one CRD 
linked to a non-lectin domain; and (iii) tandem-repeat type galectins (galectin-4, -6, -
8, -9 and -12), consisting of two CRDs joined by a linker peptide which has a 
sequence of up to 70 amino acids (173).  
Galectins show different binding preferences to saccharides with galactose in 
the structure (177, 178) and have higher affinities toward galactoside-terminated 
complex carbohydrates and glycoconjugates. The most well know galactoside-
containing carbohydrates include lactose (4-(β-D-galactosido)-D-glucose) and N-
acetyllactosamine (Galβ1, 4GlcNAc). 
 
1.4.1.1 Galectin Structure 
It is known that galectins form dimers by self-association, or in some occasions, 
form higher oligomers. The formation of dimers is unrelated to the CRD and is 
dominated by other factors, including amino acid residues on the contact surface 
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when the monomer was formed.  
There are three types of dimers known that galectins form:  (i) through 
hydrophobic forces between N- and C-terminal residues of two monomers, called the 
“terminal” dimer. Two folded rotation axes which are nearly vertical to the β-sheets 
surface interact with each other. Such dimers are formed by galectin-1. (ii) The 
interactions of β-strands β1 and β6 from each monomer result in the “non-
symmetric sandwich” dimer (179) which is found in fungal galectin-2. The 
electrostatic forces among residues within the convex surfaces of the monomers are 
responsible for its stability. (iii) The “symmetric sandwich” dimer has weaker 
interactions between individual’s contact surfaces though the interactions are also 
kept by electrostatic forces.  
The dimer types may be functionally different from each other. There is a theory 
that if free energies per residue for one type of dimer are greater to another, the 
existence of this dimer will dominate in solution. However, the real situation 
observed is quite complicated. For example, human galectin-1 consistently forms 
dimers in solution, even at low concentrations (2µM) when run on a native gel (180, 
181). For other galectins, the situation may not be the same, for the galectin 
oligomeric state varies depending on conditions. Thus, at certain concentrations, 
galectin-5 and -7 exist as monomers in solution (182, 183), while galectin-5 also 
showed properties of agglutinating cells in the same time, indicative of cross-linking 
and subsequent self-association.  
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With regard to galectin-3, the N-terminal domain, rich in proline, glycine and 
tyrosine, greatly contributes to the formation of higher order oligomerization (184). 
After processing by transglutaminase (185), galectin-3 forms dimers or higher order 
oligomers through chemical interactions of their N-terminal domains (186), 
especially when the CRD of galectin-3 binds to synthetic carbohydrates on the cell 
surface (187). Oligomerization by the N-terminal domains results in galectin-3 
forming an important pentameric state, which is unique in the galectin family (176). 
For the tandem repeat galectins, galectin-4, -6, -8 and -9, the dimerization is 
essential for many of their functions, such as mediating cell adhesion and migration. 
However, even as monomers, tandem-repeat galectins already possess two CRDs, 
allowing them to share some similarities with prototype galectins in the dimer state, 
like galectin-1. Two CRDs on the galectin made them enable to bind to more than 
one β-galactoside containing motifs on varies of glycoconjugates, therefore 
mediating intermolecular cross-linking. 
Self-association of galectins occurs among all galectin CRDs, and has great 
influence upon their functional effects. For example, it is observed that as the 
concentration of galectin-1 increases, galectin-1 induced mitogenicity of fibroblasts is 
reduced, whereas the cell division rate of HEP-2 carcinoma cells is increased (188). 
The reason for this phenomenon lies in the galectin-1 monomer-dimer equilibrium as 
determined by the concentration (180, 181). When the concentration of galectin-1 is 
higher than a certain threshold, the galectin-1 exists in the solution in the dimer 
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state, which mainly exerts a growth inhibitory activity (188). This biological effect 
diminishes if the galectin-1 concentration is enhanced and monomers dominate. The 
threshold of this alteration is about 40-80 µg/ml where the concentrations of 
monomers and dimers are similar. 
Recognizing the structure of CRDs is important for understanding their function. 
The secondary structure of galectin CRDs consists of several β-strands folded in 
consecutive antiparallel β-sheets. There are 11 β-strands in the galectin structure. 
These amino acid sequences in the β-strands are generally homologous and highly 
conserved, especially within the motifs in the carbohydrate-binding site (189). The 
tertiary structure of the galectin CRD consists of two antiparallel β-sheets of five (β1-
β5) and six (β6-β11) β-strands. They are arranged in a β-sheet sandwich structure 
with one concave and one convex surface and no helical segments. This structure of 
CRD is a universal characteristic among all the galectins. 
 
1.4.1.2 Galectin Functions 
Due to their bivalent or multivalent binding properties, galectins tend to form 
arrays or lattice structures consisting of the lectins and their multivalent conjugates 
(190). They do not exert their functions simply by binding to specific glycoconjugate 
receptors. On the contrary, each of them binds to various different oligosaccharides 
on the cell surface or in the extracellular matrix glycoproteins (191). Based on their 
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glycosylation and in turn of their activation of certain glycosyltransferases, different 
cell types have variable sensitivities to individual galectin family members (192). The 
intracellular functions of galectins, however, result from their interactions with non-
glycosylated nuclear and cytosolic biomolecules. 
 
1.4.1.3 Extracellular function 
Galectins often bind to and cross-link glycoproteins and other glycoconjugates 
on the surface of various cell types to accomplish their extracellular functions (190). 
Many studies have shown that galectins are involved in the regulation of the 
apoptosis of immune cells such as T cells, which contribute to the regulation and 
control of immune and inflammatory responses. Thus, by binding to cell surface 
glycoproteins, galectin-1, -2, -3 and -9 induce T cell apoptosis. Galectins also impact 
on T-cell differentiation into subsets of Th1, Th2, or Th17 (193). Galectin-1 interacts 
with glycoconjugates on the extracellular matrix as well as those on endothelial cells 
(194) and T cells such as CD7, CD43 and CD45, to induce apoptosis (195). Galectin-2 
interacts with cell surface molecule, leading to exposure of phosphatidylserine on 
the cell membrane surface in activated neutrophils, resulting in binding to 
lymphotoxin-α (196). This phenomenon has not been observed on activated cells 
(197). Galectin-7 specifically expressed on keratinocytes is involved in the process of 
p53-induced apoptosis in keratinocytes (198) and in colon carcinoma (199). High 
levels of galectin-10 are found in eosinophil and basophil leukocytes, whose 
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autogenic aggregation promotes the formation of Charcot-Leyden crystals (200).  
Galectin-3 is widely expressed by epithelial cells and macrophages, and its 
function is mediated by pleiotropic binding to glycoconjugates including laminin, 
fibronectin, vitronectin, elastin, neural cell adhesion molecule (N-CAM), Lysosomal-
associated membrane protein (LAMP) 1/2, and integrin α5β3 on the extracellular 
matrix. Besides CD43 and CD45, galectin-3 can also bind to CD66, IgE and receptor as 
well as the Mac-2 binding protein on leukocytes. The level of galectin-3 is elevated in 
inflammatory conditions (201), and it is induced by cytokines such as CXC chemokine 
CXCL8 (202).  
Amongst the tandem-repeat galectins, the expression of galectin-4 and galectin-
6 is mainly limited to epithelial cells from the gastrointestinal tract (203). Galectin-4 
binds to glycolipids in microvillus rafts, defining and stabilizing enterocytes (204). 
Galectin-8 is frequently found in various cancer cells (205). It has a close relationship 
to prostate carcinoma tumour antigen-1 (PCTA-1), which is a marker on the cell 
surface of prostate cancer cells (206). Galectin-8 promotes anti-metastasis by binding 
to cell surface ganglioside GM3 (sialosyl lactosyl ceramide) (207, 208). Similarly to 
galectin-1 and galectin-3 (209), galectin-9 plays a role as a urate transporter to 
promote apoptosis in T cells (210). It also interacts with matrix type IV collagen and is 
chemotactic to eosinophils (211). 
It can be shown by using different cell types and under various experimental 
conditions in vivo, that each galectin may perform contradictory effects, either 
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potentiation or suppression, contributing to inflammatory responses, compared to 
their behaviour in vitro. For instance, galectin-9 can attract eosinophils to 
inflammatory sites which is considered as a pro-inflammatory process. However, in 
the whole animal, the presence of galectin-9 reduces the inflammatory response by 
inducing apoptosis of immunocytes. Galectin-1 invariably induces suppression of 
immune response in a variety of animal models (212), while injection of endogenous 
galectin-3 into mouse model enhances the responses (213).  
A question follows that, given that CRDs share significantly similarities in their 
structural folds, how can the differing functions of various galectins be explained? 
This could be partly due to amino acid residues within the carbohydrate-binding 
domain having conservation of different degrees. Thus, some of the amino acid 
residues are highly conserved and may not be able to interact with glycans on the 
surface of target cells. Competitive binding of galectins on the given 
glycoconjugate(s) and galectin heterooligomerization (214) may also contribute to 
the varied functional responses. 
 
1.4.1.4  Intracellular functions of galectins 
Some of the galectins play significant roles inside the cells by interaction with 
cytoplasmic and nuclear proteins, thus modulating signalling pathways. 
By interaction with H-Ras, intracellular galectin-1 accelerates H-Ras-GTP 
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phosphorylation (215). Galectin-1 enhances the binding of the C-terminal cysteine of 
Ras to a farnesyl moiety anchored in the intracellular membrane, thereby increasing 
activity of Ras. This galectin-1 effect is not mediated through its carbohydrate binding 
properties (216). This observation was further supported by a later study, showing 
that the galectin-Ras interaction is through hydrophobic prenyl-binding plane on 
galectins and farnesyl group on the C-terminal of Ras (217). By modelling the 
structure of farnesyl modified H-Ras, it has been shown that the structures of both 
Ras and galectin-1 have β-sheet like domain that fit together. The farnesyl group on a 
hydrophobic domain and a β-sheet domain on galectin-1 form a hydrophobic ternary 
complex (218).  
Inside the cell, the binding of galectin-3 appears to be pleiotropic. The binding 
profile includes Ras as well as other cytosolic molecules (217). It has been 
demonstrated that galectin-3 interaction with Bcl-2 promotes cell growth and 
apoptosis (219). The interaction to Bcl-2 for galectin-3 can be inhibited by saccharide 
ligands, which indicates that galectin-3 participates in the interaction through its 
carbohydrate binding domain. Other evidence has shown that galectin-3 may also 
play a role in promoting tumor proliferation and progression in thyroid cancer by 
interaction with thyroid-specific transcription (220). Moreover, galectin-3 regulates 
mitochondrial integrity and cytochrome c release by interaction with synexin, which 
is essential for apoptosis regulation (221). 
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1.4.2 Galectins and Cancer 
Each member of galectin family has its own distribution pattern. Some of the 
galectins are widely expressed, while others are limited to several specific organs. 
The expression varies under different stages of cell development in physiological 
conditions as well as in pathological conditions (222). The galectins show a unique 
manner of expression in tumor cells (204, 223-227). Galectins are often over 
expressed in tumor cells and a specific galectin can appear in cell types in which it is 
not normally expressed, including tumor cells and surrounding stroma cells. 
Conversely, when some cells become cancerous, the original highly expressed 
galectins can be down regulated. Not only the level of the galectins, but also their 
localisation alters during the transition from normal cells to cancer (224). These 
observations suggest the hypothesis that galectins play roles in several aspects of 
cancer development, such as tumor initiation, transformation, apoptosis as well as 
tumor metastasis, which includes cell adhesion, migration and angiogenesis. 
 
1.4.2.1 Galectin Effects on Tumour transformation 
Galectin-1 and -3 may be critically involved in the initial stages of tumour 
transformation. Thus, galectin-1 is required in the process of transforming the 
phenotype of human glioma cells (228). Similarly, reduced levels of galectin-3 result 
in decreased growth rate of breast carcinoma cells and thyroid papillary carcinoma 
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cells in cell culture (229). On the other hand, galectin-3 cDNA transfection induces a 
transformed phenotype in a normal thyroid follicular cell line (230). It is shown that 
effects induced by both galectin-1 and galectin-3 are due to interactions with 
oncogenic Ras (215, 231). Oncogenic Ras proteins (H-RAS, K-RAS & N-RAS) participate 
in various aspects of neoplasia. They have to be anchored to the plasma membrane 
to perform their functions, in which galectin-1 is an important mediator to interact 
with the partners of HRAS. It is observed that overexpression of galectin-1 increases 
not only the content of Ras on the membrane, but also the process of cellular 
transformation (215). Galectin-1 also induces long-term activation of Raf proto-
oncogene serine/threonine-protein kinase 1 (RAF1) and extracellular signal-regulated 
kinase (ERK) (232), indicating that the galectin-1 is involved in signalling transduction, 
in which transcription factors are activated to induce aberrant gene expression, 
leading to tumor transformation. Moreover, galectin-3 binding to Ras proteins 
(preferentially to K-RAS), induces the activation of signalling cascades to regulate 
gene expression at the transcriptional level by activation of RAF1 and 
phosphatidylinositol 3-kinase (PI3K) (231). 
 
1.4.2.2 Regulation of Apoptosis 
Exogenously added recombinant galectins have been shown to induce cell 
apoptosis. Conversely, intracellular galectin-3, resulting from transfection of a cDNA 
encoding galectin-3, has been shown to inhibit apoptosis in several tumor cells when 
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exposed to apoptotic stimuli (233). The sensitivity of tumor cells to 
chemotherapeutic agents has been shown to be affected by galectin-3 (234, 235). It 
is observed that galectin-3 translocates from either cytosol or nucleus into the 
mitochondria when exposure to apoptotic stimuli (221) which inhibits the potential 
on the mitochondrial membrane, and subsequently reduces apoptosis (236). In the 
cell, galectin-3 exists in a phosphorylated form (237). If the Ser6 residue is replaced 
by alanine or glutamic acid due to mutation, galectin-3 loses its phosphorylation, 
along with its anti-apoptotic activity (238), indicating that phosphorylation is the 
essential structure modification for galectin-3 to perform its function. 
Phosphorylated galectin-3 is also known to regulate the mitogen activated protein 
kinase (MAPK) pathway (234). 
Galectin-3 has an Asp-Trp-Gly-Arg (NWGR) motif in its C-terminal, which is 
similar to the motif on BCL2. It is the very same motif that is essential for BCL2 
function as a suppressor of apoptosis (219). In galectin-3, the NWGR motif is 
essential for its carbohydrate-binding ability. Replacement of glycine to alanine in this 
motif results in reduction of anti-apoptotic activity (239). Galectin-3 also interacts 
with other intracellular molecules which contribute to its anti-apoptotic activity, such 
as synexin (annexin VII). When cells are treated with apoptotic stimuli, galectin-3 
interacts with synexin to translocate to the perinuclear membranes (221). Although 
cytosolic galectin-3 functions as an anti-apoptosis factor, while in the nucleus 
galectin-3 promotes apoptosis (240).  
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Other galectins also show functions in regulating apoptosis. Tumour cells tend 
to be apoptotic when galectin-7 overexpression is observed (198, 241). It is also 
observed that galectin-12 at high level in a fibroblast cell line promotes apoptosis 
(242).  
Galectins are also shown to regulate tumourigenesis by regulating cell growth. 
Thus, galectin-1 suppresses cell growth in an autocrine manner (243). This is further 
verified by the observation that in human glioma cells the inhibition of galectin-1 
results in lower rate of cell growth (228). Galectin-7 transfectants induce slower 
growth rate in a colon carcinoma cell line (244), and both exogenous galectin-1 and 
galectin-7 reduce the growth of neuroblastoma cells (245, 246). Alternatively, 
galectin-3 acts as a positive growth regulator in some cases. It has been found that 
after galectin-3 transfection, the human T lymphoma Jurkat cells have a higher 
growth rate in vitro, whereas inhibition of galectin-3 results in slower growth in 
breast carcinoma cells and thyroid papillary carcinoma cells in vivo (229, 247). There 
are also examples showing that galectin-3 transfection induce slower growth rate in 
the prostate cancer cell line LNCaP in vitro and in vivo (248). A follow-up study 
revealed that the presence of cytosolic galectin-3 is shown to increase anchorage-
independent growth in vitro, whilst nuclear galectin-3 reduces the growth of the cells 
(240), indicating that endogenous galectin-3 functions through different mechanisms 
depending on the subcellular localisation of the protein. 
Galectins can regulate progression of the cell cycle. For example, galectin-3 
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inhibits the cell-cycle of breast cancer cells in vitro via down-regulation of cyclin E 
and cyclin A expression and increasing cyclin D1 expression (249). Subsequent 
studies have indicated that galectin-3 induces the activation of cyclin D1 by binding 
to β-catenin (250, 251). 
 
1.4.2.3 Effects on Cell Adhesion during Metastasis 
During tumour metastasis, tumour cells invade the tissues nearby, disseminate 
through the blood/lymphatic circulation systems and form secondary tumours at 
organs distant from original sites. Various galectins contribute to this metastasis 
process by altering cancer cell adhesion migration, angiogenesis and escape from the 
immune response. 
Galectins derived from the tumor cell can influence homotypic aggregation of 
cancer cells as well as adhesion between cancer cells and the endothelium. Galectins 
can either promote adhesion by directly binding, or inhibit it by steric hindrance to 
block the interactions between cells involved in the adhesion, subsequently disabling 
the cell-cell or cell-matrix interactions. Galectin-1 and galectin-3 prevent tumor cell 
adhesion to extracellular matrix proteins when added exogenously (252-254), while 
soluble galectin-8 reduces the adhesion of several cell lines to culture plates (255).  
 Galectins can also promote cell adhesion by forming a connection between 
cells or cell-extracellular matrix due to their bivalent or multivalent properties. They 
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promote tumour cell-cell homotypic aggregation and tumour cell adhesion to 
endothelial cells at distant organs in metastasis (256-258). Galectins bind integrins 
and several galectin-induced effects are reported to be mediated by integrins, thus s 
galectin-1 binds to α7β1 integrin (259), galectin-3 binds to integrin α1β1  (260), and 
galectin-8 binds to α3β1 and α6β1 integrins (255) as well as integrin αMβ2 (261). 
 
1.4.2.4 Regulation of Tumour Invasiveness and Angiogenesis 
The expression of galectins has been shown to influence the migration of tumor 
cells as well as their invasion. In breast carcinoma cells, it has been shown that 
exogenous galectin-3 can bind receptors on the cell surface, and results in increased 
migration of breast cancer cells through Matrigel (262). Conversely, in another study, 
exogenously added galectin-3 inhibited the migration of human colon cancer cell 
lines (HCT-15, LoVo, DLD-1, and CoLo201) (263). This might be due to galectin-3 
recognising different cell-surface receptors. In addition, high levels of galectin-3 were 
found in the lung cancer cell line DLKP which exhibits increased cell motility and 
invasiveness in vitro (264). Moreover, a study using human astrocytes tumour cells 
has shown that the increased expression of galectin-1 is correlated with an enhanced 
migratory ability. When galectin-1 was exogenously added to astrocyte tumour cells, 
it increased the motility of the cells (265). In contrast, galectin-8 was shown to be an 
inhibitor of the migration of some colon cancer cell lines in vitro (266). It has been 
shown that galectin-3 increases angiogenesis in vitro and in mice (267). This 
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angiogenic activity could be a result of galectin-3 inducing the migration of 
endothelial cells. 
 
1.4.3 Galectin-3 
1.4.3.1 General 
Galectin-3, also known as CBP35, CBP30, Mac-2, L-29, L-31 and L-34, is one of 
the most studied galectin family members. It is expressed in variety of human cells, in 
particular epithelium and immunocytes. There are three major structural domains in 
galectin-3, (1) a N-terminal domain which contains a serine phosphorylation site, 
important for the regulation of intracellular signalling, which is unique for galectin-3 
in the galectin family; (2) a repeated collagen alpha-like domain, which is sensitive to 
the presence of matrix metalloproteinase MMP-2 and MMP-9; (3) and a C-terminal 
sequence with a single carbohydrate recognition-binding domain (CRD). The Asp-Trp-
Gly-Arg amino acid sequence (NWAG) on the C-terminal is responsible for the anti-
apoptotic function of galectin-3 (171, 219, 268-270). Galectin-3 can form a β-
sandwich shape when it complexes with lactose or N-acetyllactosamine (271). 
Nuclear magnetic resonance spectroscopy revealed that galectin-3 exists as a 
monomer in solution, and that the N-terminal section can extend by unfolding and 
has been found to interact with the CRD (272). 
The galectin-3 N-terminal domain consists of nearly 120 amino acids. Although 
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this N-terminal section lacks carbohydrate-binding activity, it is still important for 
galectin-3 to perform its full biological activity (271). With the help of carbohydrate 
ligands, the N-terminal domain enables galectin-3 to form pentamers, which cross-
link with glycoconjugates on the cell surface to form lattice like structures, 
subsequently influence the signalling pathways in cells (187). Through Tyr102 and 
adjacent residues, the N-terminal domain plays a role in oligosaccharide binding 
along with the CRD (273). It is also responsible for multimer formation, lectin binding 
to immobilised ligand clusters (274) and the cellular secretion of galectin-3 (275). To 
verify the function of N-terminal domain, experiments have shown that dissection of 
the first eleven amino acids of the N-terminal domain disable secretion of galectin-3 
(269), while mutation of the conserved Ser6 structure results in galectin-3 losing its 
anti-apoptotic function (238). 
The C-terminal domain of galectin-3 accommodates the whole carbohydrate-
binding site (186, 270). Its structure of two folded anti-parallel β-sheets, which is 
observed by using X-ray crystal structure analysis, is typical compared with that of 
other galectins (271). The CRD, when binding to advanced glycation end-products 
(AGE), shows a stronger binding affinity than intact galectin-3 (276). Although 
galectin-3 only possesses one carbohydrate-recognition domain, it exhibits 
bi/multivalent binding properties (277, 278) through polymerisation. The C-terminal 
and N-terminal domains both participate in the formation of multimers of galectin-3 
(187). 
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Galectin-3 is synthesised in the cytoplasm as a cytosolic protein but can be 
transported and expressed in multiple subcellular localisations from the cell nucleus 
to the cell surface, or can be secreted outside cells through a non-classical secretory 
pathway (175). It is shown that galectin-3 exerts different functions while in different 
locations. Extracellular galectin-3 mediates cell-cell and cell extracellular matrix 
interactions by cross-linking adjacent cells (279). Cytoplasmic galectin-3 functions as 
an apoptosis inhibitor by suppressing mitochondrial depolarisation and preventing 
the release of cytochrome C (221), while nuclear galectin-3 is shown to participate in 
the basic cellular functions including pre-mRNA splicing (280, 281), and in contrast to 
cytoplasmic galectin-3, has pro-apoptotic activity (240). The shift of galectin-3 from 
the nucleus to the cell cytoplasm can be observed in many types of human cancers, 
including colorectal (282, 283), prostate (284) and tongue (229), and closely 
correlates with tumour progression as stable galectin-3 gene transfection increases 
cancer cell invasion and promotes tumour angiogenesis in vitro (240). 
It is shown that galectin-3 is expressed in various cells involved in the immune 
response and inflammation, such as macrophages, dendritic cells, eosinophils, mast 
cells, uterine NK cells and activated T and B cells (279). Galectin-3 induces apoptosis 
in T cells, such as human T leukaemia cell lines, human peripheral blood 
mononuclear cells (PBMC) and activated mouse T cells (285, 286). Galectin-3 
activates the mitochondrial apoptotic pathway via cytochrome-c and caspase-3 by 
binding to CD7 and CD29 molecules (286), and galectin-3 also binds to CD45 (285). 
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Galectin-3 also induces monocytes to secrete superoxide anion (287) and is 
chemotactic to immunocytes (288). Exogenous recombinant galectin-3 increases 
human neutrophil (289) adhesion to laminin as well as endothelium (290). Galectin-3 
was also reported to participate in the process by which macrophages devour 
apoptotic neutrophils, functioning as an opsonin (291). On the other hand, it has also 
been reported that the presence of galectin-3 inhibits T cell activation. Galectin-3 
may bind to T cell receptor (TCR) glycans, forming complexes, thereby limiting the 
formation of receptor clustering, which is essential for TCR-mediated signalling (292).  
 
1.4.3.2 Galectin-3 Expression in Cancer 
Galectin-3 has recently attracted attention in cancer both as a possible 
diagnostic marker and as a potential therapeutic target.  
Thus, in thyroid cancer, increased serum galectin-3 concentrations are observed, 
particularly in patients with metastasis (293, 294). Galectin-3 has also been 
considered as a supplementary marker for cytological diagnosis of papillary thyroid 
cancer (295). Overexpression of galectin-3 has also been used to distinguish 
parathyroid carcinoma from benign adenoma (296). For example, in 92.3% of 
parathyroid carcinomas elevated galectin-3 was observed, while only 3.3% of 
parathyroid adenomas were galectin-3 positive. Besides, all parathyroid carcinoma 
with metastasis were found to have high expression of galectin-3 (297). 
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There is accumulating evidence that the level of galectin-3 expression correlates 
with tumor progression in various cancers and also correlates inversely with the 
degree of tumor differentiation (298). Galectin-3 expression also correlates with 
lymph node metastasis of colon cancer (299) and circulating galectin-3 
concentrations are higher in colon cancer patients with liver metastasis (300). 
Galectin-3 expression correlates with tumour TNM staging in gastric carcinoma. 
Nuclear expression of galectin-3 in oesophageal squamous cell carcinoma correlates 
with the degree of invasion and inversely with differentiation while cytoplasmic 
galectin-3 has no such relationship (301). Increased expression of galectin-3 has been 
observed in the clear cell ovarian carcinomas (302, 303), renal cell neoplasms (304)as 
well as in mature Sertoli cells and Leydig cells of malignant testicular cancer (305), 
suggesting that the expression of galectin-3 was involved in differentiation. 
 
1.4.3.3 Role of Galectin-3 in Cancer Progression and Metastasis 
It has been shown that galectin-3 plays a role in cancer cell viability and anoikis, 
adhesion, embolism, and proliferation, as well as angiogenesis in metastasis (191, 
306, 307). Inhibition of galectin-3 expression has been shown to reduce the 
malignant potential of breast carcinoma cells (229, 247) and introduction of galectin-
3 antisense transfectants decreases tumor growth in experimental models in vivo 
(229). 
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After detachment from the primary tumour, only a tiny population (0.1-0.01%) 
of tumour cells may successfully develop metastatic foci (308). Most of the 
circulating cancer cells die as a result of anoikis. Anoikis happens to some types of 
cells when they detached from and lose contact with the extracellular matrix (ECM) 
(279). It has been reported that increased expression of galectin-3 reduces death 
from anoikis when cells are exposed to apoptotic stimuli (187, 309, 310). This 
apoptotic regulation by galectin-3 could also promote anti-cancer drug resistance 
(236, 311).  
Galectin-3 influences the adhesion of cancer cells to extracellular matrix (289, 
290, 312) due to its binding to cell surface proteins such as laminin, Lamp I and II, IgE 
and Mac-2 binding protein (238, 272, 313, 314). Cell surface-associated extracellular 
galectin-3 induces detachment of cancer cells from primary sites by increasing 
tumour cell adhesion and invasion through interactions with basement matrix 
glycans (307). The over-expressed cell surface-associated galectin-3 in epithelial 
cancer cells interacts with galactoside-terminated glycans expressed on the surface 
of adjacent cells, leading to cancer cell homotypic aggregation and heterotypic 
adhesion to endothelial cells in cancer cell haematogenous dissemination (258, 315). 
During cancer cell extravasation, cell surface-associated galectin-3 has also been 
shown to stabilise the epithelial-endothelial interaction (275). Inhibition of the 
expression of galectin-3 in melanoma cells reduces tumour cell invasiveness and 
angiogenesis on collagen matrices (316), while the suppression of galectin-3 
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expression in metastatic human colon(317) and breast (229) cancer cells before 
injection resulted in significantly reduced metastasis in nude mice. 
The formation of secondary tumours is significantly increased if the circulating 
cancer cells form emboli by aggregation with other tumour cells or host cells. Cancer 
cells with superior aggregation potential in vitro often demonstrate greater 
metastasis formation in vivo (318). By interacting with Mac-2-binding protein (319), 
galectin-3 stimulates the formation of multicellular aggregation [30]. Galectin-3 may 
also participate in tumor cell transformation through its interaction with oncogene 
Ras proteins (231). Galectin-3 binds to K-Ras preferentially, induces the activation of 
phosphatidylinositol 3-kinase (PI3K) and Raf-1, thus modifying gene expression at the 
transcriptional level (217, 231). Galectin-3 can also regulate the cell cycle to promote 
tumourigenesis (307, 320). It down-regulates cyclin E and cyclin A as well as 
enhancing cyclin D by interacting with β-catenin and c-Myc (251, 320). Conversely it 
can also up-regulate the expression of p21 (WAF1) and p27 (KIP1) to inhibit the cell 
cycle (249). 
 
1.4.3.4 Circulating Galectin-3  
Although little is known regarding a physiological role for circulating galectin-3, 
recent investigations have shown that the concentration of free-circulating galectin-3 
is increased up to 30-fold in the sera of patients with varies types of cancer including 
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breast, colorectal (321), lung (322), bladder (323), and head and neck cancers (324) 
and melanoma (325). Furthermore, even higher concentrations of galectin-3 are found 
in the serum of patients with metastasis. The source of increased serum galectin-3 has 
been speculated to be tumour cells as well as the peri-tumoral stromal cells (322). In 
vitro, under static as well as fluid flow conditions, cancer cells showed significantly 
increased adhesion to macro- and micro-vascular endothelial cells with the 
introduction of recombinant galectin-3 at concentrations similar to that found in the 
sera of cancer patients (326). This galectin-3 induced effect is at least in part due to its 
binding to the Thomsen-Friedenreich carbohydrate (galactose β1, 3N-
acetylgalactosamine, TF) antigen, which is expressed by the transmembrane mucin 
protein MUC1 (327). The TF antigen is the core 1 structure of O-linked mucin type 
glycans whose expression is commonly increased in various types of human cancer 
(327). 
The mucin protein MUC1 is a large and heavily glycosylated protein which is 
over-expressed and aberrantly glycosylated in most epithelial cancer cells (328). 
Unsubstituted TF antigen is often carried by MUC1, and expression of both MUC1 
and TF are each independently associated with high metastatic potential and poor 
prognosis in several kinds of cancers, including colorectal and breast cancers (329, 
330). Because of the large size of MUC1, overexpression results in the formation of a 
protective shield around the cell surface and prevents the adhesion of cancer cells to 
endothelial cells (326). Interaction with galectin-3 causes MUC1 cell surface 
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polarisation, leading to the protective shield breaking down and exposure of smaller 
cell adhesion molecules, resulting in adhesion of the cancer cells to endothelial cells. 
That is supported by in vivo experimental metastasis assays which show that pre-
treatment of MUC1 positive, but not MUC1 negative, transfected human melanoma 
cells with recombinant galectin-3 before inoculation of the cells into immune 
deficient mice causes significant increase of metastasis (326). 
Free circulating galectin-3 may also play a role in the inhibition of anti-tumour 
immunity by mediating the regulation of T cell activity (331). Free soluble galectin-3 
binds to cell surface activated tumour-reactive T cells to produce immunosuppressive 
cytokines and induce T cell apoptosis. The concentration of galectin-3 required in 
these studies goes up to 25µg/ml however, which is much higher than the level seen 
in cancer patients. However, cell surface binding of galectin-3 often induces 
clustering of the receptors on the cell surface which may enhance the galectin-3 
binding affinity up to 10,000-fold (285, 327, 332, 333). Therefore, the high 
concentration required for driving tumour-reactive T cell activation and apoptosis 
could be achieved, and could be a factor in the avoidance of tumour cell destruction 
by immune surveillance. 
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1.5 Glycosylation Changes in Cancer 
1.5.1 General 
Glycosylation is a fundamental cellular process that occurs in all cells. By the 
actions of enzymes, saccharides are joined with proteins, lipids or other biological 
molecules to form glycoconjugates. In cells, carbohydrates serve as signalling 
molecules or as structural components, which are especially important for mediating 
and/or modulating interactions between cells and one another or with the matrix. 
Glycosylation is initiated within the rough endoplasmic reticulum (ER) but continues 
in the Golgi apparatus. 
 
1.5.2 O- and N-linked Glycosylation 
It is estimated that more than half of mammalian proteins are modified by 
glycosylation with O- or N-linked glycans (334). N-linked glycosylation occurs on 
asparagine in the sequence Asn-X-Ser/Thr, and follows pre-synthesis of a dolichol-
oligosaccharide precursor as well as other process in the ER. N-linked glycans 
typically contain glucose, mannose, and N-acetyl glucosamine (GlcNAc) molecules, 
with the initial linkage to asparagine occurring via N-acetylglucosamine. N-linked 
glycosylation usually occurs on membrane-associated and secreted proteins in 
eukaryote cells (335). N-linked glycans share a common branched tri-mannosyl core 
Man3GlcNAc2-Asn, which is essential for the formation of a diverse number of 
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heterogeneous, often quite large and bulky, bi-, and tri- or tetra-antennary glycans 
(334). 
O-linked glycosylation occurs in many cell membrane and secreted proteins in 
the later stages of protein processing. The O-linked glycans tend to be smaller and 
less branched as well as more diverse than N-linked glycans. As one of the most 
common glycans, O-glycans are defined by GalNAc monosaccharide α-linked to the 
hydroxyl group of serine or threonine residues. Mucins, secreted onto the apical 
surface of epithelial cells, are heavily O-glycosylated and owe much of their 
protective effects to the O-glycans. The O-linked glycans on membrane-bound or 
secreted mucins typically comprise up to 50% of the mucin molecular weight (336) in 
epithelial cells, leukocytes and vascular endothelial cells (335, 337). Glycans 
modulate various aspects of the proteins that they attached to. For example, O-
glycans can confer protease resistance of the proteins by protecting thermolysin-
sensitive regions of the polypeptide (338). 
At least eight different core structures have been reported to occur on mucin 
type (O-linked) glycans. All of these core structures are based on the core-GalNAc 
residue, which is further substituted at C3, C6 or at both positions with β-galactose 
(Gal) at C3, β-GlcNAc at C3 and/or C6, and α-GalNAc at C3 or C6 (339). This results in 
the formation of either core 1, core 2 or core 3 structures. Some of the mucin-type 
O-linked glycans are cancer-associated antigens, this includes GalNAc- (Tn), sialyl-
GalNAc (sialyl-Tn) and Galβ1, 3GalNAc- (Thomsen-Friedenreich or TF) antigens (340). 
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Some of these carbohydrate antigens have been studied as therapeutic targets for 
cancer treatment (341). 
 
1.5.3 Molecular Mechanisms of Altered Glycosylation in Cancer 
In cancer cells, changes in cellular glycosylation are common. Alterations of N-
glycosylation in tumours include the increased expression of β1-6 branched complex-
type sugar chains (342) and the increased expression of the three β-N-
acetylglucosaminyltransferases; GnT-III, -IV and –V have all been reported in cancer 
cells (343). 
The molecular mechanism of the changes in O-linked glycosylation in cancer are 
probably much more complex. Cancer cells normally carry shorter and less branched 
O-linked carbohydrate chains, with increased sialylation and reduced sulphation 
(344-346). At first, altered expressions or activities of the relevant 
glycosyltransferases were thought to be the primary reason for altered O-linked 
glycosylation in cancer. Brockhausen et al. found that many glycosyltransferases 
activities were altered in epithelial cancers (347). Thus the activity of a 
sialyltransferase (CMP-sialic acid Gal β 1-3GalNAc α 3-sialyltransferase) was increased 
4-fold in three breast cancer cell lines: BT20, MCF-7 and T47D. The Gal-β 1-3GalNAc 
(GlcNAc to GalNAc) β 6-GlcNAc-transferase activity was found to be deficient in 
mammary cancer cell lines BT20 and T47D but expressed in MCF-7 breast cancer cells 
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(347). 
Tn (GalNAcα-Ser/Thr), sialosyl-Tn and TF (Galβ1-3GalNAcα1-Ser/Thr) antigens 
are often overexpressed in cancer cells. The Galβ1-3GalNAcα1-Ser/Thr structure is 
revealed in many human cancer cells (348, 349) when the originally attached sialic 
acids, sulphates or other chain structures were removed (350). However, the levels of 
the relevant glycotransferases that control the biosynthesis of these glycans are 
similar in paired specimens of normal and cancerous tissues (351). Furthermore, the 
enzyme activities of the glycosyltransferases do not change when the location, stage 
or histological type of the tumour changes in cancerous tissues (351). This indicates 
that the expression of glycosyltransferases alone may not account for the altered 
glycosylation changes in cancer cells. 
It is shown that redistribution of the glycosyltransferases in the Golgi apparatus 
may have some relevance to the abnormal glycosylation of proteins (352, 353). In 
cancerous conditions, the level of core 2 β1,6-GlcNAc-transferase is greatly 
decreased, leading to reduced expression of core 2 structure as well as increased 
expression of core 1 structure, which include the TF antigen (347, 354). The 
increased TF expression could also be induced by enhanced activity of nucleotide 
sugar substrate UDP-galactose for core 1 β1, 3 Gal-transferase (355). Another 
mechanism that result in increased TF expression can due to alteration in intra-Golgi 
pH (356-358). Elevation of the Golgi pH by treatment of the cells with bafilomycin A 
or pH calibration buffers increases TF antigen expression in breast and colorectal 
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cancer cells (356, 358) and similar Golgi disarray has been shown to occur in human 
cancer cells (359).  
 
1.5.4 Roles of Altered Glycosylation in cancer 
Alteration of cellular glycosylation is a common characteristic of human cancer 
(360-362). Amongst the commonest glycosylation changes are the increased 
occurrence of GalNAcα1-Ser/Thr (Tn antigen), Neu5Acα2-6GalNAc (sialyl-Tn antigen) 
and Galβ1-3GalNAcα1-Ser/Thr (TF or T antigen)(363). Overexpression of sialyl-Tn has 
been shown to be related to resistance of the cancer cells to chemotherapy (364). In 
experimental mouse models, the inhibition of sialylation (365) and enhancement of 
mucin glycosylation (366) reduces cancer cell metastasis. Beta 1-6 branched N-linked 
oligosaccharides are consistently increased in neoplasia of human breast and colon 
and this has been shown to correlate with the pathological staging (367). Golgi β1, 
6N-acetylglucosaminyltransferase V (MGAT5) is required in the biosynthesis of β1, 
6GlcNAc-branched N-linked glycans, and tumour growth and metastasis were 
inhibited in Mgat5-deficient mice (368). At the cell surface, the increased expression 
of highly branched N-glycans is correlated with tumour formation and alters adhesive 
properties of tumour cells in vivo (369). It has been suggested that the increased 
expression of cell surface N-glycans contributes directly to reducing cell-cell contact 
as well as cell growth in an immortalised lung epithelial cell line (370).  
74 
 
Sialyl-Lewisa and Sialyl-Lewisx [NeuAcα2-3Galβ1-4/3(Fucα1-3/4) GlcNAc-R] are 
two tetra-saccharide carbohydrates that contribute to the cell-cell interaction when 
present on cell surface O-glycans. Overexpression of sialyl-Lewisx/a have been used as 
tumour markers in  human adenocarcinoma of the colon (371, 372) and breast 
cancer (373). It has been shown that increased expression of Sialyl-Lewisx/a on the 
cell surface correlates with the metastatic potential of both human colon and 
stomach cancer cells (343, 374-377). The precursor of Sialyl-Lewisx is α2, 3-sialylated 
galactose residue of GlcNAc, whose N-acetylgalactosaminylated form is the precursor 
of Sda antigen. The Sda carbohydrate [GalNAcβ1-4(NeuAcα2-3) Galβ1-4GlcNAc] is a 
blood group structure expressed on glycolipids and glycoproteins, which can be 
found in the normal gastrointestinal mucosa. It is reported that the level of Sda as 
well as the enzyme β1, 4-N-acetylgalactosesaminyltransferase (β1, 4GalNAcT) which 
is responsible for its synthesis is remarkably reduced in cancer lesions (378, 379). 
Through the competitive activity of glycosyltransferase Sda-β1, 4GalNAcT, Sda 
determinant efficiently eliminated the presence of sialyl Lewisx/a, therefore abolished 
their role of promoting metastasis (380). 
 
1.5.5 Interactions between TF antigen and Galectin-3 
The Thomsen-Friedenreich (Galβ1, 3GalNAcα-, TF) antigen is a disaccharide 
comprised of galactose linked to N-acetylgalactosamine (GalNAc), present as a core 
structure O-linked to serine/threonine. It behaves as an oncofetal antigen, 
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overexpressed in normal foetal tissue and in cancerous or precancerous tissue (350). 
It is absent or masked by further glycosylation in healthy tissues, while expressed in 
many cancers.  
It has already been discussed that elevated levels of galectin-3 in the blood 
circulation promote cancer metastasis in an animal metastasis model (326). This 
action of galectin-3 is partially attributed to its interaction with the oncofetal TF 
disaccharide on the transmembrane mucin-type protein MUC1 expressed on cancer 
cells (327). The galectin-3-MUC1 interaction induces MUC1 polarization on the 
cancer cell surface leading to exposure of the underlying adhesion molecules, 
thereby resulting in increased tumour cell heterotypic adhesion to blood vascular 
endothelium and tumour cell homotypic aggregation in the circulation (381). The 
presence of TF antigen on MUC1 expressed on the cell surface paves the way for 
galectin-3 to exert its function of enhancing the adhesion between cancer cells and 
endothelial cells. This is a mechanism by which TF expression, a most common 
glycosylation alteration in cancer, may promote cancer metastasis (Fig. 1.4). 
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 Fig. 1.4: Proposed action of galectin-3-MUC1 interaction. (Adapted from Yu et 
al)(327) (Permission acquired from American Society for Biochemistry and Molecular Biology) 
Circulating galectin-3 interacts with cancer associated, TF antigen-bearing MUC1 
on the cancer cell surface, leading to the polarization of MUC1 molecules. The 
subsequent exposure of smaller cell adhesion molecules or ligands set the stage for 
further epithelial-endothelial interaction via ligands such as E-Selectin and CD44H. 
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CHAPTER 2 Hypothesis and Aims 
2.1 Hypothesis 
Circulating galectin-3, whose concentration is commonly elevated in the 
bloodstream of cancer patients, has a MUC1-independent, as yet unidentified action 
that promotes metastasis.   
 
2.2 The aims of this study 
The aims of this study are to identify and characterize the MUC1-
independent actions of circulating galectin-3 in metastasis promotion. This will 
increase our understanding of the molecular regulation of metastasis and help in the 
identification of new therapeutic strategies to reduce metastasis.  
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CHAPTER 3 Materials and Methods 
3.1 Materials 
All cell culture flasks, multi-well plates, chemicals of analytical grade and non-
enzymatic cell dissociation solution (C1544-10ML) were purchased from Sigma-
Aldrich Ltd (Poole, UK), unless otherwise stated. 
Calcein AM (1mg/ml solution in anhydrous DMSO, C3099) was purchased from 
Invitrogen, Paisley, UK. 
Human Cytokine Array Panel Array Kit (ARY005), Human Phospho-Kinase Array 
Kit (ARY003), human cytokine ELISA kits (G-CSF: DY214, GM-CSF: DY215, IL-6: DY206 
and ICAM-1: DY720), Quantikine Mouse sICAM-1 (MIC100), recombinant galectins 
and anti-galectin antibodies were purchased from R&D Systems, Abingdon, UK. 
Human cytokine ELISA kits (G-CSF: 900-K77, GM-CSF: 900-M30, IL-6: 900-M16, 
ICAM-1: 900-M464, GRO/MGSA: 900-K38, MCP-1: 900-M31) and murine cytokine 
ELISA kits (G-CSF: 900-K103, GM-CSF: 900-K55, IL-6: 900-M50) were purchased from 
Peprotech, London, UK. 
Mouse KC (GRO-α/CXCL1) (PK-EL-65420DM) ELISA Development Kit was 
purchased from PromoKine, Heidelberg, Germany. 
RayBio antibody MMP array-1 (AAH-MMP-1-4) was purchased from Insight 
Biotechnology, Wembley, UK. 
Anti-integrin α5β1 (ab25076) was purchased from Abcam, Cambridge, UK. 
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In Vitro Angiogenesis Assay Endothelial Cell Invasion Kit (3471-096-K) and In 
Vitro Angiogenesis Assay Tube Formation Kit (3470-096-K) were purchased from 
AMS Biotechnology (Europe) Ltd, Abingdon, UK. 
 
3.2 Cell Lines 
ACA19-: MUC1 transfection of human melanoma A375 cells with full-length 
cDNA encoding MUC1 and the subsequent selection of the MUC1 negative 
transfectants cultured in Dulbecco’s modified Eagle’s medium. It was kindly provided 
by Dr. John Hilkens (Netherlands Cancer Institute) (382). 
HCT116: Human colon carcinoma cells were from the European Cell Culture 
Collections via the Public Health Laboratory Services (Porton Down, Wiltshire, 
UK)(383). HCT116 cells were MUC1-negative malignant cells isolated from a male 
with colonic carcinoma and cultured in McCoy’s 5a medium.  
HMVEC-Ls: Human micro vascular lung endothelial cells (HMVEC-Ls) were 
obtained from Lonza (Wokingham, UK). HMVEC-Ls cells were cultured in EBM-2 
endothelial growth media. Fewer than five passages of the cells were used in all the 
experiments. The culture medium was changed every four days. 
HUVEC: Human umbilical vein endothelial cells (HUVECs) were obtained from 
Lonza (Wokingham, UK) and cultured in EGM endothelial growth media (Lonza). 
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3.3 Cell Culture Medium 
(1) Dulbecco’s modified Eagle’s medium (DMEM) from Sigma-Aldrich 
Complete culture medium contains 10% FCS (fetal calf serum), penicillin 100 
U/ml, streptomycin 100 µg/ml, glutamine 2mM. 
Serum-free DMEM contains 0.5% bovine serum albumin, penicillin 100 U/ml, 
streptomycin 100 µg/ml, glutamine 2mM. 
(2) McCoy’s 5a from Sigma-Aldrich 
Complete medium contains 10% FCS, penicillin 100U/ml, streptomycin 100 
µg/ml, glutamine 2mM. 
Serum-free McCoy’s contains 0.5% bovine serum albumin, penicillin 100 U/ml, 
streptomycin 100 µg/ml, glutamine 2mM. 
(3) EBM-2 from Lonza 
Complete EBM-2 contains fetal bovine serum (BSA) 25ml/500ml, 
hydrocortisone 0.2ml/500ml, hFGF-B 2ml/500ml, VEGF 0.5ml/500ml, R3-Insulin-like 
growth factor-1 0.5ml/500ml, ascorbic acid 0.5ml/500ml, hEGF 0.5ml/500ml and GA-
1000 (Gentamicin Sulfate and Amphotericin-B) 0.5/500ml. 
Serum-free EBM-2 contains 0.5% bovine serum albumin, hydrocortisone 
0.2ml/500ml, hFGF-B 2ml/500ml, VEGF 0.5ml/500ml, R3-Insulin-like growth factor-1 
0.5ml/500ml, ascorbic acid 0.5ml/500ml, hEGF 0.5ml/500ml and GA-1000 
(Gentamicin Sulfate and Amphotericin-B) 0.5/500ml. 
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(4) EBM from Lonza 
Complete EBM contains Fetal Bovine Serum 10ml/500ml, hydrocortisone 
0.5ml/500ml, hEGF 0.5ml/500ml, GA-1000 0.5/500ml, BBE 2ml/500ml. 
 
3.4 Cell Counting 
Cell numbers were counted with a haemacytometer. The number of cells was 
obtained with the following equation: cell density (cells/ml) = number of cells per 
grid square X 104.  
3.5 Cell Culture 
All cells were grown as monolayers. ACA19- cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM); HCT116 were cultured in McCoy’s 5a medium; 
HMVEC-Ls were cultured in EBM-2 endothelial growth media and supplements and 
HUVEC were cultured in EBM and supplements. Cells were maintained at 37℃ in a 
humidified atmosphere of 5% CO2, 95% air. ACA19- and HCT116 cells were released 
from T25 cm2 flasks with 1ml Trypsin (0.5mg/ml in sterile PBS) and routinely 
passaged at a 1:6 subculture ratio when they had become 60%-80% confluent. Cells 
at a ~80% confluence were used for all experiments. HMVEC-Ls and HUVEC cells 
were released from T25 cm2 flasks with 1ml Trypsin (0.5mg/ml in sterile PBS) and 
routinely passaged at a 1:3 subculture ratio when they had become 60%-80% 
confluent. Cells at ~80% confluence were used for all experiments.  
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3.6 Cell Thawing and Plating 
The cell culture medium was warmed up to 37℃ in the water bath (about 20 
minutes) before use. The freezing vial of cells from the liquid N2 cell bank was 
warmed up to 37℃ in the water bath. The cell suspension was then added to 10ml 
of pre-warmed cell culture medium in a 15ml tube. (To defrost HMVEC-Ls and 
HUVEC cells, the cells were added directly into one or two T25 cell culture flasks.) 
After centrifugation of the cell suspension for 5 minutes at 1000 (*g), the 
supernatant was discarded. The cell pellet was resuspended in 10ml pre-warmed cell 
culture medium and seeded into a T25 cell culture flask. The cells were incubated at 
37℃ in a humidified atmosphere of 5% CO2, 95% O2. The culture medium was 
changed every four days. 
 
3.7 Detachment of the Cells with Trypsin or Non-enzymatic Cell 
Dissociation Solution 
Sub-confluent cells in T-25 cell culture flasks were rinsed with 10ml each time 
PBS before 1ml Trypsin (with 0.5% porcine Trypsin and 0.2% EDTA) or 2ml non-
enzymatic cell dissociation solution (NECDS) was added into each T25 flask for 5 to 
10 minutes at 37℃ until the cells became detached from the flasks. After addition of 
10ml pre-warmed culture medium, the cell clumps were dispersed by repeated 
aspiration of the cell suspension 10 times using a 10ml pipette, to produce a 
dispersed cell suspension. 
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3.8 Cell Adhesion Assay 
HMVECs were released from the culture flasks by trypsinization and suspended 
at 2 x 105/ml before application of 200μl/well to each well to be used in 96-well 
plates. The medium in each well was replaced with 200μl/well fresh EGM-2 medium 
after three hours in order to remove residual Trypsin. The cells were incubated at 
37℃ for one day for the formation of the cell monolayers. The HMVEC-Ls 
monolayers were treated with or without 1µg/ml of galectin-3 or BSA in the 
presence or absence of lactose (100µM) for 1 hr or 24 hrs. The HMVEC monolayer 
was then washed with PBS and used for subsequent assessment of cancer cell 
adhesion. 
The HMVEC cells used for obtaining the conditioned medium were released 
from the culture flasks by trypsinization and suspended at 2 x 105/ml with EBM-2 
culture medium before application of 2ml/well to each well to be used in six-well 
plates. The medium in each well was replaced with fresh EGM-2 medium after three 
hours in order to prevent the harmful effect Trypsin could have. The cells were 
incubated at 37℃ for one day for the formation of cell monolayers before they were 
treated with 1µg/ml of galectin-3 or BSA in the presence or absence of lactose 
(100µM) for 1 hr or 24 hr. The conditioned medium from each well was collected for 
future use. 
The ACA19- and HCT116 cancer cells used for acquiring the conditioned medium 
were detached from the culture plates by trypsinization before their confluence 
reached 80%. They were suspended at 1 x 106/ml with serum-free DMEM medium 
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before application of 2ml/well in six-well plates in which each well to be used was 
coated with Poly-HEMA 3ml/well twice. The cells were incubated at 37℃ for one day 
before 1µg/ml galectin-3 or BSA was added to each well. After 1 hr or 24 hr 
treatment, the conditioned medium from each well was collected. 
The ACA19- and HCT116 cancer cells used for assessment of cell adhesion were 
detached from the culture plates with NECDS before their confluence reached 80%, 
which released the cells from the culture flasks while still keeping the cell surface 
proteins intact, washed and resuspended at 5x106cells/ml in serum-free DMEM 
medium. The ACA19- and HCT116 cancer cells were labeled with 10μl/ml Calcein AM 
Cell Labeling Solution at 37℃ for 30 minutes.  
The ACA19- and HCT116 cancer cells were washed and resuspended with 
obtained conditioned medium or serum-free DMEM medium at concentration of 
5x104/ml before application (5x103/well) to the HMVEC monolayer for 1 hr at 37℃. 
The HMVEC monolayer was washed twice with PBS and the endothelial cell-
associated fluorescence was measured with a TECAN infinite F200 fluorescent 
microplate reader with Excitation Wavelength 485nm, Emission Wavelength 535 nm, 
Excitation Bandwidth 20nm, Emission Bandwidth 25nm and Gain 50 Manual. 
 
3.9 Electrophoresis and Lectin/Immunoblotting 
Up to 80% confluent cells in a T25 flask were washed with PBS 10ml twice. A 
1ml/T25 flask SDS (sodium dodecyl sulfate) – sample buffer (see below) – was added 
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and incubated for 20 minutes at room temperature. The cell lysates were collected 
in a 1.5ml tube and kept at -20℃ until use. 
Table 3.1 SDS- sample buffer: 
 2 fold 4 fold 
Stacking buffer 2.5ml 0 
Glycerol 1.0ml (20%) 2ml 
Mercaptoethanol 0.5ml (10%) 1ml 
20% SDS 1.0ml (4%) 2ml 
1% Bromophenol blue 50μl 0.1ml 
 
Table 3.2 Separating gel preparation: 
Separating gel 4% 7.5% 10% 15% 
Deionized water 6ml 4.85ml 4.2ml 2.35ml 
1.5M Tris-HCl resolving gel 2.5ml 2.5ml 2.5ml 2.5ml 
Buffer 
10% (w/v) SDS 100μl 100μl 100μl 100μl 
30% 
acrylamide/bisacrylamide 
1.35ml 2.5ml 3.33ml 5ml 
TEMED 5μl 5μl 5μl 5μl 
10% ammonium persulfate 65μl 50μl 50μl 50μl 
 
Table 3.3 Stacking gel preparation: 
Stacking gel 3.75% 4.00% 
Deionized water 3.09ml 3.05ml 
0.5M Tris-HCl stacking gel buffer 1.25ml 1.25ml 
10%(w/v)SDS 50μl 50μl 
30% acrylamide/bisacrylamide 0.625ml 0.665ml 
TEMED 10μl 10μl 
10% ammonium persulfate 65μl 50μl 
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After the glass plates and spacers (1.0mm thick) were assembled, the running 
gel was poured to about 1cm below the wells of the comb (~4.9ml). Then 80μl 
water-saturated butanol-1 was added on top of the gel (added from the corner of 
the gel). When the gel had set (~ 40 minutes), the butanol was poured off and the 
gel was rinsed with about 2ml deionized water three times. Stacking gel was added 
and the 1.0mm thick comb inserted immediately. When the stacking gel had set, the 
glass plates were placed in a gel rig and immersed in buffer. Prior to running the gel, 
the wells were flushed out thoroughly with running buffer. 
Table 3.4 Running buffer preparation: 
Running buffer:  
Tris-Base 30.67g 
Glycine 64.04g 
SDS 2.2g 
Make up with ddH2O 4L 
 
Running the gels 
The samples were heated at 100℃ for 10minutes before being loaded onto the 
gels.  
Then the protein was transferred to nitrocellulose membrane 
Table 3.5 Transfer buffer preparation: 
Transfer buffer  
Tris-Base 12.12g 
Glycine 57.65g 
Methonal 800ml 
Make up with ddH2O 4L 
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The gel was sandwiched as negative pole (black) - sponge – filter paper – gel – 
nitrocellulose membrane – filter paper – sponge – positive pole (white) and 
transferred at 100V for 1 hr. 
After electrode transfer, the nitrocellulose membrane was stained with 
Ponceau S (0.1% Ponceau S in 1% acetic acid) solution for 2-3 minutes to visualize 
the protein bands. To get a clearer view of the bands, the blots were washed several 
times with 1% acetic acid. The Ponceau staining was removed by washing the blot 
several times with PBS. 
Immunoblotting 
The membrane was blocked in blocking buffer (1% BSA in 1% TWEEN20 in PBS) 
for 30 minutes at room temperature or 4℃ overnight. 
The first antibody in 1% BSA in TWEEN20 in PBS was then applied to the 
membrane according to the concentrations specified in the results section for 1 hr at 
room temperature. The blot was washed three times with 1% TWEEN20 in PBS 
100ml/time with rolling on a rolling machine for 10 minutes each time. After removal 
of the solution, the secondary antibody diluted in 1% BSA in TWEEN20 in PBS was 
applied for 1 hr at room temperature. After the membrane was washed 3-5 times 
with 1% TWEEN20 in PBS 100ml each time, the binding was visualized by means of 
enhanced chemiluminescence (ECL) through Bio-RAD Image LabTM and Bio-RAD 
software version 2.0. 
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3.10 Human Cytokine Array 
All reagents were brought to room temperature. The vial of Detection Antibody 
Cocktail which is lyophilized biotinylated antibodies was reconstituted in 100µl of 
deionized water. The bottle of 40ml of 25X Wash Buffer Concentrate was diluted 
into 960ml deionized water.  
Two milliliters of Array Buffer 4 were pipetted into each well of the four-well 
multi-dish used. The membranes to be used were removed from between the 
protective sheets by flat-tip tweezers and placed in one well of the dish. The array 
number was kept facing upward. The membranes were incubated for 1 hr on a 
rocking platform to block non-specific bindings.  One ml of the supernatant to be 
tested was taken out and added to separate tubes with 0.5ml of Array Buffer 4. 
Fifteen microliters of reconstituted Cytokine Array Panel Detection Antibody Cocktail 
was added to each prepared sample and mixed incubated at room temperature for 1 
hr. After 1 hr of blocking, Array Buffer 4 was aspirated from the wells of the dish and 
prepared sample/antibody mixtures were added. The four-well multi-dish was then 
incubated overnight at 2-8 ℃ on a rocking platform with the lid on. 
The next day, each membrane was removed and placed in individual plastic 
containers with 20ml of 1X Wash Buffer. The four-well multi-dish was rinsed with 
deionized water and dried thoroughly. Each membrane was washed three times on a 
rocking platform shaker, 10 minutes for each wash. The Streptavidin-HRP was 
diluted in Array Buffer 5 to a ratio of 1:2000, and 1.5ml of diluted Streptavidin-HRP 
was pipetted into each well of the four-well multi-dish. The dish was incubated for 
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30 minutes on a rocking platform with the lid on. After that, each membrane was 
washed three times more, and incubated with chemiluminescent detection reagent 
for two minutes. The binding was visualized with enhanced chemiluminescence (ECL) 
through Bio-RAD Image LabTM and Bio-RAD software version 2.0. The quantification 
tool in the software enabled a relative reading to be taken for each spot and the 
average of each pair was considered as the reading for each cytokine.  
 
3.11 Human Phospho-Kinase Array 
To prepare the samples, eighty per cent confluent HMVEC-Ls cells were 
incubated with 1µg/ml galectin-3 or BSA control at 37℃ for 24 hr before release 
from the culture flasks by trypsinization and centrifuged at 1000 (*g) for five minutes 
to remove the supernatant. The cell pellets were resuspended by 10ml PBS before 
the cell suspension was immediately transferred into two tubes pre-cooled on an ice 
box. After centrifugation at 1000 (*g) for five minutes at 4℃, the tubes were put 
back on the ice box and the supernatants from the samples were completely 
removed. The cell pellet was lysed by 0.4ml/tube Lysis Buffer 6 from the Human 
Phosphorylation Kinase Array Kit, pipetted up and down several times and left on the 
rocking platform in the ice box for 30 minutes. Then each tube was centrifuged at 
14000 x g for five minutes, before the supernatants were transferred into clean 
tubes and used as samples. 
To prepare the array, 1.0ml of Array Buffer 1 was added to four wells of an 
eight-well multi-dish. Each membrane to be used was removed from between the 
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protective sheets and placed in each well with buffer. After 1 hr incubation on a 
rocking platform, Array Buffer 1 was removed and 334ul/each sample was added to 
1666µL/each of Array Buffer1 and 1.0ml of each diluted sample was added to both 
Part A and Part B membranes. The plate was incubated overnight with a lid on at 2-
8℃ on a rocking platform. 
The next day, each membrane was removed and placed in individual plastic 
containers, and washed by 20ml of 1x Wash Buffer for 10 minutes on a rocking 
platform three times. For each Part A membrane, 20µL of reconstituted Detection 
Antibody Cocktail a was diluted to 1.0mL with 1X Array Buffer 2/3, and 1.0ml diluted 
Detection Antibody Cocktail A was added to the wells of an eight-well multi-dish. 
Each Part A membrane was returned to the wells containing the diluted Detection 
Antibody Cocktail A. For each Part B membrane, 20µL of reconstituted Detection 
Antibody Cocktail B was diluted to 1.0mL with 1X Array Buffer 2/3, and 1.0ml diluted 
Detection Antibody Cocktail A was added to the wells of an eight-well multi-dish. 
Each Part A membrane was returned to the wells containing the diluted Detection 
Antibody Cocktail B. After the plate was covered by the lid, it was placed on the 
rocking platform to incubate for two hours at room temperature. After that, each 
membrane was placed in individual plastic containers with 20ml of 1X Wash Buffer, 
and washed three times for ten minutes on a rocking platform. The Streptavidin-HRP 
was diluted in 1X Array Buffer 2/3 and 1.0 mL diluted Streptavidin-HRP was added 
and incubated for 30 minutes in each well of the eight-well multi-dish. After three 
more washes, the membranes were exposed to chemiluminescent reagents for 2 
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minutes and visualized with enhanced chemiluminescence (ECL) through Bio-RAD 
Image LabTM and Bio-RAD software version 2.0. 
 
3.12 Sandwich ELISA Assay for Cytokine quantification in Cell 
Culture Supernatants and Human Serum Samples 
HMVECs were released from the culture flasks by trypsinization (1ml Trypsin for 
each T25 flask) and suspended at 1 x 105/ml with EBM-2 culture medium. HMVEC 
suspensions were cultured in a 12-well plate (1ml/well) at 37℃ for 24 hr before 
introduction of a certain concentration of recombinant galectin-3 or BSA for 24 hr. 
The conditioned medium (CM) was collected and the concentrations of cytokines in 
the conditioned medium were analyzed using Cytokine ELISA kits (R&D systems)  
Wells of a high-binding 96-well plate of half volume were coated with 50μl of 
Cytokine Capture Antibody (either anti-G-CSF: 2.0µg/ml; anti-GM-CSF: 2.0µg/ml; 
anti-IL-6: 2.0µg/ml; or anti-ICAM-1: 4.0µg/ml). The plate was sealed and left 
overnight at room temperature. On the next day, the plate was washed three times 
with 150μl per well washing buffer (0.05% Tween20 in PBS) and 150μl of Reagent 
Diluent (1% Bovine Serum Albumin (BSA) in PBS, pH 7.2-7.4) was applied to each well 
for a minimum of 1 hr as blocking buffer. The wells were washed another three 
times with 100μl washing buffer per well per time. To provide samples, the 
conditioned medium was collected and centrifuged at 1000 (*g) for 1 min to remove 
floating cells, while the human serum samples were diluted with PBS. Then 6-9 
points’ serial twofold standard dilutions as well as 50μl of samples were added to the 
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wells and incubated for at least two hours. After that, the wells were washed three 
times with 100μl washing buffer per well and 50μl of detection antibody, were 
added to the wells (biotinylated anti-G-CSF: 200ng/ml; biotinylated anti-GM-CSF: 
500ng/ml; biotinylated anti-IL-6: 50ng/ml; biotinylated anti-ICAM-1: 100ng/ml, 
diluted in reagent diluent) and incubated for at least two hours. The wells were 
washed three times with 100μl washing buffer per well per time, and 50μl of 
Streptavidin-HRP at working concentration (1:200) was added to each well and 
incubated for 20 minutes at room temperature. The wells were washed three times 
with 100μl washing buffer per well. Sigma-Aldrich FAST OPD tablets (Sigma-Aldrich) 
were dissolved in 20ml distilled H2O and 50μl applied to each well for approximately 
20 minutes until the color turned from an yellow/orange color developed in the 
standard curve of the cytokine standard. The reaction was stopped with 25μl 4M 
sulphuric acid, concentration-associated visible light intensity was measured with a 
TECAN Sunrise microplate reader in which the subtract readings setting was 492nm. 
 
3.13 In vivo experiments to assess effects of galectin-3 on cytokine 
secretion 
In the study, balb/c nude female mice age 7-8 weeks were used.  They were 
housed in specific pathogen free conditions with a 12:12 hour light: dark cycle with 
free access to food and water.  The project license number is 40/3392. 
To assess the influence of galectin-3 on cytokine secretion in vivo, we injected 
galectin-3, at concentrations designed to reproduce similar circulating 
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concentrations to those found in patients with metastasis, intravenously via the tail 
vein into the mice and 100µl blood was taken from three mice without galectin-3 
injection to use as control. Then 100µl galectin-3 (5µg/mouse) was injected into 
three mice and after 24 hr, these three mice were sacrificed by CO2 and intra-cardiac 
puncture was carried out. Then 5µg/mouse galectin-3 (100µl) was injected into 
another three mice and after 48 hr the mice were sacrificed by CO2 and intra-cardiac 
puncture was carried out. The cytokine concentrations in the collected sera were 
later assessed by means of ELISA. 
 
3.14 Sandwich ELISA Assay for the quantification of cytokines in Mouse 
Sera 
Wells of a high-binding 96-well plate of half volume were coated with 50μl of 
Cytokine Capture Antibody (either anti-G-CSF: 0.5µg/ml; anti-GM-CSF: 0.5µg/ml or 
anti-IL-6: 2.0µg/ml). The plate was sealed and left overnight at room temperature. 
On the next day, the plate was washed three times with 150μl per well washing 
buffer (0.05% Tween20 in PBS) and 150μl of Reagent Diluent (1% BSA in PBS, pH 7.2-
7.4) was applied to each well for a minimum of 1 hour as blocking buffer. The wells 
were washed another three times with 100μl washing buffer per well per time. 
Mouse serum samples were diluted by PBS after pilot studies to assure that the final 
concentration was in the measuring range of the kit. Then 6-9 points’ serial twofold 
standard dilutions as well as 50μl of samples were added to the wells and incubated 
for at least two hours. After that, the wells were washed three times with 100μl 
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washing buffer per well. Then 50μl of detection antibody were added to the wells 
(either biotinylated anti-G-CSF: 250ng/ml; anti-GM-CSF: 250ng/ml or anti-IL-6: 
500ng/ml) and incubated for at least two hours. The wells were washed three times 
with 100μl washing buffer per well and 50μl of Streptavidin-HRP at working 
concentration (1:2000) were added to each well and incubated for 20 minutes at 
room temperature. The wells were washed three times with 100μl washing buffer 
per well per time. Sigma-Aldrich FAST OPD tablets (Sigma-Aldrich) were dissolved in 
20ml distilled H2O and 50μl applied to each well for approximately 20 minutes until 
the color turned from an yellow/orange color developed in the standard curve of the 
cytokine standard. The reaction was stopped with 25μl 4M sulphuric acid, 
concentration-associated visible light intensity was measured with a TECAN Sunrise 
microplate reader in which the subtract readings setting was 492nm. 
 
3.15 Quantification of sICAM-1 in Mouse Sera by ELISA  
Mouse sera obtained as above were diluted and the levels of sICAM-1 were 
assessed with Quantikine ELISA kits. 
The Kit Control was reconstituted with 1.0mL distilled water. Then 25mL Wash 
Buffer concentrate was added to distilled water to obtain 625 mL of Wash Buffer. 
Then 20 mL of Calibrator Diluent RD5-26 Concentration was added to 60 mL of 
distilled water to prepare 80 mL of Calibrator Diluent RD5-26 (1X). Mouse sICAM-1 
Standard was reconstituted by adding 5.0 ml of Calibrator Diluent RD5-26 (1X). After 
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the standard had been thoroughly mixed it was kept for 5 minutes with gentle 
mixing prior to making dilutions.  
Then 50μl of Assay Diluent RD1-21 was added to each well followed by 50μl of 
standard and samples, and incubated for 2 hours. Each well on the plate was washed 
three times with 400μl Wash Buffer per well five times. After the last wash, any 
remaining wash buffer was removed by inverting the plate and blotting it against 
clean paper towels. Next 100μl of Mouse sICAM-1 Conjugate was added to each well 
followed by two hours' incubation. After another five washes, 100μl of Substrate 
Solution was added to each well and incubated for 30 minutes without exposure to 
the light. The reaction was stopped with 100μl Stop Solution from the kit and read by 
a plate microreader (Tecan), in which the subtract readings setting was OD 570nm 
from the reading at OD 450nm. 
 
3.16 Assessment of Endothelial Cell Surface Adhesion Molecule 
expression by Flow Cytometry 
Sub-confluent HMVEC-Ls cells were treated with galectin-3 (1.5µg/ml) in the 
presence or absence of 10µM lactose for 24 hr or recombinant G-CSF (2.5ng/ml), 
GM-CSF (30pg/ml), IL-6 (200pg/ml) and sICAM-1 (500pg/ml) as a group or separately 
for 1 hr before they were released by 1ml non-enzymatic cell dissociation solution 
(0.5mg/ml) incubated for 5-10 minutes at 37℃.The cells were washed with 10ml 
sterile PBS and the supernatant discarded after centrifugation at 1000 (*g) for five 
minutes. After removal of the supernatant, 5ml 2% paraformaldehyde was added to 
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fix the cells for at least 25 minutes at room temperature. Then the cells were washed 
twice with 10ml PBS and centrifuged at 1000 (*g) to remove the supernatants. The 
number of cells was counted and the cells were resuspended at a concentration of 
106/ml with PBS and incubated with 5% goat serum for 30 minutes at room 
temperature on the roller. After removal of the supernatant following centrifugation 
at 1000 (*g) for 5 minutes, the cells were resuspended at the concentration of 
106/ml in the 1% goat serum in PBS and divided 1ml/tube in 1.5ml tubes. Antibodies 
against CD44 (1mg/ml), α5β1 (1mg/ml), α5β3 (1mg/ml), E-selectin (1mg/ml), VCAM 
(1mg/ml) and ICAM (1mg/ml) all in 1:400 dilution with PBS were applied to the cell 
solutions for 1 hr at room temperature on the roller (or overnight at 4℃). After they 
were washed twice with PBS, fluorescence (FITC)-conjugated secondary antibodies 
(1:400 in 1% BSA in PBS) were applied for 1 hour at room temperature. After three 
washes with PBS, the cells were resuspended in PBS in 0.5ml/tube. The cell surface 
expression of CD44, α5β1, α5β3, E-selectin, VCAM and ICAM was analyzed by flow 
cytometry. Fluorescent conjugated secondary antibody without addition of the 
primary antibody was used as a negative control in all the experiments. 
 
3.17 In Vitro Angiogenesis Assay- Endothelial Cell Invasion 
The HMVEC cells were released by trypsinization and were seeded into a 24-
well plate for 24 hours at a concentration of 1 x 105/ml in EBM-2 medium. Then to 
each pair of wells were added 1.5µg/ml BSA (control), recombinant galectins-3 or 
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recombinant galectins-3 + 100µM final concentration of lactose. The plate was 
incubated at 37℃ for 48 hr for production of the conditioned medium (CM).  
To obtain an invasion device 5ml of 1X BME solution were made in a sterile 
15ml conical tube and gently inverted to mix on ice and 50μl of BME Coat and then 
50μl 1X Coating Buffer were added to the top chamber of each well of a 24-well cell 
invasion device. Dispersion of coating of wells can be visually inspected by gently 
tapping the side of the cell invasion chamber a few times. The cell invasion chamber 
was incubated overnight at 37℃ in a CO2 incubator. 
A fresh flask of HMVEC-Ls cells was harvested with Trypsin and washed with 
PBS. After being centrifuged at 1000 (*g) for five minutes, the cells were 
resuspended at a concentration of 4 x 105cells/ml with EBM-2 medium. The cell 
suspension was mixed and aliquoted to 200µl/each to sterile centrifuge tubes. The 
cells were then centrifuged at 1000 (*g) for five minutes and resuspended with 
200µl CMs collected from the 24-well plate of the HMVEC-Ls culture with and 
without addition of neutralizing anti-cytokine antibodies or recombinant cytokines 
(BSA-treated control group; Gal-3-treated group; Gal-3-plus 100μM lactose inhibitory 
group; Gal-3-treated group plus four anti-cytokine antibodies (G-CSF, GM-CSF, IL-6 
and sICAM-1); BSA-treated control plus four recombinant cytokines (G-CSF, GM-CSF, 
IL-6 and sICAM-1)). Coating solution was carefully aspirated from the top chamber of 
the cell invasion device, and the top and bottom chambers were kept wet all the 
time. Then 50μl of cell suspension (20,000 cells /well) were added to each well of the 
top chamber and 150μl/well of serum-free EBM-2 medium were added to each well 
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of the bottom chamber. Then the cells were incubated at 37℃ in a CO2 incubator for 
24 hours. 
After incubation, the top chamber was aspirated and washed with 100μl of 1X 
wash buffer without puncturing the membrane. The bottom chamber wells were 
also aspirated by disassembling and reassembling device with the assay chamber 
plate for minimal background signal. Then 10μl of Calcein-AM solution were mixed 
with 10ml of 1X Cell Dissociation Solution and 250μl/well of Cell Dissociation 
Solution/Calcein AM were added to the bottom chamber at 37℃ in the CO2 
incubator for 30 minutes. The plate was tapped 10 times on the side gently and 
incubated at 37℃ for an additional 30 minutes (1 hr in total). After disassembly of 
the cell migration device, the assay chamber (bottom) was read at 485nm excitation 
/ 520nm emission. 
 
3.18 In Vitro Angiogenesis Assay - Endothelial Tube Formation  
Endothelial cells (HMVEC-Ls/HUVEC) were seeded in a T25 tissue culture flask 
until 80% confluence was reached prior to assay. Cultrex RGF BME was thawed at 2-
4℃ overnight in a refrigerator. The tips and 96-well plates to be used were also kept 
in the refrigerator overnight. 
50μl of BME solution were aliquoted into each well of a 96-well plate on ice. 
The plate was centrifuged at 1000 (*g) for 5 minutes at 4℃ to make sure no air 
bubbles were trapped in the BME and then the plate was incubated at 37℃ for 45 
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minutes. Then 5μl of 2mM Calcein AM Working Solution were added to 5ml EBM-2 
to make a 2μM Calcein AM solution. HMVEC-Ls/HUVEC cells were incubated with 
Calcein AM solution (5 ml per T25 flask) for 30 minutes at 37℃ in a CO2 incubator. 
The cells were washed twice with 5ml sterile room temperature PBS and 1ml of 
Trypsin was added, before the cells were incubated at 37℃ for four minutes. After 
that, 10ml of PBS were added and the cells were transferred into a 15ml conical 
tube. The cells were centrifuged at 1000 (*g) for four minutes, and the supernatant 
was removed. The cells were resuspended with 200μl PBS. The cells were diluted in 
CM collected from HMVECs treated with/without galectin with/without the presence 
of the inhibitors and with/without anti-cytokine antibodies or recombinant cytokines 
as above. Then 100μl of diluted cells (1 x 105 cells /ml) were added slowly to each 
well containing gelled BME. The plate was then incubated at 37℃ in a CO2 incubator 
for three to 24 hours. The tube formations were visualized by microscope. The 
pictures of the whole wells of each group were taken and the number of tubes and 
nodules as well as the length of each tube within were measured and recorded.  
 
3.19 Human Matrix metalloproteinase Array 
HMVEC-Ls were released from the culture flasks by trypsinization (1ml 
Trypsin for each T25 flask) and suspended at 2 x 105/ml with EBM-2 culture medium 
before the application of 200μl/well to each well on the top chamber of the cell 
invasion device while 150μl/well serum-free EBM-2 were added to each well on the 
bottom chamber before incubation for 24 hr at 37℃. The medium in the top 
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chamber wells was replaced with fresh EGM-2 medium after three hours to remove 
residual Trypsin. On the next day, the medium in the top chamber wells was 
replaced by a medium with 1.5µg/ml BSA (control) or recombinant galectins-3 
respectively, and the serum-free EBM-2 was renewed as well. After 24 hr incubation 
at 37℃, the medium in the bottom chamber wells was collected and the levels of 
MMP were analyzed. 
Each membrane in the array was placed into the provided eight-well tray before 
2 ml 2X Blocking Buffer were added and incubated at room temperature for 30 
minutes. After Blocking Buffer was decanted, 1 ml of collected conditioned medium 
was added to each well to incubate with the membrane overnight at 4℃. After the 
conditioned medium was discarded from each well, each membrane was washed 
three times (each for 5 minutes) with 2 ml of 1X Wash Buffer I at room temperature 
with shaking, followed by two washes (each for 5 minutes) with 2 ml of 1X Wash 
Buffer II at room temperature with shaking. Then 1 ml of diluted biotin-conjugated 
antibodies was added to each membrane and incubated at room temperature for 
two hours. After each well was decanted, each membrane in the well was washed 
three times (each for 5 minutes) with 2 ml of 1X Wash Buffer I at room temperature 
with shaking, followed by two washes (each for 5 minutes) with 2 ml of 1X Wash 
Buffer II at room temperature with shaking. Then 2 ml of diluted HRP-Conjugated 
Streptavidin were added to each well and incubated for two hours. Each well was 
decanted, and each membrane in the well was washed three times (each for 5 
minutes) with 2 ml of 1X Wash Buffer I at room temperature with shaking, followed 
by two washes (each for 5 minutes) with 2 ml of 1X Wash Buffer II at room 
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temperature with shaking. For each membrane, 250µl of 1X Detection Buffer C and 
250µl of 1X Detection Buffer D was mixed, which was pipetted onto the membrane 
on a clean plastic sheet provided by the kit and incubated for 2 minutes. After the 
detection reagent was drained off, another piece of plastic sheet was placed on the 
array and the chemiluminescence signal was visualized with Bio-RAD Image LabTM 
and Bio-RAD software version 2.0. 
 
3.20 In Vivo Assessment of the effect of Galectin-3 Induced 
Cytokine Secretion on Metastasis in Mice 
To directly assess the influence of galectin-3-induced cytokine secretion on 
metastasis, either PBS or a combination of cytokines (2µg ICAM-1 and 20ng each of 
GM-CSF, G-CSF and IL-6) was injected at similar levels to those observed in mouse 
serum following galectin-3 injection.  One dose was administered 4 hr prior to 
injection of ACA19- cells mixed with a second dose of PBS or cytokines. Eight mice 
were treated per experimental group. One mouse per group was sacrificed after four 
weeks and six weeks post-injection and metastatic foci in the lungs were examined 
by direct observation through a microscope and by section staining. Remaining 
animals were scarified eight weeks post-injection in order to develop macroscopic 
tumors, and metastases on the lung, liver, brain and kidney were all examined (this 
part of the experiment was conducted by Dr Carrie Duckworth in our department). 
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3.21 Human Samples 
Fifty serum samples from colorectal cancer patients (aged 25 to 91), 39 without 
clinically detectable metastasis (25 males and 14 females) and 11 with liver 
metastasis (seven males and four females) were obtained from the Cancer Tissue 
Bank Research Centre (CTBRC) cancer tissue bank (Liverpool, UK). These serum 
samples were obtained from patients at the time of primary tumor resection at the 
Royal Liverpool University Hospital. The length of survival of these patients in the 
next 10 years was followed up. Thirty-one serum samples from healthy people (13 
Male and 19 female) were obtained from Sera Laboratories International (Haywards 
Heath, UK). The patients’ ages were from 25 to 91 (mean age 63). 
 
3.22 Statistics 
Data were analyzed using independent t test, analysis of variance and one-way 
ANOVA followed by Bonferroni or Spearman rank correlation depending on the 
experiment or context. Two-sided p-values with values < 0.05 were reported as 
statistically significant. 
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CHAPTER 4 INVESTIGATION OF THE MUC1-INDEPENDENT 
ACTION OF CIRCULATING GALECTIN-3 ON METASTASIS 
PROMOTION 
4.1 Hypothesis and Aim 
4.1.1 Hypothesis 
Circulating galectin-3 has MUC1-independent actions in its effect on metastasis 
promotion that may be mediated via cytokine release and its subsequent impact on 
cell-endothelial adhesion. 
 
4.1.2 Aim 
To investigate the MUC1-independent actions of circulating galectin-3 on 
metastasis promotion, including effects on cytokine production and cell-endothelial 
adhesion. 
 
4.2 INTRODUCTION 
Galectin-3 is a galactoside-binding, multi-functional protein that is expressed by 
many types of human cells. Galectin-3 is found inside cells, extracellularly on the cell 
surface as well as in the blood circulation. Intracellular galectin-3 is an apoptosis 
inhibitor and mRNA splicing promoter (384) whereas cell surface-associated 
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extracellular galectin-3 acts as an adhesion molecule in cell-cell and cell-matrix 
interactions and facilitates cancer progression and metastasis(385). The 
concentrations of free circulating galectin-3 are increased up to 30-fold in the 
bloodstream of various cancer patients including breast, colorectal(321), lung(322), 
bladder(323), head and neck(324) and melanoma(325). Patients with metastatic 
disease are also seen to have higher concentrations of circulating galectin-3 than 
those with only localized tumors. In patients with melanoma, a high serum galectin-3 
level has been shown to correlate significantly with poor outcome (386). 
Our recent studies have shown that galectin-3 binds to the TF antigen on 
cancer-associated MUC1 and induces MUC1 cell surface polarization and exposure of 
the underlying adhesion molecules, which results in increased cancer cell adhesion 
to the vascular endothelium and increased cancer cell homotypic aggregation for the 
formation of tumor emboli in the circulation. Co-injection of galectin-3 with MUC1-
positive human melanoma ACA19+ cells to the tail vein of nude mice caused 
increased lung metastasis (326). These results suggest an important role of the 
increased circulation of galectin-3 in promoting tumor cell metastatic spread. 
Interestingly, co-injection of galectin-3 with the MUC1-negative human melanoma 
ACA19- cells also caused a smaller increase of lung metastasis of the animals (327). 
This indicated that circulating galectin-3 probably has another MUC1-independent 
action in its promotion of metastasis. 
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4.3 METHODS 
4.3.1 Collection of conditioned medium from cancer cells 
ACA19- and HCT116 cancer cells were detached from the culture plates by 
trypsinization and suspended at 2 x 105/ml with serum-free DMEM medium before 
application in six-well plates in which every well to be used was pre-coated with 
Poly-HEMA. The cells were incubated for 24 hr at 37 ℃ before 1µg/ml galectin-3 or 
BSA was added to each well. After 1 hr or 24 hr treatment, the conditioned medium 
from each well was collected. 
 
4.3.2 Collection of conditioned medium from HMVEC-Ls  
As regards the HMVEC-Ls cells used for obtaining the conditioned medium, 
HMVEC-Ls were released from the culture flasks by trypsinization and suspended 
with EBM-2 culture medium at concentration of 2 x 105/ml before application 
(2ml/well) to each well to be used in six-well plates. The medium in each well was 
replaced with fresh EGM-2 medium after three hours. The cells were incubated (one 
day) until the formation of cell monolayers before they were treated with 1µg/ml of 
galectin-3 or BSA in the presence or absence of lactose (10µM) for 1 hr or 24 hr. The 
conditioned medium from each well was collected for future use. 
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4.3.3 Assessment of galectin-3-mediated cancer cell-endothelial 
adhesion 
HMVEC-Ls were released from the culture flasks by trypsinization and 
suspended with EBM-2 culture medium before application of 200µl/well to each well 
to be used in 96-well plates. The medium in each well was replaced with 150µl fresh 
EGM-2 medium after three hours. The cells were incubated at 37 ℃ until the 
formation of cell monolayers (one day) before they were treated with 1µg/ml of 
galectin-3 or BSA in the presence or absence of lactose (10µM) for 1 hr or 24 hr. The 
HMVEC monolayer was then washed and used for subsequent assessment of cancer 
cell adhesion. 
HMVEC-Ls were released from the culture flasks by trypsinization and 
suspended at 2 x 105/ml with EBM-2 culture medium before application of 
200µl/well to each well to be used in 96-well plates. The medium in each well was 
replaced with 150µl fresh EGM-2 medium after three hours for one day for the 
formation of cell monolayers (one day). The HMVEC monolayer was then washed 
and used for subsequent assessment of cancer cell adhesion. 
The ACA19- and HCT116 cancer cells used for assessment of cell adhesion were 
detached from the culture plates with NECDS, washed and resuspended in serum-
free DMEM medium (for ACA19 or McCoy’s 5a medium for HCT116). The ACA19- and 
HCT116 cancer cells were labeled with Calcein AM Cell Labeling Solution (10 µl for 1 
ml of cell suspension). The ACA19- and HCT116 cancer cells were washed and 
resuspended with serum-free medium at concentration of 5 x 104/ml before 
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application 100µl/well to HMVEC monolayer for 1 hr. The HMVEC monolayer was 
washed and the endothelial cell-associated fluorescence was measured. 
 
4.3.4 Cytokine Determination by Human cytokine array 
HMVEC-Ls were released from the culture flasks by trypsinization (1ml Trypsin 
for each T25 flask) and suspended at 1 x 105/ml with EBM-2 culture medium. 
HMVEC-Ls suspensions were cultured in a six-well plate (2ml/well) at 370C for 24 hr 
before the introduction of 1.0µg/ml recombinant galectin-3 or BSA for 24 hr. The 
conditioned media were collected and the concentrations of cytokines in the culture 
media were analyzed by Human Cytokine Protein Arrays. 
For the assessment of galectin-3 effect on cytokine secretion from cancer cells, 
ACA19- cells were released from the culture flasks by trypsinization (1ml Trypsin for 
each T25 flask) and were seeded at a concentration of 5x105cells/ml into six-well 
plates that were pre-coated with 10mg/ml poly-HEMA for 24 hr (381). The cells were 
cultured under suspension condition in the presence of 1.0µg/ml galectin-3 or BSA 
for 24 hr at 37℃. The culture media were collected by 1000 (*g) centrifugation of 
the cell suspension and the concentrations of cytokines in the culture media were 
analyzed by Human Cytokine Protein Arrays.  
Briefly, 1ml of the conditioned medium was added to a separate tube with 15µl 
reconstituted Cytokine Array Panel Detection Antibody Cocktail. At the same time, 
the kit membranes to be used were incubated with blocking buffer for 1 hr to block 
108 
 
non-specific bindings. After removal of the blocking buffer by aspiration, the 
conditioned medium/detection antibody mixtures prepared were applied to the 
membrane for overnight incubation. The next day, each membrane was removed 
and washed three times for 10 minutes each time. Then 1.5µl diluted Streptavidin-
HRP was incubated with membrane for 30 minutes followed by another three 
washes and two minutes’ incubation with chemiluminescent detection reagent. The 
arrays were then visualized with the chemiluminescence testing device Bio-RAD 
Image LabTM. 
 
4.4 RESULTS 
4.4.1 Investigation of effect of long-term treatment of cancer cells with 
galectin-3 on their behavior in subsequent cancer cell-endothelial 
adhesion 
Earlier studies in our lab have shown that galectin-3-MUC1 interaction-
associated cancer cell adhesion occurs rapidly, within an hour (381, 387, 388). In 
searching for the MUC1-independent action of circulating galectin-3, we investigated 
whether the long-term presence of galectin-3 (24 hr) has any influence on the 
behaviors of MUC1-negative cancer cells. Cancer cells (ACA19- and HCT116) cultured 
in suspension at a concentration of 1 x 106/ml were treated with 1µg/ml galectin-3, 
BSA or TNF-α (10μg/ml) (positive control) for 24 hr. After washing with PBS, labeling 
with Calcein AM, and further washing with PBS, the cancer cells were centrifuged for 
five minutes. The cell pellets were resuspended at a concentration of 1 x 105/ml and 
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100µl of the suspension was added to the HMVEC-Ls monolayer for 1 hr. After two 
washes with PBS to remove the non-adhesion cells, the fluorescent intensity in each 
well was determined. 
 
 
Fig. 4.1: Long-term presence (24 hr) of galectin-3 increases MUC1-negative cancer cell 
adhesion to HMVEC-Ls. (A) The ACA19- cells were treated with 1.0 µg/ml galectin-3, BSA or 
10µg/ml TNF-α for 24 hr under suspension culture before 1 hr adhesion to HMVEC-Ls monolayer 
was assessed. (B) The ACA19- or HCT116 cells were treated with 1.0 µg/ml galectin-3 or BSA for 
24 hr under suspension culture before 1 hr adhesion to HMVEC-Ls monolayer was assessed. The 
data are expressed as mean ± SD of triplicate determinations of three independent experiments. 
*p<0.05 (one-way ANOVA followed by Bonferroni) 
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It was found that, the presence of TNFα for 24 hr in the culture as a positive 
control showed an increase in ACA19- cell adhesion (Fig. 4.1 A). The presence of 
galectin-3 at a concentration (1μg/ml) similar to that seen in the blood circulation of 
cancer patients for 24 hr in the culture also resulted in significant increase of 
adhesion of ACA19- (48.2±8.5%) and HCA116 (22.9±4.4%) to HMVEC-Ls (Fig. 4.1 B).  
 
Fig. 4.2: Short-term (1 hr) presence of galectin-3 does not influence MUC1-negative cancer 
cell adhesion to HMVEC-Ls. The ACA19- or HCT116 cells were treated with 1µg/ml galectin-3 or 
BSA for 1 hr under suspension culture before 1 hr adhesion to HMVEC-Ls monolayer was 
assessed. The data are expressed as mean ± SD of triplicate determinations of three independent 
experiments (unpaired t test). 
 
Short-term (1 hr) presence of galectin-3 at 1.0 µg/ml did not seem, however, to 
have any significant influence on adhesion of MUC1-negative ACA19- and HCT116 
cells to HMVEC-Ls (Fig. 4.2). 
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4.4.2 Investigation of effect of the conditioned medium obtained from 
galectin-3-treated cancer cells on subsequent cancer cell adhesion to 
HMVEC-Ls 
It was found that the culture medium (CM) obtained from 24 hr galectin-3 
(1µg/ml) treated ACA19- or HCT116 cells had no effect on subsequent adhesion of 
fresh ACA19- or HCT116 cells to fresh HMVEC-Ls. 
 
Fig. 4.3: Galectin-3 does not induce secretion of soluble molecules from cancer cells that 
cause cancer cell-endothelial adhesion. The 24-hr conditioned medium (CM) obtained from 
ACA19- or HCT116 cells treated with or without 1μg/ml galectin-3 under suspension condition 
were used as culture medium to assess adhesion of fresh ACA19- or HCT116 to the fresh HMVEC-
Ls monolayer. The data are expressed as mean ± SD of triplicate determinations of three 
independent experiments (unpaired t test). 
 
This indicates that long-term treatment of galectin-3-mediated cancer cell 
adhesion is not related to cancer cell secretion of soluble factors (Fig. 4.3). 
0
20
40
60
80
100
120
140
ACA19- HCT116
Ca
nc
er
 c
el
l a
dh
es
io
n 
to
 H
M
VE
C-
Ls
(%
 o
f c
on
tr
ol
)
CM of control
cancer cells
CM of Gal3-treated
cancer cells
112 
 
4.4.3 Investigation of effect of long- or short-term treatment of 
HMVEC-Ls with galectin-3 on their behavior in subsequent cancer cell-
endothelial adhesion 
HMVEC-Ls monolayers were treated with 1.0 µg/ml galectin-3 for 1 hr/24 hr 
before washed by PBS. Fresh cancer cells (ACA19- or HCT116) were detached from 
the culture plates with NECDS and washed before being labeled with Calcein AM for 
half an hour. The cancer cells were washed again by PBS before being resuspended 
at a concentration of 1 x 105/ml and 100µl cell suspension was added to each well to 
adhere to the galectin-3-pretreated HMVEC-Ls monolayer for 1 hr. After two washes 
with PBS, the fluorescent intensity of each well was determined. 
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Fig. 4.4: The long-term (24 hr) but not the short-term (1 hr) presence of galectin-3 in 
HMVEC-Ls increases subsequent cancer cell-endothelium adhesion. The HMVEC-Ls monolayer 
was treated with 1µg/ml galectin-3 for 1 hr/24 hr before 1 hr adhesion was assessed. The data 
are expressed as mean ± SD of triplicate determinations of three independent experiments. 
*p<0.05 (unpaired t test) 
 
Pretreatment of the HMVEC-Ls with galectin-3 for 24 hr (Fig. 4.4 B), but not 1 hr 
(Fig. 4.4 A) at (1μg/ml) similar caused a significant increase (48.2±8.5% and 
22.9±4.4%, respectively) in ACA19- and HCT116 cell adhesion. 
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4.4.4 Investigation of the effect of the conditioned medium obtained 
from galectin-3-treated HMVEC-Ls in cancer cell-endothelial adhesion 
The conditioned medium obtained from 24 hr galectin-3 (1µg/ml) treated 
HMVEC-LS cells was collected and used as culture medium to assess adhesion of 
ACA19- or HCT116 to fresh HMVEC-Ls. 
 
Fig. 4.5: Galectin-3 induces secretion of soluble molecules from endothelial cells that 
cause cancer cell-endothelial adhesion in 1 hr. The 24 hr-conditioned medium (CM) from 
HMVEC cells treated with or without 1μg/ml galectin-3 was used as culture medium to assess 
adhesion of fresh ACA19- or HCT116 to fresh HMVEC-Ls monolayer. The data are expressed as 
mean ± SD of triplicate determinations of three independent experiments. *P<0.05 (unpaired t 
test)  
 
The conditioned medium obtained from HMVEC-Ls cells treated with galectin-3 
(1μg/ml) for 24 hr appeared to induce a similarly increased adhesion of fresh ACA19- 
(43.0±14.3%) and HCT116 (74.4±21.2%) cells to fresh HMVEC-Ls (Fig. 4.5). This result 
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indicated that the presence of galectin-3 for a longer period induced release of 
soluble molecules from HMVEC cells, and this release by the endothelial cells is 
largely responsible for galectin-3-mediated adhesion of MUC1-negative cells to 
endothelial cells. 
 
4.4.5 Investigation of effect of galectin-3 treatment with HMVEC-Ls or 
ACA19- cells on cytokine(s) secretion 
Knowing that inflammatory cytokines such as TNFα, IL-1 and IL-6 are important 
metastasis-promoters and are known to promote several steps of the metastatic 
cascade including cancer cell adhesion to endothelium (389, 390), we investigated 
whether the soluble molecule(s) secreted by HMVEC-Ls in response to galectin-3 and 
responsible for galectin-3-mediated adhesion of MUC1-negative cells includes 
cytokine(s). We compared the cytokine profiles in the culture media of HMVEC-Ls 
and ACA19- cells treated with and without galectin-3 using a human cytokine array 
that covers 36 of the most common human cytokines. 
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Fig. 4.6: The presence of galectin-3 induces secretion of four cytokines secreted from 
HMVEC-Ls (A) but not ACA19- cells (B). The levels of 36 common cytokines in the conditioned 
medium (CM) from HMVEC-Ls (A) cells treated with 1.0 µg/ml galectin-3 or BSA for 24 hr or from 
ACA19- cell (B) under suspension were assessed by cytokine protein array. Four cytokines (IL-6, 
G-CSF, GM-CSF and sICAM-1) showed more than twofold increase in the CM of galectin-3-treated 
HMVEC-Ls. The graph shown is representative of 2 independent experiments. 
 
It was found that treatment of HMVEC-Ls with galectin-3 (1µg/ml) for 24 hr 
resulted in increased concentrations of four cytokines - IL-6 (2.1-fold), G-CSF (2.2-
fold), GM-CSF (3.2-fold) and sICAM-1 (2.3-fold) - in the culture medium (Fig. 4.6 A) 
whereas galectin-3 treatment of ACA19- cells showed no difference in the cytokines 
in the culture medium (Fig. 4.6 B). This suggests that the presence of galectin-3 
enhances cytokine secretion from HMVEC-Ls but not ACA19- cells. 
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4.4.6 Investigation of galectin-3-induced cytokine secretion from 
endothelial cells 
4.4.6.1 Investigation of effect of freeze-thaw cycle on galectin-3-
induced cytokine secretion 
We tested the effect of the freezing-thawing cycle of the conditioned medium 
obtained from galectin-3-treated HMVECs on the sensitivity of detection of these 
cytokines. 
HMVEC-Ls cells were treated after 24 hr with various concentrations of galectin-
3. The culture media were collected and separated into two groups.  One group of 
samples was first frozen at -80℃ overnight before the levels of cytokines were 
tested and the other groups of samples were tested immediately. 
 
Fig. 4.7: Galectin-3-induced secretion of G-CSF and IL-6 in the conditioned medium could 
not be detected after the samples were frozen and thawed. HMVEC-Ls were treated with 
various galectin-3 concentrations for 24 hr before the concentrations of G-CSF and IL-6 in the 
culture media were determined. n=3. *p<0.05 (one-way ANOVA followed by Bonferroni). 
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 It was found that the freezing and thawing cycle completely diminished the 
detection of these cytokines in the culture medium (Fig. 4.7), suggesting that the 
cytokines in the culture medium are sensitive to the freezing and thawing cycle. All 
the subsequent analyses were therefore conducted with fresh conditioned medium. 
 
4.4.6.2 Investigation of the dose-dependency of the galectin-3 effect 
on cytokine secretion 
To investigate whether the G-CSF, GM-CSF, IL-6 and sICAM-1 secretions induced 
by galectin-3 were dose-dependent, confluent HMVEC-Ls cell monolayers were 
treated with galectin-3 in different concentrations (BSA control, 0.1, 0.2, 0.5, 1 and 
2µg/ml) for 24 hr. Then the levels of G-CSF, GM-CSF, IL-6 and sICAM-1 in the 
conditioned medium were determined by individual cytokine ELISA.  
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 Fig. 4.8: Galectin-3 induces dose-dependent secretion of G-CSF, GM-CSF, IL-6 and sICAM-1 
from endothelial cells. HMVEC-Ls were treated with or without various pathological galectin-3 
concentrations (BSA control, 0.1, 0.2, 0.5, 1 and 2µg/ml) for 24 hr before the concentrations of 
each cytokine in the culture media were determined. n=3. *p<0.05, **p<0.01 (one-way ANOVA 
followed by Bonferroni). 
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It was found that the galectin-3-mediated cytokine secretion from HMVEC-Ls 
was galectin-3 dose-dependent and this induction occurred at galectin-3 
concentrations similar to those found in the blood circulation of cancer patients (Fig. 
4.8 and Table 4.1). At 2.0 µg /ml, galectin-3 induced increase of secretion of G-CSF, 
GM-CSF, IL-6 and sICAM-1 by 981.0±17.6%, 157.4±4.1%, 201.2±7.8% and 
236.1±6.9%, respectively). 
Table 4.1 Galectin-3 induces dose-dependent secretion of G-CSF, GM-CSF, IL-6 and 
sICAM-1 from endothelial cells (n=3) 
 Concentration 
(µg/ml) 
Increase 
compare to 
dose 0 (%) 
Standard 
Deviation 
P value 
G-CSF 0.1 103.5 2.96 0.595 
0.2 108.7 2.52 0.437 
0.5 96.2 6.76 0.354 
1 121.9 24.80 0.167 
2 980.9 17.63 0.005 
GM-CSF 0.1 108.9 7.24 0.169 
0.2 103.8 7.02 0.243 
0.5 110.1 1.89 0.156 
1 143.5 3.57 0.034 
2 157.4 4.12 0.018 
IL-6 0.1 105.3 7.35 0.506 
0.2 103.8 5.10 0.344 
0.5 118.5 10.50 0.387 
1 189.9 7.05 0.029 
2 201.1 7.80 0.026 
ICAM-1 0.1 101.7 0.89 0.419 
0.2 103.0 3.02 0.423 
0.5 102.7 6.92 0.678 
1 222.0 5.28 0.021 
2 236.1 6.92 0.017 
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4.4.6.3 Investigation of the time-response of the galectin-3 effects on 
cytokine secretion from endothelial cells 
A confluent HMVEC-Ls cell monolayer in a 96-well plate was treated with 
galectin-3 at 1µg/ml for different times (0, 4, 8, 10, 12, 14, 16, 18, 20, 24 and 48 hr) 
before the levels of G-CSF, GM-CSF, IL-6 and sICAM-1 in the conditioned medium 
were determined by individual cytokine ELISA. 
 
Fig. 4.9: Galectin-3 induces time-dependent secretion of G-CSF, GM-CSF, IL-6 and ICAM-1 
from endothelial cells. HMVEC-Ls were treated with 1.5µg/ml galectin-3 or BSA for various time 
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points before the concentrations of G-CSF in the conditioned medium were determined. n=3. 
*p<0.05, **p<0.01 (one-way ANOVA followed by Bonferroni). 
In comparison with the control BSA-treated cells, galectin-3 at 1.5ug/ml induced 
115.7±9.7%, 17.9±3.2%, 107.1±1.3% and 73.9±16.3%, respectively (Fig. 4.9 and Table 
4.2), increasing secretion of G-CSF, GM-CSF, IL-6 and sICAM-1 from HMVECs after 24 
hr. 
Table 4.2 Galectin-3 induces time-dependent secretion of G-CSF, GM-CSF, IL-6 and 
ICAM-1 from endothelial cells (n=3) 
 Time point 
(hr) 
Increase 
compare to 
BSA treated 
control (%) 
Standard 
Deviation 
P value 
G-CSF 18 41.6 8.50 0.2157 
20 73.6 10.12 0.0178 
24 100.3 7.12 0.0025 
48 115.7 9.71 0.0011 
GM-CSF 20 9.9 15.04 0.3257 
24 31.4 6.24 0.0247 
48 17.9 3.15 0.0350 
IL-6 20 2.61 11.86 0.7245 
24 117.7 5.43 0.0028 
48 107.1 1.25 0.0018 
ICAM-1 14 33.6 28.12 0.2384 
16 45.7 11.07 0.0485 
18 32.1 7.78 0.0853 
20 31.4 4.31 0.03211 
24 37.8 14.19 0.03119 
48 73.9 16.26 0.00402 
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4.4.7 Investigation of effect of lactose on galectin-mediated cytokine 
secretion from HMVEC-Ls and on cancer cell adhesion 
To further confirm the effect of galectin-3 on secretion of cytokines by HMVEC-
Ls, we assessed the effect of the presence of the galectin-binding inhibitor lactose on 
galectin-mediated cytokine secretion. 
 
 
Fig. 4.10 Galectin-3-mediated cytokine secretion can be inhibited by the presence of 
lactose. HMVEC-Ls were treated with 1μg/ml BSA or galectin-3 in the presence or absence of 
10µM lactose for 24 hrs before the cytokine levels in the conditioned medium were determined. 
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The data are expressed as mean ± SD of triplicate determinations of three independent 
experiments. *p<0.05 (one-way ANOVA followed by Bonferroni). 
 
It was found that the increased secretion of G-CSF, GM-CSF and sICAM-1 
induced by galectin-3(38.4 ± 9.4%, 37.4 ± 27.4% and 7.8 ± 1.2%, respectively) was 
abolished by the presence of lactose, whereas the increased secretion of IL-6 
induced by galectin-3(74.2 ± 18.9%) was largely inhibited (84.4 ± 12.0%) in the 
presence of lactose (Fig. 4.10). 
 
 
Fig. 4.11 Lactose abolishes galectin-3-induced cancer cell-endothelial adhesion.  
HMVEC-Ls cells were treated with or without 1.5µg/ml galectin-3 in the presence or 
absence of 100µM lactose for 24 hr before adhesion of the fresh cancer cells to HMVEC-Ls were 
assessed. The data are expressed as mean ± SD of triplicate determinations of three independent 
experiments. *p<0.05 (One-way ANOVA followed by Bonferroni) 
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 The presence of lactose also proved to effectively inhibit galectin-3-mediated 
ACA19- cell adhesion to HMVEC-Ls (Fig. 4.11). These results indicate that galectin-3-
mediated cytokine secretion by endothelial cells and subsequent increased adhesion 
were mediated through the galectin-3 carbohydrate-binding sites. 
4.4.8 Investigation of effect of a combination of anti-cytokine 
antibodies on galectin-3-mediated cancer cell-endothelial adhesion 
To determine whether the galectin-3-induced secretion of IL-6, G-CSF, GM-CSF 
and sICAM-1 from HMVEC-Ls was responsible for galectin-3-mediated MUC1-
negative cells adhesion to endothelium, we assessed the effect of antibodies against 
IL-6, G-CSF, GM-CSF and sICAM-1 on galectin-3-mediated ACA19- cell adhesion to 
HMVEC-Ls. 
Confluent HMVEC-Ls cell monolayers in each well in a 96-well plate were 
treated with galectin-3 (1.5µg/ml) for 24 hr and BSA was used as negative control. 
After 24 hr incubation, the medium in wells were collected. An anti-cytokine 
antibody mixture [anti-G-CSF (50ng/ml), anti-GM-CSF (600pg/ml), anti-IL-6(4ng/ml) 
and anti-ICAM-1 (10ng/ml)] were added to the conditioned medium as an additional 
group. Fresh ACA19- cells were cultured with the collected medium or the collected 
medium with anti-cytokine antibodies mixture for an hour, and then the treated 
ACA19- suspension at a concentration of 1 x 105/ml was added (100µl/well) to each 
well of the fresh HMVEC-Ls monolayer for 1 hr. 
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 CM of control HMVEC-Ls + - - + 
CM of Gal-3-treated HMVEC-Ls - + + - 
Anti-cytokine mAbs - - + + 
 
Fig. 4.12 Galectin-3-mediated cancer cell-endothelial adhesion can be inhibited by the 
presence of anti-cytokine neutralizing antibodies. The HMVEC monolayer was treated with 
1.5μg/ml galectin-3 or BSA for 24 hr before the conditioned medium was obtained and fresh 
ACA19- was treated with the obtained medium with/without the presence of a combination of 
neutralizing antibodies against G-CSF (50ng/ml), GM-CSF (600pg/ml), IL-6 (4ng/ml) and sICAM-1 
(10ng/ml). The data are expressed as mean ± SD of triplicate determinations of three 
independent experiments. *p<0.05 (one-way ANOVA followed by Bonferroni). 
 
The presence of a combination of four antibodies against G-CSF, GM-CSF, IL-6 
and sICAM-1 completely prevented ACA19- cell adhesion induced by the conditioned 
medium from galectin-3-treated HMVEC-Ls (Fig. 4.12). 
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4.4.9 Investigation of the effect of the presence of a combination of 
recombinant cytokines on cancer cell-endothelial adhesion 
To further determine whether the increased secretion of cytokines by HMVEC-
Ls in response to galectin-3 was responsible for the galectin-3 mediated cancer cell-
endothelial adhesion, recombinant cytokines were included in the adhesion 
assessment. The presence of a combination of G-CSF, GM-CSF, IL-6 and sICAM-1 in a 
concentration similar to that in the conditioned-medium from 1µg/ml galectin-3-
treated HMVEC-Ls was treated with HMVEC-Ls monolayers for 1 hr before 1 hr 
cancer cell-endothelial adhesion.  
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Fig. 4.13: Recombinant cytokines increase cancer cell-endothelial adhesion. ACA19- and 
HCT116 cell adhesion to HMVEC monolayer was assessed in the presence or absence of a 
combination of G-CSF (2.5ng/ml), GM-CSF (30pg/ml), IL-6 (200pg/ml) and sICAM-1 (500pg/ml). 
The data are expressed as mean ± SD of triplicate determinations of three independent 
experiments. p*<0.05 (unpaired t test). 
 
It was found that the combination of cytokines induced a similar increase of 
ACA19- (40.1±6.8%) and HCT116 (35.6±7.7%) cell adhesion (Fig. 4.13) to that of the 
conditioned medium from galectin-3-treated HMVEC-Ls. These results indicate that 
galectin-3-induced secretion of G-CSF, GM-CSF, IL-6 and sICAM-1 by HMVEC-Ls is 
essential for galectin-3-induced MUC1-negative cancer cell adhesion to endothelial 
cells. 
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4.4.10 Investigation of the effect of galectin-3-induced cytokine 
secretion on metastasis in mice 
The effect of circulating galectin-3 on cytokine secretion was further analyzed in 
vivo in nude mice. Five µg/mouse (2.5µg/ml, assuming a 2ml blood volume) galectin-
3, which is a pathological galectin-3 concentration seen in cancer patients with 
metastasis (321), was injected intravenously into the tail vein. Animals were 
sacrificed at 0, 24 and 48 hr and the serum concentrations of G-CSF, GM-CSF, IL-6 
and sICAM-1 were determined by individual cytokine ELISAs. 
  
Fig. 4.14: Galectin-3 induces cytokine secretion in mice.  
Galectin-3 induces cytokine secretion in vivo. Mice (three mice per group) were injected 
with 5µg/mouse recombinant galectin-3 via the tail vein. The animals were sacrificed at 0, 24 and 
48 hr and serum concentrations of sICAM-1, G-CSF, GM-CSF and IL-6 cytokine were determined. 
P*<0.05, **p<0.01, ***p<0.001 (One-way ANOVA followed by Bonferroni). 
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 There was a significant increase in G-CSF, GM-CSF, IL-6 and sICAM-1 levels. A 
45.1±14.4% increase of G-CSF, 293.7±93.7% of GM-CSF, 111.2±26.7% of IL-6 and 
57.6±6.0% of sICAM-1 in the sera was observed 48 hr after galectin-3 injection (Fig. 
4.14 and Table 4.3). This provides strong evidence of an influence of circulating 
galectin-3 on secretion of these cytokines in vivo.  
Table 4.3 galectin-3 induce cytokine secretion in mouse in vivo 
 Time after 
Injection (hr) 
Increase 
compare to 
time 0 (%) 
Standard 
Deviation 
P value 
G-CSF 24 2.83 12.8 1 
48 44.56 14.5 0.142 
GM-CSF 24 26.21 10.8 1 
48 292.63 93.8 0.033 
IL-6 24 -21.94 10.8 10.021 
48 111.01 26.7 0.021 
ICAM-1 24 19.09 0.6 0.216 
48 57.59 6.0 0.001 
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4.5 Discussion 
The experiments described here show that the presence of galectin-3 in the 
pathological concentrations seen in cancer patients induce dose- and time-
dependent secretion of metastasis-promoting cytokines IL-6, sICAM-1, G-CSF and 
GM-CSF from the vascular endothelium. The secretion of these cytokines 
autocrinely/paracrinely increases the adhesion of MUC1-negative cells to vascular 
endothelial cells in vitro. 
Vascular endothelium is an extraordinarily complex network of cells with 
multitudes of distinct anatomic, metabolic and immunologic properties. Endothelial 
cells can produce many diverse biologically active molecules such as cytokines and 
growth factors. Since endothelium forms the internal lining of the entire vascular 
system, the production of such active molecules can have profound influence either 
directly or indirectly on the processes of tumourigenesis, angiogenesis, progression 
and metastasis, locally and symmetrically. 
Cytokines are multi-functional proteins. Pro-inflammatory cytokines such as 
TNFα, IL-1 and IL-6 are now well recognized as important regulators in cancer 
progression, metastasis and tumor immune suppression. These cytokines can 
regulate tumor cell behaviors directly or indirectly through regulation of the tumor 
microenvironment in an autocrine or paracrine manner. This study shows that 
circulating galectin-3 induces secretion of four cytokines from the blood vascular 
endothelium to the circulation including pro-inflammatory cytokine IL-6 and G-CSF.   
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IL-6 is a pleiotropic and pro-inflammatory cytokine and is known to be secreted 
by various cell types including fibroblasts, macrophages, and lymphocytes, epithelial 
and endothelial cells. IL-6 plays diverse roles as a regulator of the acute 
inflammatory response and as a growth and survival factor. IL-6 binds its receptor IL-
6Rα on the cell surface that recruits the cell membrane gp130, leading to the 
formation of a signaling complex. This results in activation of at least three signaling 
pathways of JAK/STAT, Ras/ERK and PI-3/Akt (391), leading to the unregulated 
expression of a large variety of genes involved in cell proliferation and growth.  
In cancer, high serum levels of IL-6 correlate with cancer severity, presence of 
metastasis and poor prognosis of many types of cancers including colorectal (392), 
prostate (393), breast(394) and gastric cancer(395). IL-6 can stimulate the release of 
angiogenesis-promoting factors such as VEGF and bFGF and promote angiogenesis 
(396). IL-6 expression and secretion can increase epithelial-mesenchymal transition 
in cancer by promoting E-cadherin expression or JAK/STAT-3 signaling (397). As a 
pro-inflammatory cytokine, IL-6 can activate the Stat-3 signaling in regulator T cells 
and help tumor cells escaping from immune surveillance (59). Recently it has been 
revealed that IL-6 production in a primary tumor can promote the recruitment of 
circulating tumor cells back to their primary tumor, creating a process called tumor 
self-seeding that accelerates tumor growth, angiogenesis and stromal cell 
recruitment(398). The IL-6-mediated activation of Stat-3 signaling in inflammatory 
cells can also lead to transcriptional activation of NF-Kappa B for secreting additional 
IL-6 and IL-8 to act on tumor cells, thus generating a positive feedback loop between 
immune cells and tumor cells that further stimulates the tumor cell progression and 
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metastasis (399). As a result of such divergent influences of IL-6 on tumor 
progression and metastasis promotion, inhibition of IL-6-mediated cell signaling has 
been the subject of intense investigation in the past few years in cancer treatment. 
Several phase I and II clinical trials using either anti-IL-6 antibody or IL-6 inhibitors, 
alone or in combination with other therapies, are currently under way (391, 400, 
401).  
G-CSF is a cytokine that stimulates bone marrow to produce granulocytes. It is 
widely used for the treatment of congenital neutropenia and to aid haematopoietic 
recovery following thermotherapy for a range of solid tumors. G-CSF binds to its cell 
surface receptor G-CSFR and induces receptor multimerization and activation of 
several intracellular signaling pathways of JAK/STAT, Ras/ERK and PI3K/Akt (402). 
Serum G-CSF levels have been reported to be higher in urothelial cancer patients 
than in healthy people and patients with an undetectable level of serum G-CSF have 
higher disease-specific five-year survival rates than those with an elevated level of 
serum G-CSF(403).  Recently G-CSF has been shown to be able to mobilize 
Ly6G+Ly6C+ granulocytes in pre-metastatic tissues in distant organs before the 
arrival of tumor cells, facilitate subsequent tumor cell homing at this newly-created 
pre-metastatic environment and promote tumor cell migration, angiogenesis and 
metastasis (404). Direct injection of recombinant G-CSF into the tail vein of nude 
mice for five consecutive days before and after tumor cell injection has been shown 
to cause significant increase of the lung metastasis of animals injected not only with 
metastatic but also with non-metastatic breast cancer cells (404).  
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GM-CSF is a cytokine that, like G-CSF, stimulates the bone marrow to produce 
granulocytes.  It is often used to stimulate the production of white blood cells 
following chemotherapy in cancer patients. Serum GM-CSF levels have been shown 
to be higher in breast cancer patients than in healthy people (405). The presence of 
GM-CSF promotes the invasiveness of lung cancer cells and prolongs tumor cell 
survival by activation of MEK/ERK and PI3K/Akt signaling in vitro (406)and in lung 
cancer xenograft (407). 
sICAM-1 is a soluble form of the transmembrane cell adhesion molecule ICAM-
1. ICAM-1 is weakly expressed in leukocytes, epithelial and resting endothelial cells 
and is up-regulated upon stimulation by inflammatory mediators such as cytokines 
and LPS. ICAM-1 binds to Mac-1 (macrophage adhesion ligand-1) and integrin LFA-1 
(leukocyte function-associated antigen-1) and promotes cell-cell interactions. Higher 
sICAM-1 levels are seen in various cancers (408) including breast, gastrointestinal, 
lung, stomach, melanoma, ovary and bladder cancer patients (409) and in particular 
those with metastasis(410). High serum levels of sICAM-1 correlate significantly with 
TNM stage and lymph node in colorectal cancer patients (411) and a high pre-
operative level of sICAM-1 has been shown to be an independent prognostic marker 
for stage II colorectal cancer (412). The circulation of sICAM-1 inhibits T cell 
interaction with tumour cells (413), blocks NK cell-mediated toxicity of tumour cells 
(414) and promotes tumour cell escape from immune surveillance. 
Thus, IL-6, G-CSF, GM-CSF and sICAM-1 can all have a divergent and positive 
influence on cancer progression and metastasis. The increased secretion of these 
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cytokines in the blood circulation by the blood vascular endothelium in response to 
the increased circulation of galectin-3 in cancer patients will therefore have 
profound influence on cancer progression and metastasis, not only as regards the 
cancer cell adhesion and angiogenesis shown in this study but as regards other 
behaviors of tumor cells as well as the tumor micro-environment locally, remotely 
and systematically.  
Although IL-6, G-CSF, GM-CSF and sICAM-1levels have all been shown 
previously to be increased in cancer patients, the source of these increased 
circulating cytokines is unclear. Mice bearing human colon cancer MC-38 cells did 
not show a significant increase of circulating IL-6, indicating that tumor-derived IL-6 
may not have a measurable effect on systemic IL-6 levels (415). Mice bearing human 
MDA-MB-231 tumors on the other hand showed increased plasma levels of both 
human and mouse G-CSF, suggesting that host cells are a significant source of 
circulating G-CSF(404). The discovery that circulating galectin-3 increases the 
secretion of IL-6, G-CSF, GM-CSF and sICAM-1 in the blood vascular endothelium 
supports an important contribution of the host cells such as the blood vascular 
endothelium to the increased circulation of these cytokines in the circulation of 
cancer patients.  
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CHAPTER 5 Investigation of the influence of galectin-3-induced 
endothelial secretion of cytokines on endothelial behaviors 
relevant to angiogenesis and metastasis 
5.1 Hypothesis and Aim 
To explore the hypothesis that galectin-3-induced cytokine secretion affects endothelial 
cell behavior in a way likely to promote metastasis. 
. 
5.2 Introduction 
Cytokines such as IL-6 and G-CSF are multifunctional proteins. Their pleiotropic 
actions not only include effects on the immune system and modulation of 
inflammatory responses but also include effects on progression of various steps of 
tumor growth, angiogenesis and metastasis (94). The discovery of the increased 
secretion of IL-6, G-CSF, GM-CSF and sICAM1 by vascular endothelium in its response 
to galectin-3 implies that the galectin-3-induced secretion of these cytokines may 
promote these pro-angiogenic and pro-metastasis steps in cancer.  
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5.3 Methods 
5.3.1 Assessments of cell surface adhesion molecules by flow 
cytometry 
Sub-confluent HMVEC-Ls were treated with galectin-3 (1.5µg/ml) for 24 hr at 
37℃. The cells were released from the culture flasks by trypsinization. After the cells 
had been washed once with PBS, 5ml 2% paraformaldehyde was added in to fix for 
at least 25 minutes at room temperature. Then the cells were washed twice with 
10ml PBS and centrifuged to remove the supernatants. After the addition of 0.5ml 
PBS, cells were counted and resuspended into 106/ml with 5% goat serum/PBS for 30 
minutes at room temperature on the roller platform. After removal of the 
supernatant following centrifugation, the cells were resuspended in 1% goat serum 
in PBS and 1ml/tube of the cell suspension was aliquoted into 1.5ml tubes. 
Antibodies against CD44 (1mg/ml), integrin α5β1 (1mg/ml), E-selectin (1mg/ml), 
sICAM-1 (1mg/ml) and VCAM (1mg/ml) in PBS (1:400 dilution) were applied to the 
cells for 1 hr at room temperature on the roller (or overnight at 4℃). After two 
washes with PBS, FITC-conjugated secondary antibodies (1:400 in 1% BSA in PBS) 
were applied for 1 hr at room temperature. After three washes with PBS, the cells 
were resuspended in PBS in 0.5ml/tubes. The cell surface expression of CD44, 
integrinα5β1, E-selectin, sICAM-1 and VCAM was analyzed by flow cytometry. 
Application of FITC-conjugated secondary antibody without the primary antibody 
was used as a negative control in all the flow cytometry analyses.  
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5.3.2 Assessment of endothelial tubule formation using an in vitro 
Angiogenesis Assay Kit 
HMVEC-Ls (1 x 105/well) were cultured in a 12-well plate at 37℃ for 24 hr 
before the introduction of 1.5µg/ml recombinant galectin-3 or BSA with or without 
the addition of a combination of anti-cytokine antibodies mixture (final 
concentration: G-CSF (25ng/ml), GM-CSF (300pg/ml), IL-6(2ng/ml) and sICAM-1 
(5ng/ml) or recombinant cytokines (a combination of recombinant cytokines G-CSF 
(2.5ng/ml), GM-CSF (30pg/ml), IL-6 (200pg/ml) and sICAM-1 (500pg/ml)) for 24 hr. 
The conditioned medium was collected for the following assessment steps. The 
culturing time was precisely calculated so that the conditioned medium was fresh. 
Cultrex RGF BME was thawed at 2-4℃ overnight in a refrigerator. The next day, 
50μl of BME solution was aliquoted into the wells (three wells per group) of a 96-
well plate on ice in the hood. The plate was centrifuged at 250 (*g) for five minutes 
at 4℃ to make sure no air bubbles were trapped in the BME and then the plate was 
incubated at 37℃ for 45 minutes to make the gel solid.  
Then 5μl of 2mM Calcein AM Working Solution was added to 5ml EBM-2 to 
make 2μM Calcein AM solution. Sub confluent HUVEC cells cultured in a T25 flask 
were incubated with the Calcein AM solution (5 ml per T25 flask) for 30 minutes at 
37℃ in a CO2 incubator before they were released by NECDS (2ml/each). The 
supernatant was discarded after centrifugation at 1000 (*g) for 5 min. Then the cell 
pellet was resuspended with 200μl PBS and further diluted to 1 x 105 cells /ml using 
the conditioned medium collected above, respectively for each group. Then 100μl of 
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diluted cells (1 x 104 cells / well) were added slowly to each well of the 96 well-plate 
containing gelled BME above. The plate was then incubated at 37℃ in a CO2 
incubator for 24 hours before tube formation was analyzed as described in the 
general method chapter. 
 
5.4 Results 
5.4.1 Investigation of the effect of galectin-3 treatment on expression 
of cell surface adhesion molecules by HMVEC-Ls 
To gain an insight into the mechanism of the galectin-3-induced, cytokine-
mediated cell adhesion, we analyzed the expression of several common cell surface 
adhesion molecules on HMVEC-Ls after treatment of the cells with galectin-3. 
HMVEC-Ls cells were treated with galectin-3 (1.5µg/ml) for 24 hr before the 
expression of endothelial cell surface adhesion molecules (Integrinα5β1, Integrinα5β3, 
CD44, E-selectin, ICAM and VCAM) were analyzed by flow cytometry. 
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Fluorescent intensity 
Fig. 5.1: Galectin-3 induces expression of cell surface Integrinα5β1, E-selectin, ICAM and 
VCAM but not Integrinα5β3 or CD44. The HMVEC-Ls monolayer was treated without (red) or with 
1.5µg/ml galectin-3 (green) for 24 hr before the expression of HMVEC-Ls cell surface adhesion 
molecules was analyzed by flow cytometry (n=3). The IgG control is shown in blue. 
 
It was found that HMVEC-Ls treated with galectin-3 (1.5ug/ml) for 24 hr showed 
increased expression of cell surface Integrinα5β1 (43.1% (95%CI 40.9, 45.3)), E-
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selectin (18.6% (95%CI 15.5, 21.7)), VCAM-1 (16.7% (95%CI 13.4, 20.0)) and ICAM-1 
(32.7% (95%CI 29.4, 36.0)) whereas the expression of cell surface CD44 and 
integrinα5β3 was not affected (n=3) (Fig. 5.1).  
To determine whether the increased expression of these endothelial cell 
surface adhesion molecules in response to galectin-3 was linked with galectin-3-
induced cytokine secretion, the expression of integrinα5β1, the adhesion molecule 
that showed the most increase in response to galectin-3, was further analyzed. 
HMVEC-Ls cells were treated with galectin-3 (1.5µg/ml) in the presence or absence 
of 10µM lactose for 24 hr before the conditioned medium was collected. Fresh 
HMVEC-Ls cells were treated with the collected galectin-3-treated conditioned 
medium in the presence or absence of a combination of neutralizing antibodies 
against G-CSF (25ng/ml), GM-CSF (300pg/ml), IL-6 (2ng/ml) and sICAM-1 (5ng/ml) for 
1 hr. Then the expression of endothelial cell surface adhesion molecule Integrinα5β1 
was analyzed by flow cytometry. 
 
Fluorescent intensity 
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Fig. 5.2: Galectin-3 induced expression of cell surface Integrinα5β1 can be inhibited by the 
presence of lactose or a combination of neutralizing antibodies. HMVEC-Ls monolayer was 
treated 1 hr with conditioned medium obtained from HMVEC-Ls treated with galectin-3 with the 
presence (blue) or absence of lactose (green) for 24 hr, or the HMVEC-Ls monolayer was treated 
1 hr with conditioned medium obtained from HMVEC-Ls treated with galectin-3 for 24h and then 
a combination of neutralizing antibodies against G-CSF, GM-CSF, IL-6 and sICAM-1 (purple) was 
added in, before the expressions of HMVEC-Ls cell surface adhesion molecule Integrinα5β1 were 
analyzed by flow cytometry (n=3). IgG control shows in red. 
 
It is observed that a combination of neutralizing antibodies against G-CSF, GM-
CSF, IL-6 and sICAM-1 in the culture medium resulted in 30.4% reduction of the 
galectin-3-mediated increase of integrinα5β1 expression while pretreatment of 
lactose fully abolished the increased integrinα5β1 expression that galectin-3 induced 
(Fig. 5.2). 
 
To further determine whether the galectin-3 induced increased expressions of 
endothelial cell surface adhesion molecule integrinα5β1 was mediated by galectin-3-
induced cytokine secretion, HMVEC-Ls cells were incubated with a combination of 
recombinant G-CSF (2.5ng/ml), GM-CSF (30pg/ml), IL-6 (200pg/ml) and sICAM-1 
(500pg/ml) at concentrations similar as that in the conditioned medium of galectin-
3-treated HMVEC-Ls. Then the expression of endothelial cell surface adhesion 
molecule Integrinα5β1 was analyzed by flow cytometry. 
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Fig. 5.3: A combination of recombinant cytokines in concentration similar to that in the 
conditioned medium of galectin-3-treated HMVEC-Ls induces expression of cell surface 
Integrinα5β1. The HMVEC-Ls monolayer was treated without (red) or with a combination of 
recombinant G-CSF, GM-CSF, IL-6 and sICAM-1 at concentrations similar to that in the 
conditioned medium of galectin-3-treated HMVEC-Ls for 1 hr before the expression of HMVEC-Ls 
cell surface adhesion molecule Integrinα5β1 was analyzed by flow cytometry (n=3). 
 
Furthermore, as was seen with recombinant galectin-3, incubation of HMVECs 
with a combination of recombinant G-CSF (2.5ng/ml), GM-CSF (30pg/ml), IL-6 
(200pg/ml) and sICAM-1 (500pg/ml) concentrations similar to those in the 
conditioned medium of galectin-3-treated HMVECs caused a 40.3% increase in cell 
surface Integrinα5β1 expression (Fig. 5.3). This indicates that the increased expression 
of endothelial cell surface adhesion molecules induced by galectin-3 is associated 
with the autocrine/paracrine actions of galectin-3-induced secretion of cytokines in 
endothelial cells.  
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To investigate the relative impacts of the four cytokines induced by galectin-3 
on promoting the expression of endothelial cell surface adhesion molecules, the 
effects of these four cytokines on Integrinα5β1 cell surface expression were assessed 
individually. HMVEC-Ls cells were incubated individually with recombinant G-CSF 
(2.5ng/ml), GM-CSF (30pg/ml), IL-6 (200pg/ml) or sICAM-1 (500pg/ml) at 
concentrations similar to that in the conditioned medium of galectin-3-treated 
HMVEC-Ls. Then the expression of endothelial cell surface adhesion molecule 
Integrinα5β1 was analyzed by flow cytometry.  
  
  
Fluorescent intensity 
Fig. 5.4: Each recombinant cytokine at concentrations similar to that in the conditioned 
medium of galectin-3-treated HMVEC-Ls induces expression of cell surface Integrinα5β1. The 
HMVEC-Ls monolayer was treated without (red) or with recombinant G-CSF (cyan), GM-CSF 
(brown), IL-6 (orange) and sICAM-1 (green) at concentrations similar to that in the conditioned 
G-CSF GM-CSF 
IL-6 ICAM-1 
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medium of galectin-3-treated HMVEC-Ls  for 1 hr before the expression of HMVEC-Ls cell surface 
adhesion molecule Integrinα5β1 was analyzed by flow cytometry (n=3). IgG control is shown in 
blue. 
 
Each of these four cytokines increased Integrinα5β1 expression on HMVEC-Ls, 
albeit to different extents. A 33.9% increase was observed for 2.5ng/ml G-CSF, 31.6% 
for GM-CSF (30pg/ml), 17.3% for IL-6 (200pg/ml) and 35.8% for ICAM-1 (500pg/ml) 
(Fig. 5.4). This suggests that the galectin-3-induced cytokines probably all make a 
contribution to the galectin-3-mediated increase in expression of endothelial cell 
surface adhesion molecules. 
 
To investigate the relationship between increased expression of the endothelial 
cell surface adhesion molecules induced by galectin-3 and galectin-3-mediated 
adhesion of MUC1-negative cancer cells, we assessed the effect of antibodies against 
the cell adhesion molecules on galectin-3-mediated ACA19- adhesion.  
Confluent HMVEC-Ls cell monolayers in 96 well plates were treated with 
galectin-3 (1.5µg/ml) for 24 hr and BSA was used as negative control. After 24 hr 
incubation, the conditioned medium in wells was collected. A combination of 
neutralization antibodies against Integrinα5β1 (10µg/ml), E-selectin (10µg/ml), 
VACM-1 (10µg/ml) and ICAM-1 (10µg/ml) were added to the collected conditioned 
medium before fresh HMVEC-Ls were treated with them for 1 hr. Then, ACA19- at a 
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concentration of 5 x 104/ml cell was used for adhesion to the treated HMVEC-Ls for 1 
hr before assessment. 
 
CM from control HMVEC-Ls + - - + 
CM from Gal3-treated HMVEC-Ls - + + - 
Anti-CAM mAbs - - + + 
 
Fig. 5.5: The presence of antibodies against the cell surface adhesion molecules inhibits 
galectin-3-mediated cancer cell adhesion. The HMVEC-Ls monolayer was first treated with or 
without galectin-3 for 24 hr and then ACA19- cell adhesion to the HMVEC-Ls monolayer was 
assessed in the presence or absence of a combination of neutralization antibodies against 
Integrinα5β1, E-selectin, VACM-1 and ICAM-1(n=3). P*<0.05 (One-way ANOVA followed by 
Bonferroni). 
 
A combination of neutralizing antibodies against integrinα5β1, E-selectin, VCAM-
1, and ICAM-1 (10µg/ml for each) resulted in a 71.1% decrease of galectin-3-
associated ACA19- cell adhesion to HMVECs (Fig. 5.5). Collectively, these results 
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indicate that the cytokine-induced expression of the endothelial cell surface 
adhesion molecules in response to galectin-3 is responsible for the increased 
adhesion of MUC1-negative cells induced by galectin-3.  
 
5.4.2 Investigation of effect of galectin-3 treatment on HMVEC-Ls cell 
migration 
As pro-inflammatory cytokines such as IL-6 have been shown previously also to 
promote angiogenesis (391) and the galectin-3-induced secretion of cytokines from 
the vascular endothelium included the pro-inflammatory cytokines IL-6 and G-CSF, 
we further speculated that the release of these cytokines by the blood vascular 
endothelium in response to circulating galectin-3 might also influence endothelial 
behavior during angiogenesis. We therefore assessed the effect of galectin-3-
induced cytokine secretion by HMVECs on endothelial cell migration through 
basement matrix proteins as well as on endothelial micro-tubule formation, two 
important components of the angiogenesis process.  
Confluent HMVEC-Ls were treated with either BSA, or galectin-3 (1.5µg/ml) in 
the presence or absence of 10µM lactose for 48 hr.  A fresh flask of HMVEC-Ls was 
harvested, washed with PBS, centrifuged and resuspended at the concentration of 1 
x 107cells/ml in EBM-2. The suspension was aliquoted (200µl/well) to sterile 
centrifuge tubes and diluted to 4 x 105cells/ml with conditioned medium collected 
from the incubation with and without the addition of neutralizing anti-cytokine 
antibodies (a combination of neutralizing antibodies against G-CSF (25ng/ml), GM-
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CSF (300pg/ml), IL-6 (2ng/ml) and sICAM-1 (5ng/ml)) or recombinant cytokines (a 
combination of recombinant cytokines G-CSF (2.5ng/ml), GM-CSF (30pg/ml), IL-6 
(200pg/ml) and sICAM-1 (500pg/ml)). Then their invasion abilities through the 
basement matrix were assessed by the use of pre-set devices provided by the In 
Vitro Angiogenesis Assay Endothelial Cell Invasion Kit. 
 
CM from BSA-treated HMVEC-Ls + - - - + 
CM from Gal-3-treated HMVEC-Ls - + + + - 
CM from Gal-3/Lac-treated HMVEC-Ls - - + - - 
Cytokine neutralizing antibodies - - - + - 
Recombinant cytokines - - - - + 
 
Fig. 5.6: Galectin-3-induced cytokine secretion promotes endothelial cell migration. 
The HMVEC-Ls monolayer was treated with 1.5µg/ml BSA or galectin-3 in the presence or 
absence of lactose for 24 hr. The CM were collected and used for subsequent assessment of 
fresh HMVEC cell migration through basement matrix proteins in the presence or absence of a 
combination of neutralizing antibodies, or a combination of recombinant cytokines. The data are 
expressed as percentages compare to BSA-treated as control (n=3). P*<0.05, p***<0.001 (One-
way ANOVA followed by Bonferroni). 
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 The conditioned medium from 24-hr galectin-3 (1.5µg/ml)-treated HMVECs 
caused 48.8%±2.5% increase in migration of fresh HMVECs through basement matrix 
proteins compared with the BSA-treated control medium (Fig. 5.6). A combination of 
neutralizing antibodies against G-CSF (25ng/ml), GM-CSF (300pg/ml), IL-6 (2ng/ml) 
and sICAM-1 (5ng/ml) markedly reduced (65.2%±2.0%) galectin-3-associated 
HMVEC-Ls cell migration, suggesting that the galectin-3-induced secretion of these 
cytokines is responsible for the observed increase in HMVEC-Ls migration. This was 
further supported by a similar increase in HMVEC cell migration (63.1%±10.6%) 
when a combination of recombinant G-CSF (2.5ng/ml), GM-CSF (30pg/ml), IL-6 
(200pg/ml) and sICAM-1 (500pg/ml) at similar concentrations to those of the 
conditioned medium from galectin-treated HMVECs was added to the culture.  
 
5.4.3 Investigation of effect of galectin-3 treatment on HUVEC cell tube 
formation 
To test the impact of galectin-3 treatment on HUVEC cell tube formation, the 
conditioned medium from 24 hr galectin-3 (1.5µg/ml)-treated HMVEC-Ls was 
collected and used as culture medium with or without the addition of neutralizing 
anti-cytokine antibodies (a combination of neutralizing antibodies against G-CSF 
(25ng/ml), GM-CSF (300pg/ml), IL-6 (2ng/ml) and sICAM-1 (5ng/ml)) or recombinant 
cytokines (a combination of recombinant cytokines G-CSF (2.5ng/ml), GM-CSF 
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(30pg/ml), IL-6 (200pg/ml) and sICAM-1 (500pg/ml)) to culture HUVECs cells on the 
surface of matrix before the tubule formation ability of HUVEC cells was analyzed. 
 
BSA CM Gal3 CM Gal/Lac CM 
   
   
Gal3 CM + Cytokine 
mAbs 
BSA CM + rCytokines  
  
 
 
  
A 
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CM from BSA-treated HMVEC-Ls + - - - +  + - - - + 
CM from Gal-3-treated HMVEC-Ls - + + + -  - + + + - 
CM from Gal-3/Lac-treated 
HMVEC-Ls 
- - + - -  - - + - - 
Cytokine neutralizing antibodies - - - + -  - - - + - 
Recombinant cytokines - - - - +  - - - - + 
 
Fig. 5.7: Galectin-3-induced cytokine secretion promotes endothelial tubule formation. 
HUVEC cells were cultured on top of matrix proteins in the conditioned medium (CM) 
obtained from HMVECs treated with BSA or galectin-3 (1.5µg/ml) for 24 hr in the presence or 
absence of 10µM lactose, with or without introduction to the conditioned medium of a 
combination of neutralizing antibodies against G-CSF, GM-CSF, IL-6 and sICAM-1 or a 
combination of recombinant G-CSF, GM-CSF, IL-6 and sICAM-1 for 24 hr at 370C. Picture of each 
well was taken and representative pictures were shown (A), while tubule length and branch 
points (B) were quantified. The data are expressed as percentages compare to BSA-treated 
controls from three independent experiments, each in triplicate (n=3). P***<0.001 (One-way 
ANOVA followed by Bonferroni). 
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When the tubule formation ability of endothelial cells was analyzed, the 
HUVECs (the most commonly used endothelial cells for investigating in vitro tubule 
formation) cultured in the conditioned medium obtained from 24 hr galectin-3 
(1.5μg/ml)-treated HMVECs showed significant increase in tubule length 
(219.7±7.7%) and branch points (329.9±52.6%) compared with HUVEC cells cultured 
in the conditioned medium from 24 hr BSA-treated HMVECs (Fig. 5.7). These effects 
were prevented when the galectin-3 inhibitor lactose was introduced as galectin-3 or 
a combination of neutralizing antibodies against G-CSF, GM-CSF, IL-6 and sICAM-1 
was added to the conditioned medium. Moreover, introduction of a combination of 
recombinant G-CSF, GM-CSF, IL-6 and sICAM-1 to the BSA-treated control medium 
resulted in similar increases in HUVEC tubule length (247.1±30.7%) and formation of 
branch points (321.8±58.8%) to those induced by the galectin-3-conditioned 
medium. Together, these results suggest that galectin-3-induced secretion of 
cytokines from the vascular endothelium also promotes endothelial angiogenesis. 
 
5.4.4 Investigation of effect of galectin-3 treatment on MMP secretion 
by HMVEC-Ls cells 
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases which 
are capable of degrading all kinds of extracellular matrix proteins, as well as carrying 
out a number of other bio-activities. They are known to be involved in the cleavage 
of cell surface receptors, the release of apoptotic ligands and cytokine activation 
(416). MMPs are also largely responsible for endothelial cell invasion by digesting the 
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basement matrix (417). As several cytokines have been reported to induce 
endothelial secretion of MMPs, we investigated whether galectin3-induced secretion 
of cytokines increases endothelial cell secretion of MMPs using a transwell system. 
HMVEC-Ls were released from the culture flasks by trypsinization and suspended at 
2 x 105/ml with EBM-2 culture medium before application of 200μl/well to each well 
on the top chamber of a cell invasion device and 150μl/well serum-free EBM-2 was 
added to each well on the bottom chamber before incubation for 24 hr at 37℃. The 
medium in the top chamber wells was replaced with fresh EGM-2 medium after 
three hours to remove residual Trypsin. On the next day, the medium in the top 
chamber was replaced by medium containing 1.5µg/ml BSA (control) or recombinant 
galectins-3 respectively, and the serum-free EBM-2 at the bottom wells was also 
renewed. After 24 hr incubation at 37℃, the medium (1ml/well) in the bottom 
chamber wells was collected and the levels of MMP were analyzed with the RayBio 
Human MMP Array, which include MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-
10, MMP-13, TIMP-1, TIMP-2, TIMP-4. 
    
A B 
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Fig. 5.8: The presence of galectin-3 does not affect MMP secretion by HMVEC-Ls. 
 The level of MMPs in the galectin-3-treated (A) or control wells of HMVEC-Ls in the 
chamber device were tested with the human MMPs array.  
 
No detectable difference in the MMP levels in the medium from control or 
galectin-3-treated HMVEC-Ls was observed (n=2) (Fig. 5.8). 
 
5.4.5 Investigation of galectin-3 binding to endothelial cells 
To gain insight into the action of galectin-3-induced cytokine secretion by the 
endothelial cells, galectin-3 blotting of HMVEC-Ls was conducted. 
Each flask of HMVEC-Ls cells was harvested by Trypsin (1ml Trypsin for each T25 
flask) and lysed by 50µl 10% SDS sample buffer. Then 30µl of the cell lysis was loaded 
to each lane. In the blotting, the membranes were probed with or without 10µg/ml 
galectin-3 followed by probing with Biotinylated-anti galectin-3 as first antibody 
(10µg/ml) and Avidin-peroxidase conjugate bind to biotin of the biotinylated-anti 
galectin-3 (10µg/ml) as secondary antibody.  
 
Endothelial Cells (HMVEC-Ls): 
kDa 
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 Rhgalectin-3 + - - 
Biotinylated-anti galectin-3 + + - 
Avidin-peroxidase conjugate bind to biotin  
of the biotinylated-anti galectin-3 
+ + + 
 
Fig. 5.9: Galectin-3 recognizes several HMVEC-Ls proteins. A T25cm2 flask of HMVEC-Ls 
cells was cultured to 80% confluence and released with Trypsin then lysed in sample buffer and 
the cell extracts were electrophoresed on an SDS PAGE (10%) electrophoresis gel. 
 
Several HMVEC-Ls proteins have proved to be recognized by galectin-3 when 
assessed by galectin-3 blotting (Fig. 5.9). By comparing first two lanes, it is shown 
that galectin-3 could recognize several proteins on the HMVEC-Ls. One of these 
proteins may represent the galectin-3 ligand responsible for galectin-3-mediated 
cytokine secretion. Flow cytometry could be further used to identify the specific 
galectin-3 binding ligand. 
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5.4.6 Investigation of effect of galectin-3 treatment on expression of 
phosphorylation in HMVEC-Ls cells 
HMVEC-Ls cells were further investigated by means of a Human Phospho-Kinase 
Array that covers the 46 phosphorylation sites.  
Each flask of the HMVEC-Ls monolayer was cultured in EBM-2 medium with the 
presence or absence of 1.0µg/ml galectin-3 or 1.0µg/ml BSA for 24 hr at 37℃ before 
being washed by PBS three times (10ml/time). The supernatants were removed 
completely before 0.4ml of Lysis Buffer 6 (from the kit) was added, mixed and left on 
a rocking platform for 30 minutes on ice to lyse the cells. After being centrifuged at 
1000 (*g) for 5 minutes, the supernatant was transferred into a clean test tube and 
immediately used for the Phospho-array. 
 
Fig. 5.10: The presence of galectin-3 does not induce phosphorylation change in ACA19.- 
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 Forty-six phosphorylation sites on the HMVEC-Ls cells treated with 1.0µg/ml BSA or with 
1.0 µg/ml galectin-3 for 30 minutes were tested by the Human Phospho-Kinase Array. No 
statistical significance was observed. 
 
No apparent phosphorylation difference was observed between HMVEC-Ls 
cultured with galectin-3 or BSA (Fig. 5.10). 
 
5.4.7 Investigation of effect of galectin-3 induced cytokine secretion 
on metastasis formation in mice 
To directly assess the influence of galectin-3-induced cytokine secretion on 
metastasis, we injected either PBS or a combination of GM-CSF, G-CSF, IL-6 and 
ICAM-1, at similar levels to those observed in mouse serum following galectin-3 
injection. Eight mice were treated per experimental group. One mouse per group 
(PBS and cytokines injection) was sacrificed after four weeks and the rest were 
sacrificed six weeks post-injection and metastatic foci in the lungs were examined.  
 
Control Treated 
A B 
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Fig. 5.11: Injection of a combination of cytokines (G-CSF, GM-CSF, IL-6 and sICAM-1) 
followed by galectin-3 promotes metastasis (B) in mice compared with BSA-treated control 
group (A). The pictures represent 7 mice each group after six weeks’ treatment. 
 
More microscopic metastatic nodules were observed in the cytokine-treated 
compared with the control mice after four weeks (15 vs. 0) and after six weeks (6 vs. 
2) assessed by histology (Fig. 5.11). This result is not statistically significant 
(p=0.151). This may relate to the large standard deviation within the cytokine-
treated group, which might be caused by failed injection. 
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5.4.8 Investigation of relationship between circulating galectin-3 and 
cytokine levels in colon cancer patients 
To confirm whether the influence of galectin-3 on cytokine secretion observed 
in mice also held true for cancer patients, we investigated the relationship between 
serum galectin-3 and serum IL-6, G-CSF, GM-CSF and sICAM-1 concentrations in 50 
colorectal cancer patients with or without clinically detectable metastasis (Table 
5.1).  
Table 5.1: Concentrations and relationship between serum galectin-3 and IL-6, G-
CSF, GM-CSF and sICAM-1 in colorectal cancer patients with the presence or 
absence of metastasis 
 Serum concentrations 
Median (range, ng/ml)  
Spearman’s rho 
correlation  
coefficient  
p  
All patients (n=50)     
            Gal-3  106.8 (7.5-5106.3)    
            IL-6  5.0 (2.1-287.8)    
           GM-CSF  15.8 (5.4-833.3)    
            G-CSF  43.0 (11.0-13266.0)    
            sICAM1  14442.0(7593.5-
30235.9)  
  
Patients without metastasis 
(n=39)  
   
            Gal-3  82.0 (7.5-1603.9)    
            IL-6  5.2(2.7-72.1)    
            GM-CSF  14.8(5.4-157.1)    
            G-CSF  33.1 (11.1-3973.0)    
            sICAM1  15148.1(8414.1-
30235.9)  
  
Patients with metastasis 
(n=11)  
   
            Gal-3  215.0 (30.9-5106.3)    
            IL-6  3.5(2.1-287.8)    
            GM-CSF  15.8(12.0-833.3)    
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            G-CSF  29.0(15.0-13266.0)    
            sICAM1  12516.7(7593.5-
21621.2)  
  
    
All patients     
            Gal-3 and IL-6     
            Gal-3 and GM-CSF   0.17  0.12  
            Gal-3 and G-CSF   0.24  0.045  
            Gal-3 and sICAM-1   -0.11  0.22  
Patients without metastasis     
            Gal-3 and IL-6   0.12  0.23  
            Gal-3 and GM-CSF   0.11  0.26  
            Gal-3 and G-CSF   0.19  0.13  
            Gal-3 and sICAM-1   -0.056  0.37  
Patients with metastasis  
            Gal-3 and IL-6   0.51  0.05  
            Gal-3 and GM-CSF   0.22  0.26  
            Gal-3 and G-CSF   0.55  0.04  
            Gal-3 and sICAM-1   0.73  0.005  
Serum concentrations of IL-6, G-CSF, GM-CSF and sICAM-1 in 50 colorectal cancer patients 
with and without clinically detectable liver metastasis were determined by galectin-3 ELISA. The 
relationship between serum galectin-3 and each of those cytokines was analyzed by Spearman 
correlation analysis. 
 
A significant correlation between circulating galectin-3 concentration was 
observed with G-CSF levels (p<0.05) but not with the other three cytokines when all 
patients were considered together (Table 5.1). When, however, serum galectin-3 and 
cytokine levels were further analyzed in the patients who did not have metastasis 
and those with metastasis, significant correlations of galectin-3 levels were observed 
with G-CSF (p=0.04), IL-6 (p=0.05) and sICAM-1 (p=0.005) in patients with metastasis 
but not in those without metastasis (Table 5.1). This further supports an active role 
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of circulating galectin-3 in secretion of these metastasis-promoting cytokines in 
cancer patients.  
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5.5 Discussion 
The experiments described here show that galectin-3-induced cytokines 
promote expression of cell surface adhesion molecules, as well as endothelial cell 
migration and micro-vascular tubule formation during angiogenesis. Thus, circulating 
galectin-3 induces the secretion from blood vascular endothelium of several 
cytokines including pro-inflammatory cytokines that promote cancer cell adhesion 
and angiogenesis. Such a conclusion is clearly supported by the observed correlation 
between circulating galectin-3 and these cytokines in colorectal cancer patients who 
suffer from metastasis.  Galectin-3-mediated secretion of IL-6, G-CSF, GM-CSF and 
sICAM-1 from endothelium increases the expression of the endothelial cell surface 
adhesion molecules integrinα5β1, E-selectin, VCAM-1 and ICAM-1.  
ICAM-1 and VCAM-1 are members of the immunoglobulin superfamily and each 
carries a different number of extracellular immunoglobulin-like domains. Selectins 
are transmembrane glycoproteins that contain a lectin domain for binding to ligands, 
an epidermal growth factor-like domain and a series of short consensus repeats 
(SCR) in the extracellular region. Each selectin differs in the number of SCR domains. 
Integrins are transmembrane adhesion molecules and each is composed of one α 
and one β chains. There are at least 20 different α chains and nine different β chains. 
These cell surface adhesion molecules are responsible for recruiting leukocytes onto 
the vascular endothelium before extravasation to the injured tissues in 
inflammation. The expressions of those cell surface adhesion molecules are also 
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believed to be crucial in adhesion of disseminating tumor cells to the blood vascular 
endothelium in cancer cell haematogenous metastasis (409, 418). 
Earlier studies have shown that pro-inflammatory cytokines such as TNFα and 
IL-1 can induce endothelial expression of cell surface adhesion molecules that 
increase the lodging of circulating tumor cells on the capillary bed both in vitro and 
in vivo (419). For example, intravenous injection of IL-1β into C57BL/6 mice 
increased the endothelial expressions of E-selectin, ICAM-1 and VCAM-1 in the 
hepatic microvasculature, causing a twofold reduction of B16F1 melanoma cell 
velocity in the blood circulation when they were subsequently injected (420). It has 
been postulated that induction of cell surface adhesion molecules by pro-
inflammatory cytokines may partly account for the promotion of inflammation in 
cancer progression. Different inflammatory cytokines can influence the expression of 
different cell adhesion molecules in different cells. TNFα and LPS for example induce 
endothelial cell expression of E-selectin, ICAM-1 and VCAM-1 whereas Il-1β showed 
no effect on expression of these cell adhesion molecules (421).  
The presence of exogenous galectin-3 in the culture medium, albeit at supra-
pathological concentrations, has been previously shown to induce endothelial cell 
morphogenesis (422) and enhance VEGF- and bFGF-mediated angiogenesis by 
binding to the N-glycans of endothelial-associated integrinα5β3 (423). As clustering of 
galectin-3 with its ligands can enhance the galectin-3 binding affinity as much as 
10,000-fold (333), the effect of galectin-3 on VEGF- and bFGF-mediated angiogenesis 
demonstrated previously with higher than pathological concentrations of galectin-3 
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may also be functionally relevant in the blood circulation and contribute to 
metastasis promotion.  
Several endothelial proteins seem to be recognized by galectin-3 when assessed 
by galectin-3 blotting. It is likely that one of these proteins represents the galectin-3 
binding ligand responsible for galectin-3-mediated endothelial secretion of 
cytokines.   
Thus, the increased circulation of galectin-3 in the bloodstream of cancer 
patients has several important and distinctive influences on cancer metastasis. It can 
interact directly with disseminating tumor cells through TF/MUC1 and increases 
cancer cell heterotypic adhesion (388) and homotypic aggregation (381). It can also 
interact with endothelial cells and induce endothelial secretion of metastasis-
promoting cytokines and indirectly enhance metastasis. The increased circulation of 
galectin-3 in the bloodstream of cancer patients is therefore an important metastasis 
promoter. Targeting the actions of circulating galectin-3 represents a very promising 
therapeutic strategy to reduce metastasis and improve cancer survival. 
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CHAPTER 6 Investigation of the effect of circulating galectin-2, -4 
and -8 on cytokine secretion by blood vascular endothelium  
6.1 Hypothesis and Aim 
To assess the hypothesis that circulating galectin-2, -4 and -8, whose levels are 
also increased in cancer patients, may affect secretion of cytokines by vascular 
endothelium in a way likely to promote metastasis. 
 
6.2 Introduction 
Galectins are a family of 15 mammalian galactoside-binding proteins that share 
a consensus amino acid sequence in their carbohydrate recognition domains 
(CRDs)(171). Recent studies in our laboratory have shown that the levels of galectin-
2, -4 and -8, like that of galectin-3, are all significantly increased in colon and breast 
cancer patients and particularly those with metastasis (321). Galectin-2 is a 
prototype galectin which contains only one CRD in its polypeptide sequences and 
galectin-4 and -8 are tandem-repeat type galectins which contain two CRDs in a 
single polypeptide chain. Although their structures are different from galectin-3, the 
only chimera-type galectin composed of a non-lectin domain linked to a CRD, they 
are all able to bind to galactoside-terminated glycans and form lattice structures on 
the cell surface. As circulating galectin-3 has been shown to induce secretion of 
cytokines by the blood vascular endothelium, we investigated whether those 
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galectin members whose levels are also increased in cancer patients also affect the 
endothelial secretion of cytokines. 
 
6.3 Materials and Methods 
6.3.1 Cytokine determination by Human Cytokine Array 
Eighty per cent confluent HMVEC-Ls were released from the culture flasks by 
trypsinization and suspended at 1 x 105/ml with EBM-2 medium. HMVEC-Ls 
suspensions were cultured in a six-well plate (2ml/well) at 37℃ for 24 hr before 
introduction of 1.5µg/ml recombinant galectin-2, -4, -8 or BSA for 24 hr. The 
conditioned media were collected and the concentrations of cytokines in the culture 
media were tested with Human Cytokine Protein Array as described in Chapter 3. 
 
6.3.2 Cytokine determination by ELISA 
HMVEC-Ls were released from the culture flasks by trypsinization and 
suspended with EBM-2 medium at 1 x 105 cells/ml. HMVEC-Ls suspensions were 
added to a 12-well plate (1ml/well) and cultured for 24 hr before introduction of 1.5 
µg/ml  recombinant galectin-2, -4, -8 or BSA for 24 hr. The conditioned medium was 
collected and the concentrations of cytokines in the conditioned medium were 
analyzed by cytokine ELISA kits as in chapter 3. 
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6.3.3 Investigation of effect of galectin-2, -4 or -8 on cancer cell-
endothelial adhesion-1 
HMVEC-Ls were released from the culture flasks by trypsinization and 
suspended with EBM-2 medium (at 2 x 105 cells/ml) before application of 200μl/well 
to each well of a 96-well plate. The medium in each well was replaced with 150 µl 
fresh EBM-2 medium after three hours. The cells were incubated until the formation 
of a cell monolayer (one day) before they were treated with 1.5µg/ml of galectin-2, -
4, -8 or BSA in the presence or absence of lactose (10μM) for 24 hr. The HMVEC 
monolayer was then washed and used for subsequent assessment of cancer cell 
adhesion. 
ACA19- and HCT116 cancer cells were detached from the culture plates with 
NECDS, washed and resuspended in serum-free DMEM medium (for ACA19 or 
McCoy’s 5a medium for HCT116) at 5x106 cells/ml.  The ACA19- and HCT116 cancer 
cells were labeled with Calcein AM Cell Labeling Solution (10 µl for 1 ml of cell 
suspension) for 30 minutes. The cells were washed and resuspended in serum-free 
medium (at 5 x 104 cells/ml) before application of 100 µl to the HMVEC monolayer. 
After 1 hr of culture, the HMVEC monolayer was washed and the endothelial cell-
associated fluorescence was measured. 
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6.3.4 Assessment of the effect of galectin-2, -4 or -8 on cancer cell-
endothelial adhesion-2 
To the HMVEC-Ls cells used for obtaining the conditioned medium, HMVEC-Ls 
were released from the culture flasks by trypsinization and suspended with EBM-2 
medium at 2 x 105/ml before application of 2 ml to each well of six-well plates. The 
medium in each well is replaced with 150 µl fresh EGM-2 medium after three hours. 
The cells were incubated for one day until the formation of a cell monolayer, when 
they were treated with 1.5µg/ml of galectin-2, -4, -8 or BSA in the presence or 
absence of lactose (3mM) for 24 hr. The culture medium (conditioned medium) was 
collected for use in the next step. 
HMVEC-Ls were released from the culture flasks by trypsinization and 
suspended with EBM-2 medium at 2 x 105/ml before application of 200μl to each 
well of a 96-well plate. The medium in each well was replaced with 150μl fresh EGM-
2 medium after three hours. The cells were incubated until the formation of a cell 
monolayer for one day. Before the adhesion, the HMVEC monolayer was washed 
and incubated for 1 hr with conditioned medium obtained earlier. Then the HMVEC-
Ls monolayers were washed and used for subsequent assessment of cancer cell 
adhesion. 
ACA19- or HCT116 cancer cells were detached from the culture plates with 
NECDS, washed and resuspended in serum-free DMEM medium (McCoy’s 5a 
medium for HCT116) at 5x106 cells/ml. The ACA19- and HCT116 cancer cells in 1 ml 
were labeled with 10μl Calcein AM Cell Labeling Solution for 1 hr, washed and 
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resuspended in serum-free medium at 5x104/ml before application of 5x103/well to 
the HMVEC monolayer for 1 hr at 37℃. The HMVEC monolayer was washed and the 
endothelial cell-associated fluorescence was measured. 
 
6.3.5 Assessment of cell surface adhesion molecules by flow cytometry 
Sub-confluent HMVEC-Ls were treated with galectin-2, -4 or -8 (1.5µg/ml) for 24 
hr at 37℃. The cells were released from the culture flasks by trypsinization. After 
they had been washed once with PBS 5ml 2% paraformaldehyde was added to fix 
the cells. Then the cells were washed twice and centrifuged to remove the 
supernatants. After addition of 0.5ml PBS, cells were counted and resuspended in 
106/ml with 5% goat serum/PBS for 30 minutes at room temperature on the roller. 
After removal of the supernatant following centrifugation, the cells were 
resuspended in 1% goat serum in PBS and aliquoted to 1ml/tube in 1.5ml tubes. 
Antibodies against CD44 (1mg/ml), integrinα5β1 (1mg/ml), E-selectin (1mg/ml) and 
VCAM (1mg/ml) in PBS (1:400 dilution) were applied to the cells for 1 hr at room 
temperature on the roller (or overnight at 4℃). After two washes with PBS, FITC-
conjugated secondary antibodies (1:400 in 1% BSA in PBS) were applied to the cells 
for 1 hr at room temperature. After three washes with PBS, the cells were 
resuspended in PBS in 0.5ml/tubes. The cell surface expression of CD44, 
integrinα5β1, E-selectin and VCAM were analyzed by flow cytometry. FITC- 
conjugated secondary antibody without the primary antibody was used as a negative 
control in all the flow cytometry analyses.  
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6.3.6 Assessment of endothelial tubule formation  
HMVEC-Ls (1 x 105/well) were cultured in a 12-well plate at 37℃ for 24 hr 
before introduction of 1.5µg/ml recombinant galectin-2, -4, -8 or BSA with or 
without the addition of a combination of anti-cytokine antibodies (final 
concentration: G-CSF(5ng/ml), IL-6(3ng/ml), GROα(20ng/ml) and MCP-1(20ng/ml)) 
for 24 hr. The conditioned medium was collected for the following assessment steps. 
The culturing time was precisely calculated so that the conditioned medium was 
fresh. 
Sub confluent HUVEC cells cultured in T25 flasks were incubated with the 
Calcein AM solution (5 ml per T25 flask) for 30 minutes at 37℃ in a CO2 incubator 
before they were released by NECDS (2ml/each), the supernatant was discarded 
after centrifugation at 1500 (x g) for 5 min. Then the cell pellet was resuspended by 
200μl PBS and further diluted to 1 x 105 cells /ml using each group of the conditioned 
medium collected above. 100μl of diluted cells (1 x 104 cells / well) was added slowly 
onto each well of the 96 well plates containing gelled BME. The plate was then 
incubated at 37℃ in a CO2 incubator for 24 hours before tube formation was 
analyzed as described in the chapter 3. 
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6.4 Results 
6.4.1 Investigation of effect of galectin-2, -4 or -8 on cytokine secretion 
by HMVEC-Ls  
The effect of galectin-2, -4 and -8 on cytokine secretion by endothelial cells was 
first assessed with HMVEC by Human Cytokine Protein Array. 
  
172 
 
  
 
Fig. 6.1: Galectin-2, -4 or -8 induce secretion of cytokines from HMVEC-Ls after 24 hr 
culture. The levels of 36 cytokines in the CM were tested by using Human Cytokine Array Panel 
Kit and four cytokines (G-CSF, IL-6, GROα and MCP-1) were shown to be increased after 
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treatment of HMVECs with 1.5µg/ml galectin-2, -4 or -8 for 24 hr (A).  Changes in these cytokines 
were quantified by densitometry scanning of the array (B) (n=2). 
After 24-hr treatment with galectins, the levels of four cytokines in the culture 
medium of HMVECs showed an increase in comparison with the control cells.  
Galectin-2 treatment appeared to cause an increase of G-CSF (3.00-fold), GROα 
(1.70-fold), and IL-6 (1.48-fold).  Galectin-4 treatment caused an increase of G-CSF 
(2.59-fold), IL-6 (1.40-fold), GROα (1.70-fold) and MCP-1 (2.99-fold) whereas 
galectin-8 treatment caused an increase of G-CSF (2.39-fold), IL-6 (1.48-fold), GROα 
(1.7-fold) and MCP-1 (2.99-fold) (Fig. 6.1). 
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To investigate whether the G-CSF, IL-6, GROα and MCP-1 secretion induced by 
galectin-2, -4 or -8 were dose-dependent, confluent HMVEC-Ls cell monolayers were  
treated with galectin-2, -4 or -8 in different concentrations (BSA control, 0.1, 0.2, 0.5, 
1 and 2µg/ml) for  24 hr  and the level of G-CSF, IL-6, GROα and MCP-1 in the culture 
medium was then determined by individual cytokine ELISA. 
 
 
Fig. 6.2: Galectin-2, -4 and -8 induce dose-dependent secretion of G-CSF, IL-6, GROα and 
MCP-1 by endothelial cells. HMVEC-Ls cells were treated with or without various pathological 
galectin-2, -4 or -8 concentration (BSA control, 0.1, 0.2, 0.5, 1 and 2µg/ml) for 24 hr before the 
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concentrations of each cytokine in the conditioned medium were determined. The data are 
expressed as mean ± SD of triplicate determinations of three independent experiments. *p<0.05, 
**p<0.01, ***p<0.001 (one-way ANOVA followed by Bonferroni). 
 
It was found that treatment of the cells with each of these galectins caused a 
dose-dependent increase of these cytokines (Fig. 6.2 and Table 6.1-6.4).  
A 33.8±3.9%, 56.3±6.4% increase of G-CSF was induced by 1 or 2µg/ml galectin-
2, 27.1±6.2% by 2µg/ml galectin-4 and 30.4±7.0%, 64.9±0.5% by 1 or 2µg/ml 
galectin-8 in comparison with the BSA-treated control cells. 
A  98.2±12.3%, 175.0±33.5% increase of IL-6 was induced by galectin-2, 
101.5±26.0%, 250.8±4.1% by  galectin-4 and 138.4±18.5%, 190.4±12.2% by galectin-8 
in the culture medium treated after treatment of the cells with 1µg/ml or 2µg/ml 
galectin-2, -4 or -8 for 24 hr in comparison with the BSA-treated control cells. 
A 2091.4±325.6% increase of GROα was induced by 1µg/ml galectin-2, 
1159.3±150.5%, 2338.9±363.8% by galectin-4 and 2559.1±513.9%, 3838.6±725.0% 
by galectin-8 in the culture medium treated with 1µg/ml or 2µg/ml galectin-2, -4 or -
8 for 24 hr in comparison with the BSA-treated control cells. 
A 4432.3±1278.6%, 12729.1±2111.8% increase in the MCP-1 level was induced 
by galectin-4 and 13202.0±2816.9%, 18945.4±626.9% by galectin-8 in the culture 
medium treated with 1µg/ml or 2µg/ml galectin-2, -4 or -8 for 24 hr in comparison 
with the BSA-treated control cells. 
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Table 6.1: Galectin-2, -4 or -8 induce G-CSF secretion from HMVEC-Ls (dose 
dependent manner) 
G-CSF Concentration 
(µg/ml) 
Increase 
compare to 
dose 0 (%) 
Standard 
Deviation 
P value 
Galectin-2 0.5 12.9 1.24 0.224 
1 34.1 0.61 0.002 
2 56.4 3.89 <0.001 
Galectin-4 1 15.6 0.44 0.459 
2 27.6 3.28 0.036 
Galectin-8 0.5 13.0 2.44 0.136 
1 31.0 1.66 0.001 
2 65.7 0.69 <0.001 
 
Table 6.2: Galectin-2, -4 or -8 induce IL-6 secretion from HMVEC-Ls (dose 
dependent manner) 
IL-6 Concentration 
(µg/ml) 
Increase 
compare to 
dose 0 (%) 
Standard 
Deviation 
P value 
Galectin-2 0.5 48.4 33.5 0.787 
1 97.3 12.3 0.043 
2 172.2 33.5 0.002 
Galectin-4 0.5 4.12 2.0 1.000 
1 101.6 26.5 0.002 
2 250.0 4.1 <0.001 
Galectin-8 0.5 35.8 13.3 0.650 
1 136.7 18.5 0.001 
2 188.8 12.2 <0.001 
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Table 6.3: Galectin-2, -4 or -8 induce GROα secretion from HMVEC-Ls (dose 
dependent manner) 
GROα Concentration 
(µg/ml) 
Increase 
compare to 
dose 0 (%) 
Standard 
Deviation 
P value 
Galectin-2 0.5 251.7 29.2 1.000 
1 649.3 225.1 0.109 
2 2059.0 325.7 <0.001 
Galectin-4 0.5 634.8 177.3 0.172 
1 1159.4 150.4 0.009 
2 2331.7 363.3 <0.001 
Galectin-8 0.5 954.8 52.3 0.611 
1 2528.6 505.7 0.007 
2 3776.1 715.1 0.001 
 
Table 6.4: Galectin-2, -4 or -8 induce MCP-1 secretion from HMVEC-Ls (dose 
dependent manner) 
MCP-1 Concentration 
(µg/ml) 
Increase 
compare to 
dose 0 (%) 
Standard 
Deviation 
P value 
Galectin-2 0.5 -45.3 24.1 1.000 
1 56.2 17.6 0.832 
2 23.0 33.2 1.000 
Galectin-4 0.5 191.8 29.1 1.000 
1 4434.4 1277.3 0.064 
2 12730.7 2074.8 <0.001 
Galectin-8 0.5 1156.7 110.3 1.000 
1 13474.4 2818.6 0.001 
2 18945.0 1046.2 <0.001 
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Further experiments were conducted to test if the galectin-mediated secretion 
of cytokines was time-dependent. A confluent HMVEC-Ls monolayer in a 96-well 
plate was treated with galectin-2, -4 or -8 (1.5µg/ml) for different times (0, 4, 8, 12, 
16, 20 and 24 hr) before the levels of G-CSF, IL-6, GROα and MCP-1 in the culture 
medium were determined by individual cytokine ELISA. 
 
Fig. 6.3: Galectin-2, -4 and -8 induce time-dependent secretion of G-CSF, IL-6, GROα and 
MCP-1 by endothelial cells. HMVEC-Ls cells were treated with 1.5µg/ml galectin-2, -4 or -8 for 
different times (0 for fresh medium, 4, 8, 12, 16, 20 and 24 hr) before the concentrations of each 
cytokine in the conditioned medium were determined. The data are expressed as mean ± SD of 
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triplicate determinations of three independent experiments. *p<0.05, **p<0.01, ***p<0.001 
(one-way ANOVA followed by Bonferroni). 
 
In comparison with the medium of BSA-treated cells, increases of 39.2±10.2% at 
20hr and 90.5±3.1% at 24 hr levels were seen for galectin-2 , a 41.4±14.6% increase 
at 20hr and 107.1±3.9% at 24 hr was seen for galectin-4, and a 48.6±9.3% increase at 
20hr and 130.7±14.4% at 24 hr of G-CSF was induced by galectin-8 (Fig. 6.3 and Table 
6.5-6.8). 
In comparison with the BSA-treated cells an increase of 56.9±17.8% at 24 hr was 
produced by galectin-2, an increase of 60.3±5.4% at 24 hr by galectin-4 and an 
increase of 58.6±6.5% at 24 hr of IL-6 by galectin-8. 
In comparison with the BSA-treated cells an increase of 65.4±16.7% at 24 hr by 
galectin-2, an increase of 52.7±12.5% at 24 hr by galectin-4 and  an increase of 
123.6±1.4% at 16hr, 116.4±1.6% at 20hr and 158.2±19.1% at 24 hr of GROα by 
galectin-8 were observed. 
In comparison with the BSA-treated cells an increase of 181.2±10.0% at 16hr, 
141.6±16.7% at 20hr and 174.5±10.2% at 24 hr by galectin-4, an increase of 
258.5±16.4% at 16hr, 194.4±12.7% at 20hr and 232.5±11.5% at 24 hr of MCP-1 by 
galectin-8 were observed. Galectin2 did not show any significant effect on MCP1 
secretion. 
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Table 6.5: Galectin-2, -4 or -8 induce G-CSF secretion from HMVEC-Ls (time-
dependent manner) 
G-CSF Time point 
(hr) 
Increase 
compare to 
BSA treated 
control (%) 
Standard 
Deviation 
P value 
Galectin-2 16 24.7 22.9 0.57 
20 39.1 10.3 0.015 
24 90.5 3.1 0.005 
Galectin-4 20 37.6 9.2 0.87 
24 41.4 14.6 0.014 
48 107.0 3.9 0.004 
Galectin-8 20 60.7 10.8 0.34 
24 48.5 9.4 0.01 
48 130.6 14.5 0.004 
 
Table 6.6: Galectin-2, -4 or -8 induce IL-6 secretion from HMVEC-Ls (time-
dependent manner) 
IL-6 Time point 
(hr) 
Increase 
compare to 
BSA treated 
control (%) 
Standard 
Deviation 
P value 
Galectin-2 20 23.0 15.4 0.28 
24 56.6 17.9 0.046 
Galectin-4 20 28.4 0 0.22 
24 59.3 5.3 0.044 
Galectin-8 20 28.4 2.9 0.22 
24 57.9 6.6 0.045 
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Table 6.7: Galectin-2, -4 or -8 induce GROα secretion from HMVEC-Ls (time-
dependent manner) 
GROα Time point 
(hr) 
Increase 
compare to 
BSA treated 
control (%) 
Standard 
Deviation 
P value 
Galectin-2 20 54.0 30.0 0.10 
24 65.4 18.2 0.004 
Galectin-4 20 32.9 5.8 0.02 
24 53.1 12.5 0.005 
Galectin-8 12 7.58 9.6 0.34 
16 123.59 1.3 0.012 
20 115.0 1.6 0.004 
24 158.0 19.1 0.003 
 
Table 6.8: Galectin-2, -4 or -8 induce GROα secretion from HMVEC-Ls (time-
dependent manner) 
MCP-1 Time point 
(hr) 
Increase 
compare to 
BSA treated 
control (%) 
Standard 
Deviation 
P value 
Galectin-2 12 55.8 27.9 0.21 
20 -28.7 4.7 0.14 
24 -34.4 6.1 0.10 
Galectin-4 12 262.2 17.5 0.32 
16 181.0 10.0 0.03 
20 141.2 16.7 0.03 
24 176.5 10.2 0.03 
Galectin-8 12 321.1 30.3 0.22 
16 258.2 16.4 0.04 
20 187.6 12.6 0.03 
24 232.6 11.5 0.02 
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Thus, galectin-2, -4 and -8 at concentrations similar to those in cancer patients 
induce dose- and time-dependent increase of several cytokines in the vascular 
endothelium. 
 
6.4.2 Investigation of the effect of lactose on galectin-mediated 
cytokine secretion in HMVEC-Ls 
To confirm whether galectin-2, -4 or -8 induce cytokine secretion was mediated 
through the galectin carbohydrate binding sites, we further assessed the effect of 
the galectin-binding inhibitor lactose on galectin-mediated cytokine secretion.  
First 1.5µg/ml of galectin-2, -4 or -8 were pre-incubated with/without 10µM of 
lactose for 10 minutes before application to (100µl/well) a 96-well plate with 
confluent HMVEC-Ls cell monolayers.  After 24 hr incubation, the levels of G-CSF, IL-
6, GROα and MCP-1 in the conditioned medium were determined by ELISA. 
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Fig. 6.4: Galectin-2, -4 or -8 induced G-CSF, IL-6, GROα and MCP-1 secretion from HMVEC-
Ls inhibited by the presence of lactose. The HMVEC-Ls monolayers were treated with 1.5µg/ml 
galectin-2, -4 or -8 mixed with/without 10µM lactose for 24 hr before the conditioned medium 
was collected and the level of G-CSF, IL-6, GROα and MCP-1 was determined. The data are 
expressed as mean ± SD of triplicate determinations of three independent experiments. *p<0.05, 
**p<0.01 (one-way ANOVA followed by Bonferroni). 
 
It was found that the increased secretions of G-CSF induced by galectin-
2(33.6±13.6%), -4(84.0±33.5%) or -8(44.3±9.9%) are all abolished in the presence of 
lactose. Similarly, the increased secretions of IL-6 induced by galectin-2(39.4±13.7%), 
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-4(79.5±30.0%) or -8(94.2±12.9%) are all abolished in the presence of lactose. The 
increased secretions of GROα induced by galectin-2(29.6±6.2%), -4(73.2±24.6%) are 
abolished, and the increased secretions of GROα induced by galectin-8(55.5±9.8%) 
are inhibited (60.4±2.6%) in the presence of lactose. Secretions of MCP-1 induced by 
galectin-4(99.8±12.8%) were abolished and the increased secretion of MCP-1 
induced by galectin-8 (150.0±32.1%) was inhibited (87.6±19.4%) in the presence of 
lactose (Fig. 6.4). 
 
6.4.3 Investigation of effect of galectin-induced cytokine secretion by 
HMVEC-Ls on cancer cell adhesion  
Earlier studies have shown galectin-3 induced secretion of IL-6, G-CSF, GM-CSF 
and ICAM1 by HMVEC-Ls can enhance cancer cell-endothelial adhesion. As galectin-
2, -4 and -8 are also able to induce the secretion of IL-6 and G-CSF, we investigated 
the effect of galectin-2, -4, -8-mediated secretion of the cytokines by HMVEC-Ls on 
subsequent cancer cell-endothelial adhesion. 
Confluent HMVEC-Ls cell monolayers in each well of a 96-well plate were 
treated with 1.5µg/ml galectin-2, -4 or -8 for 24 hrs, and BSA was used as negative 
control. After 24 hr, the culture medium from each well was discarded and 100µl 
ACA19- human melanoma cells labeled by Calcein AM at a concentration of 1 x 
105/ml were added to the HMVEC-Ls monolayer for 1 hr. After they had been 
washed twice with PBS, the fluorescent intensity in each well which represented the 
remaining cancer cells was determined. 
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Fig. 6.5: The presence of galectin-2, -4 or -8 increases ACA19- (A) or HCT116 cell (B) 
adhesion to HMVEC-Ls. The HMVEC-Ls monolayers in each well in a 96-well plate were treated 
with 1.5µg/ml galectin-2, -4 or -8 for 24 hr before 1 hr adhesion of ACA19- or HCT116 cell to the 
treated HMVEC-Ls monolayers was assessed. The data are expressed as mean ± SD of triplicate 
determinations of three independent experiments. *p<0.05, **p<0.01 (one-way ANOVA 
followed by Bonferroni). 
 
It was found that 24 hr pre-treatment of HMVEC-Ls with galectin-2, -4 or -8 
resulted in significant increase (35.4±16.1%, 28.9±9.6%, 35.4±11.1%, for galectin-2, -
4 and -8 respectively) of ACA19- cell adhesion (Fig. 6.5 A). Similarly, 24 hr treatment 
of galectin-2, -4 or -8 resulted in significant increase (38.2±19.6%, 43.7±19.2%, 
55.5±14.6%, for galectin-2, -4 and -8 respectively) of HCT116 cell adhesion to 
HMVEC-Ls (Fig. 6.5 B). 
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To test whether these galectin effects were associated with the galectin-
mediated secretion of cytokines, cell adhesion experiments were further conducted 
with the conditioned medium obtained from HMVEC-Ls treated for 24 hr with 
galectin-2, -4 or -8. After 24 hr incubation of confluent HMVEC-Ls monolayers with 
galectin-2, -4 or -8 (1.5μg/ml), the conditioned medium was collected and used to 
culture fresh HMVEC-Ls monolayers in each well in 9six-well plate for 1 hr before  
fresh ACA19- suspension(100μl/well, 2 x 105/ml) was added in for assessment of  cell 
adhere for 1 hr. 
 
Fig. 6.6: Galectin-2, -4 or -8 induces secretion of soluble molecules from endothelial cells 
that cause cancer cell-endothelial adhesion. The 24 hr treated conditioned medium (CM) from 
HMVEC-Ls cells treated with or without 1.5μg/ml galectin-2, -4 or -8 were used as conditioned 
medium to assess adhesion of fresh ACA19- (A) or HCT116 (B) to fresh HMVEC-Ls monolayer. The 
data are expressed as mean ± SD of triplicate determinations of three independent experiments. 
*p<0.05, **p<0.01, ***p<0.001 (One-way ANOVA followed by Bonferroni). 
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It was found that the conditioned medium obtained from HMVEC-Ls treated 
with galectin-2, -4 or -8 (1.5µg/ml) for 24 hr induced a similar increase of  
subsequent ACA19- adhesion to fresh HMVEC-Ls monolayers(36.4±19.8%, 36.1±12.2, 
42.9±25.0%, for galectin-2, -4 and -8 respectively) (Fig. 6.6 A and Table 6.11). The 
conditioned medium obtained from HMVEC-Ls treated with galectin-2, -4 or -8 
(1.5µg/ml) for 24 hr also showed to induce an increase of subsequent adhesion 
(53.6±20.2%, 61.9±17.6%, 50.2±9.1%, for galectin-2, -4 and -8 respectively) of 
HCT116 cells (Fig. 6.6 B).  
This result indicates that galectin-2, -4 or -8 induces endothelial secretion of 
soluble factors, that increase cancer cell-endothelial adhesion 
 
6.4.4 Investigation of effect of lactose on galectin-mediated cancer cell 
adhesion to HMVEC-Ls  
To determine whether the galectin-2, -4 or -8 induced increase of cancer cell 
adhesion was mediated through the galectin carbohydrate binding sites, the galectin 
binding inhibitor lactose was included in the adhere assay. 
In these experiments, galectin-2,-4 or -8, ( 1.5µg/ml) were first mixed 
with/without 10µM of lactose for 5mins at 37℃ before introduced to confluent 
HMVEC-Ls cell monolayers for 24 hr at 37℃. BSA was used as negative control. After 
24 hr incubation, the medium were discarded and fresh ACA19- suspension at 
concentration of 1 x 105/ml was added for 1 hr for assessment of cell adhesion. 
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Fig. 6.7: The presence of lactose abolished galectin-2, -4 or -8 induced increases of ACA19- 
cell adhesion to HMVEC-Ls. The HMVEC-Ls monolayers in each well in 96-well plates were 
treated with 1.5µg/ml galectin-2, -4 or -8 mixed with 10µM Lactose for 24 hr before 1 hr 
adhesion of ACA19- cell to the treated HMVEC-Ls monolayers were assessed. The data are 
expressed as mean ± SD of triplicate determinations of three independent experiments. *p<0.05, 
**p<0.01 (One-way ANOVA followed by Bonferroni). 
 
It was shown that, the pre-incubation of galectin-2, -4 or -8 with lactose 
abolished or nearly abolished (100.0±9.34%, 96.1±10.4%, 96.3±17.5%) the adhesion 
induced by each of the galectins (Fig. 6.7).  
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Fig. 6.8: The conditioned medium obtained from HMVEC-Ls treated with galectin-2, -4 or -
8 for 24 hr induced increases of ACA19- cell adhesion to HMVEC-Ls abolished by the presence 
of lactose. The HMVEC-Ls monolayers were treated with 1.5µg/ml galectin-2, -4 or -8 mixed 
with/without 10µM Lactose for 24 hr before the conditioned medium was collected. The 
conditioned medium was then used to culture fresh HMVEC-Ls monolayers before 1 hr adhesion 
of ACA19- cell suspension to these HMVEC-Ls monolayers. The ACA19- cells adhere to HMVEC-Ls 
was assessed. The data are expressed as mean ± SD of triplicate determinations of three 
independent experiments. *p<0.05, **p<0.01 (One-way ANOVA followed by Bonferroni). 
 
Furthermore, 1 hr treatment of fresh HMVEC-Ls with the conditioned medium 
obtained from HMVEC-Ls treated with galectin-2 for 24 hr induced-increase of 
ACA19- adhesion to HMVEC-Ls (30.1±14.4%) was abolished while the increase 
0
20
40
60
80
100
120
140
160
180
AC
A1
9-
ad
he
si
on
 to
 H
M
VE
Cs
 
(%
 o
f c
on
tr
ol
)
** 
** ** 
** * 
190 
 
induced by galectin-4 or-8 (43.2±18.0%, 51.3±7.4%) were inhibited(95.2±29.5%, 
63.8±15.3%) by the presence of lactose (Fig. 6.8). 
These results indicate that the presence of lactose can effectively inhibits  
galectin-2, -4 or -8 induced cancer cell-endothelial adhesions, thus  galectin-2, -4 or -
8-induced cell adhesion are likely through their carbohydrate binding sites. 
 
6.4.5 Investigation of effect of galectin-induced cytokine secretion on 
galectin-mediated cancer cell-endothelial adhesion 
To determine whether the increased secretion of cytokines by HMVEC-Ls in 
response to galectin-2, -4 or -8 are responsible for the galectin-2, -4 or -8 mediated 
cancer cell-endothelial adhesion, a combination of anti-cytokine antibodies 
(antibodies against G-CSF, GROα and IL-6 for galectin-2; antibodies against G-CSF, 
GROα, IL-6 and MCP-1 for galectin-4 and galectin-8) was included in the adhesion 
assessment. Confluent HMVEC-Ls cell monolayers in 96 well plates were treated with 
galectin-2, -4 or -8 (1.5µg/ml) for 24 hrs, and BSA was used as negative control. After 
24 hr incubation, the medium in wells were collected. Anti-cytokine antibodies 
mixture (G-CSF (5ng/ml), IL-6(3ng/ml), GROα (20ng/ml) were added to the  
Conditioned medium obtained from galectin2-treated HMVEC, G-CSF (5ng/ml), IL-
6(3ng/ml), GROα (20ng/ml) and MCP-1(20ng/ml) to galectin-4 or galectin-8 treated 
conditioned medium before the conditioned medium were used to test ACA19- 1 x 
105/ml cell adhesion to fresh HMVEC-Ls. 
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 Fig. 6.9: The presence of anti-cytokine antibodies mixture abolished galectin-2, -4 or -8 
treated conditioned medium induced increases of ACA19- cell adhesion to HMVEC-Ls. The 
conditioned medium from HMVEC-Ls treated with 1.5µg/ml galectin-2, -4 or -8 mixed with anti-
cytokine antibodies mixture for 1 hr before 1 hr adhesion of ACA19- cell to the treated HMVEC-Ls 
monolayers were assessed. The data are expressed as mean ± SD of triplicate determinations of 
three independent experiments. *p<0.05, **p<0.01 (One-way ANOVA followed by Bonferroni). 
 
It was found that, the conditioned medium from galectin-2, -4 or -8 treated 
HMVECs increased ACA19- adhesion to fresh HMVEC-Ls (57.6±22.7%, 46.00±18.00%, 
35.1±15.9%, respectively). The introduction of antibodies against these cytokines 
cause inhibition of galectin-2, -4 or -8 induced ACA19- adhesion to HMVEC-Ls 
(96.2±23.6%, 82.8±28.5%, 59.1±41.0%, respectively) (Fig. 6.9). 
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 Fig. 6.10: The presence of conditioned medium form HMVEC-Ls cultured with a 
combination of recombinant cytokines increases ACA19- adhesion to HMVEC-Ls. The 
combinations of cytokines (Combination 1: G-CSF (0.25ng/ml), IL-6 (0.15ng/ml) and GROα 
(1ng/ml); Combination 2: (G-CSF (0.25ng/ml), IL-6 (0.15ng/ml), GROα (1ng/ml) and MCP-1 
(1ng/ml)) were added to the HMVEC-Ls monolayer culture for 24 hr. The conditioned medium 
was applied to HMVEC-Ls during 1 hr adhesion of ACA19- cells to the HMVEC-Ls monolayers. The 
data are expressed as mean ± SD of triplicate determinations of three independent experiments. 
*p<0.05 (one-way ANOVA followed by Bonferroni). 
 
Furthermore, incubation of a combination of three [(G-CSF (0.25ng/ml), IL-6 
(0.15ng/ml) and GROα (1ng/ml)] or four [(G-CSF (0.25ng/ml), IL-6 (0.15ng/ml), GROα 
(1ng/ml) and MCP-1 (1ng/ml)] cytokines with HMVEC-Ls monolayers for 24 hr means 
the conditioned medium also caused significant increase (22.3±8.1%, 28.4±6.7% 
respectively) in ACA19- cell adhesion to the fresh HMVEC-Ls monolayers (Fig. 6.10).  
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Together these results suggest that the galectin-induced secretion of cytokines 
is responsible for the observed increase of galectin-2,-4 or 8-mediated cancer cell 
adhesion. 
 
6.4.6 Investigation of effect of galectin-2, -4 or -8 treatment on 
expression of cell surface adhesion molecules on HMVEC-Ls 
To gain an insight into the mechanism of the galectin-2, -4 or -8-induced 
cytokine-mediated cell adhesion, the expressions of several common cell surface 
adhesion molecules on HMVEC-Ls were analyzed after treatment of the cells with 
each galectin. HMVEC-Ls cells were treated with galectin-2, -4 or -8 (1.5µg/ml) for 24 
hr before the expressions of endothelial cell surface adhesion molecules 
(integrinα5β1, CD44, E-selectin, VCAM) were analyzed  by flow cytometry. 
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Fig. 6.11: Galectin-2 induces expression of cell surface integrinα5β1 and VCAM but not 
CD44 or E-selectin. The HMVEC-Ls monolayer was treated without (red) or with 1.5µg/ml 
galectin-2 (purple) for 24 hr before the expressions of HMVEC-Ls cell surface adhesion molecules 
were analyzed by flow cytometry (n=3). The IgG control is shown in blue. The graph shown is 
representitive for three independent experiments. 
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It was found that 24 hr treatment of HMVECs with galectin-2 induces increase 
of cell surface integrinα5β1 (34.8%) a slight increase of VCAM (9.8%) but not CD44 or 
E-Selectin (Fig. 6.11).  
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Fig. 6.12: Galectin-4 induces expression of cell surface integrinα5β1 and CD44 but not 
VCAM or E-selectin. The HMVEC-Ls monolayer was treated without (red) or with 1.5µg/ml 
galectin-4 (brown) for 24 hr before the expressions of HMVEC-Ls cell surface adhesion molecules 
were analyzed by flow cytometry (n=3). The IgG control is shown in blue. The graph shown is 
representitive for three independent experiments. 
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Fig. 6.13: Galectin-8 induces expression of cell surface integrinα5β1 and CD44 but not 
VCAM or E-selectin. The HMVEC-Ls monolayer was treated without (red) or with 1.5µg/ml 
galectin-8 (green) for 24 hr before the expressions of HMVEC-Ls cell surface adhesion molecules 
were analyzed by flow cytometry (n=3). The IgG control is shown in blue. The graph shown is 
representitive for three independent experiments. 
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It was found that 24 hr treatment of HMVECs with galectin-4 induced increase 
of integrinα5β1 (41.0%) and CD44 (8.9%) but not E-Selectin or VCAM and galectin-8-
treatement increased the expression of integrinα5β1 (32.4%) and CD44 (5.8%) but 
not E-Selectin or VCAM on the cell surface of HMVEC-Ls (Fig. 6.12, 6.13). 
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Fig. 6.14: A combination of cytokines (G-CSF, IL-6, GROα and MCP-1) induces expression of 
cell surface integrinα5β1, CD44, VCAM but not E-selectin. The HMVEC-Ls monolayer was treated 
without (red) or with 1.5µg/ml galectin-8 (black) for 24 hr before the expressions of HMVEC-Ls 
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cell surface adhesion molecules were analyzed by flow cytometry (n=3). The IgG control is shown 
in blue. The graph shown is representitive for three independent experiments. 
 
Treatment of HMVEC-Ls cells with a combination of recombinant cytokines (G-
CSF (0.25ng/ml), IL-6 (0.15ng/ml), GROα (1ng/ml), MCP-1 (1ng/ml)) induced increase 
of integrinα5β1 (42.8%), CD44 (11.6%), VCAM (8.7%) but not E-selectin on the cell 
surface of HMVEC-Ls (Fig. 6.14). 
 
To identify the role of cell surface adhesion molecules in galectin-mediated 
cancer cell-endothelial adhesion, antibodies against the cell surface adhesion 
molecules (CAM) were included in the assessment. In this experiment confluent 
HMVEC-Ls cell monolayers were treated with galectin-2, -4 or -8 (1.5µg/ml) for 24 
hrs, and BSA was used as negative control. After 24 hr incubation, the conditioned 
medium was collected. Anti-CAM antibody mixture [(integrinα5β1 (10µg/ml) and 
VCAM (10µg/ml) for galectin-2, integrinα5β1 (10µg/ml) and CD44 (10µg/ml) for 
galectin-4 and -8)] was added to the conditioned medium before assessment of 
subsequent ACA19- cell adhesion to fresh HMVEC-Ls.  
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 Fig. 6.15: The presence of antibodies against the cell surface adhesion molecules (CEM) 
inhibits galectin-2 (A), -4 (B) or -8 (C) mediated cancer cell adhesion. The conditioned medium 
from HMVEC-Ls treated with 1.5µg/ml galectin-2, -4 or -8 were mixed with anti-CAM antibody 
mixture for 1 hr before use as culture medium for assessment of ACA19- cell adhesion to the 
treated HMVEC-Ls monolayers. The data are expressed as mean ± SD of triplicate determinations 
of three independent experiments. *p<0.05, **p<0.01, ***p<0.001 (one-way ANOVA followed 
by Bonferroni). 
 
It was found that the conditioned medium from galectin-2-treated HMVECs 
increased ACA19- adhesion to HMVEC-Ls (58.0 ± 12.0%) and this effect was inhibited 
(44.6 ± 14.8%) by the presence of the anti-CAM antibodies.   Similarly, the 
conditioned medium from galectin-4-treated HMVECs increased ACA19- adhesion to 
HMVEC-Ls (97.9% ± 16.5%), an effect that was inhibited (59.3 ± 15.8%) by the 
presence of anti-CAM antibodies whereas the conditioned medium from galectin-8-
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treated HMVECs increased ACA19- adhesion to HMVEC-Ls (142.4 ± 19.1%) and was 
inhibited (79.4 ± 4.1%) by the presence of anti-CAM antibodies (Fig. 6.15). 
 
6.4.7 Investigation of galectin-2, -4 or -8-mediated cytokine secretion 
on endothelial tube formation in angiogenesis 
Since our earlier study has shown that galectin-3-induced cytokine secretion 
promotes endothelial cell tube formation we assessed whether the secretion of 
cytokines induced by galectin-2, -4 or -8 could also influence the ability of 
endothelial cells to form microtubules in angiogenesis.  
To test this possibility, the conditioned medium from 24 hr galectin-2, -4 or -8 
(1.5µg/ml)-treated HMVEC-Ls was collected and used as culture medium to culture 
HUVECs on matrix. It was found that HUVEC formed significantly more tubule 
structures when cultured in the conditioned medium from galectin-2 -4 or -8-treated 
HMVECs than the HUVEC cells cultured in the conditioned medium from BSA-treated 
HMVEC-Ls.   
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Fig. 6.16: Galectin-2, -4 or -8-induced cytokine secretion promotes endothelial tubule 
formation. HUVEC cells were cultured on top of matrix proteins in the conditioned medium (CM) 
obtained from HMVEC-Ls treated with BSA or galectin-2, -4 or -8(1.5µg/ml) for 24 hr, with or 
without introduction to the conditioned medium of a combination of neutralizing antibodies 
against G-CSF (5µg/ml), IL-6 (3µg/ml), GROα (20µg/ml) and MCP-1(20µg/ml) for 24 hr at 37℃. 
Representative images are shown in (A). The tubule length (B) and branch points (C) were 
quantified. *p<0.05, **p<0.01 (one-way ANOVA followed by Bonferroni). 
 
Both the tubule length (34.5±9.0%, 38.3±8.3%, 76.4±10.1% respectively) and 
branch points (75.0±15.9%, 68.2±9.1%, 95.5±9.1% respectively) were observed to be 
increased by galectin-2, -4 and -8. The addition of four anti-cytokine antibodies (G-
CSF (5µg/ml), IL-6 (3µg/ml), GROα (20µg/ml) and MCP-1 (20µg/ml)) to the  
conditioned medium before it was applied to the 24 hr HUVEC culture caused 
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inhibition of tubule length (77.7±22.2%, 100.0±21.3%, 97.5±20.7% respectively) and 
branch points (100.0±10.0%, 100.0±18.3%, 100.0±9.1% respectively) induced by the 
conditioned medium from galectin-2, -4 and -8-treated HMVECs (Fig. 6.16). 
 
6.4.8 Investigation of effect of injection galectin-2, -4 and/or -8-
induced cytokine secretion in mice 
Since our earlier study has shown that the injection of galectin-3 induced 
cytokine secretion in mice, we assessed whether the secretion of cytokines can also 
be induced by galectin-2, -4 or -8. 
First 5µg/mouse galectin-2, -4 or -8, equating approximately to circulating 
galectin concentrations seen in cancer patients with metastasis (321), was injected 
intravenously into the animals' tail vein. 
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 Fig. 6.17: In vivo experiments showing that galectins induce cytokine secretion. The graphs 
show the in vivo cytokine secretion induction effect of tail vein injection of 5µg galectin-2, -4, -8, 
individually or in combination (5µg each) on serum levels of the cytokines/chemokines at 0, 24 
and 48 hr in mice, three mice in each group. *p<0.05, **p<0.01 (one-way ANOVA followed by 
Bonferroni).  
 
A 490.7±68.6% and 683.7±83.7% increase of serum G-CSF was seen at 24 and 
48 hr for galectin-4 (Fig. 6.17). A 375.9±54.9% increase of MCP-1/CCL2 was also 
observed after 48 hr for galectin-4. Galectin-8 injection caused a 543.3±123.3% 
increase of serum IL-6 after 48 hr. Galectin-2 injection did not show any significant 
effect on serum levels of any of these cytokines/chemokines, however. Serum 
GROα/CXCL1 levels were not affected by injection of any of these galectins. Injection 
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of a combination of 5 µg/mouse of each galectin-2, -4 and -8 increased serum G-CSF 
(448.8±191.9%), IL-6 (691.7±228.3%) and MCP-1 (373.3±130.4%) after 48 hr and the 
increase of each of these cytokines/chemokines was equivalent to that produced by 
the most influential galectin member (galectin-4) when injected individually (Fig. 
6.17).  
These results provide evidence of a direct impact of circulating galectins on 
secretion of these cytokines in vivo. They also indicate that these galectin members 
may use the same endothelial receptors to exert their effects on endothelial 
secretion of these cytokines/chemokines, thus showing lack of an additive effect 
when they are present in combination. 
 
6.4.9 Investigation of the relationship between serum levels of 
galectins and cytokines/chemokines in breast and colon cancer patients  
To see whether the relationship between these galectins and 
cytokines/chemokines observed in vitro and in mice occurred in cancer patients, 
serum levels of circulating galectin-2, -4 and -8 and G-CSF, IL-6, GROα/CXCL2, and 
MCP-1/CCL1 were analyzed in breast and colon cancer patients (Table 6.9).  
 
Table 6.9: Simple and multiple regression analysis of serum galectin-2, -4 and -8 
and GCS-F, IL-6, GROα and MCP-1 levels in human breast and colon cancer patients 
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Serum concentrations of G-CSF, IL-6, GROα/CXCL-1 and MCP-1/CCL-2 in 50 colorectal cancer 
patients with and without clinically detectable liver metastasis as well as 40 breast cancer 
patients were determined by galectin-2, -4 or -8 ELISA. The relationship between serum galectin-
2, -4, -8 and each of those cytokines was analyzed by simple regression analysis and multiple 
regressions. 
 
Simple regression analysis showed significant correlation of G-CSF and IL-6 
levels, but not GROα and MCP-1, with each of the galectins in both breast and colon 
cancer patients (Table 6.9). Multiple regression analysis demonstrated significant 
correlation of G-CSF (p<0.001) and IL-6 level (p<0.001) with galectin-2 in breast and 
colon cancer. G-CSF and IL-6 levels were significantly (p=0.048) or nearly significantly 
(p=0.056) correlated with galectin-4 in colon cancer but not in breast cancer. Both G-
CSF and IL-6 showed close to significant correlation with galectin-8 in breast (p=0.06 
and 0.079) and colon cancer (p=0.051 and 0.069). These observations provide 
further support for the role of these galectins in secretion of these cytokines in the 
presence of cancer. It should be mentioned that as circulating galectin levels are 
correlated with each other in the presence of cancer, the multiple regression 
analysis is likely to identify only the significance of the strongest association but 
mask other weaker associations between the galectins and cytokines/chemokines. 
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6.5 Discussion 
The results in this chapter show that galectin-2, -4 and -8, at pathological 
concentrations found in the bloodstream of cancer patients, induce secretion of G-
CSF, IL-6, GROα/CXCL1 and MCP-1/CCL2 from the vascular endothelium in vitro and 
in mice. Such a relationship between circulating galectin-2, -4, -8 and G-CSF, IL-6 and 
MCP-1/CCL2 was also observed in the sera of breast and colon cancer patients. The 
galectin-induced secretion of these cytokines/chemokines was shown to enhance 
the expression of endothelial cell surface adhesion molecules, which causes 
increased cancer cell-endothelial adhesion, and also increases endothelial tubule 
formation, a component of angiogenesis. Thus, the increased circulation of galectin-
2, -4 and -8 found in cancer likely makes a very important contribution to the 
elevated circulating concentrations of these cytokines/chemokines that are 
frequently observed in cancer patients. 
GROα/CXCL1 and MCP-1/CCL2 are chemoattractant cytokines and, like many 
other chemokines, promote cancer progression and metastasis (424-426) through 
several mechanisms such as increased angiogenesis, activation of tumor-specific 
immune responses to weaken the host anti-tumor immunity, stimulation of tumor 
cell proliferation and metastasis(124, 424).  
Interaction of GROα/CXCL1 with its receptor CXCR2 promotes cancer cell 
invasion and migration by activation of cellular AKT/NF-kB signaling (427). 
Administration of anti-GROα/CXCL1 antibodies inhibits tumor formation and 
angiogenesis in vitro and in mice (428). Suppression of GROα/CXCL1 expression in 
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human colon cancer LS174T cells by shRNA before cell inoculation into the spleens of 
nude mice almost completely prevents liver metastasis in comparison with those 
inoculated with parental LS174T cells(429). Higher serum concentrations of 
GRO/CXCL1 are seen in cancer and, like IL-6, it promotes colonization of circulating 
tumor cells to their origin (self-seeding) thus accelerating the growth and 
angiogenesis of human breast, colon and melanoma tumors(398). Recently, 
GROα/CXCL1 has been reported to be at the center of chemo-resistance triggered by 
chemotherapeutic agents of breast cancer by helping the tumor cells to recruit pro-
survival factor S100A8/9 (425).  
MCP-1/CCL2, through interaction with its receptor CCR2 in cancer cells, 
increases cancer cell invasion and migration by activation of protein kinase C and 
protein tyrosine phosphorylation (430, 431). Inhibition of MCP-1/CCL2 biosynthesis 
by MCP-1/CCL2 inhibitor bindarit inhibits cancer cell proliferation and migration in 
vitro and significantly impairs metastasis of prostate cancer in mouse xenografts 
(432). More lung metastases were formed in MCP-1(-/-) mice than in wild-type mice 
when 4T1 breast cancer cells were transplanted into the mammary pads (433). MCP-
1/CCL2 concentrations are frequently elevated in cancer patients(434) and, like IL-6, 
it is involved in driving the “stemness” of tumor-initiating cells(434).   
Thus, IL-6, G-CSF, GROα/CXCL1 and MCP-1/CCL2 are all critical regulators of 
cancer progression and metastasis via divergent mechanisms that act locally or 
remotely. The galectin-mediated increase of these cytokines/chemokines in various 
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cancers therefore is likely to make an important contribution to cancer progression 
and metastasis.    
It is noted that although galectins-2, -4 and -8 have each been shown to induce 
secretion of IL-6, G-CSF, GROα/CXCL1 and MCP-1/CCL2 by vascular endothelial cells 
in vitro, direct correlation of serum galectin concentrations in cancer patients was 
observed predominantly with G-CSF and IL-6 and there was less or no correlation 
with MCP-1/CCL2 and GROα/CXCL1. It is possible that the galectin-mediated 
secretion of GROα/CXCL1 and MCP-1/CCL2 may be a secondary effect consequent 
on galectin stimulation of IL-6 and G-CSF secretion. Both GROα/CXCL1 and MCP-
1/CCL2 have been shown previously to be inducible by pro-inflammatory cytokines. 
For example, IL-1 or TNFα can induce the secretion of GROα/CXCL1 in cancer as well 
as cancer stromal cells (435, 436) and IL-6 can induce the secretion of MCP-1/CCL2 in 
tumor cells (437).  The observation that these galectins had no significant effect on 
GROα/CXCL1 levels when injected directly into the animal tail vein is in keeping with 
this possibility. Further investigation to determine the identity and nature of the 
galectin-binding ligands on endothelial cells that are responsible for the galectin-
mediated secretion of these cytokines should help us to understand the actions of 
these galectins. 
Thus, the increased circulation of galectin-2, -4 and -8 seen in cancer enhances 
endothelial secretion of G-CSF, IL-6, GROα/CXCL1 and MCP-1/CCL2 in the blood 
circulation. As these cytokines/chemokines are important promoters in cancer 
progression and metastasis via divergent mechanisms locally and remotely, the 
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galectin-mediated increase of these cytokines/chemokines in cancer patients 
probably has a profound influence on cancer progression and metastasis and 
represents a good target for cancer therapy.  
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CHAPTER 7 Summary of the main findings 
• Incubation of recombinant galectin-3, at concentrations found in sera from 
cancer patients, with HMVEC-Ls enhances subsequent adhesion of MUC1-negative 
cancer cells to HMVEC-Ls. 
• The supernatant from galectin-3-treated HMVEC-Ls, when incubated with 
cancer cells, promotes their adhesion to endothelial cells. 
• Galectin-3 shows binding to several ligands expressed by HMVECs. 
• Galectin-3 at pathological concentrations induces dose- and time- dependent 
secretion of four cytokines (G-CSF, GM-CSF, IL-6 and sICAM-1) from blood vascular 
endothelial cells in vitro. 
• The galectin-3-induced secretion of cytokines enhances the endothelial 
expression of cell surface adhesion molecules including integrin α5β1, E-Selectin, 
ICAM-1 and VCAM on the cell surface of HMVEC-Ls. 
• The galectin-3-induced secretion of cytokines promotes endothelial cell 
migration and tubule formation in angiogenesis. 
• Intravenous introduction of a pathological circulating galectin-3 
concentration into nude mice resulted in significant increase of G-CSF, GM-CSF, IL-6 
and sICAM-1 concentrations in the blood circulation within 48 hr. 
• Direct injection into nude athymic mice of a combination of these four 
cytokines at galectin-3-induced levels increased lung metastasis of MUC1-negative 
human melanoma ACA19- cells. 
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• Galectin-3 concentrations are significant correlated with G-CSF, IL-6 and 
sICAM-1 levels, but not with GM-CSF level, in colon cancer patients with metastasis. 
• Galectin-3 also shows binding to cancer cells and induces tyrosine 
phosphorylation. 
• The presence of galectin-2, -4 or -8 as well as the supernatant from galectin-
2, -4 or -8 treated HMVEC-Ls induces cancer cell adhesion to endothelial cells. 
• The presence of galectin-2, -4 or -8 also stimulates secretion of G-CSF, IL-6, 
GROα and MCP-1 from HMVEC-Ls.  
• Galectin-4 and -8 induce secretion of G-CSF, IL-6, GROα and MCP-1 in dose- 
and time-dependent manners, and galectin-2 induces secretion of G-CSF, IL-6 and 
GROα in dose- and time-dependent manners. 
• The secretion of these cytokines in response to these galectins enhances the 
expression of endothelial expression of cell surface adhesion molecules integrin 
α5β1, CD44 or VCAM, causing cancer cell adhesion to vascular endothelium. 
• The galectin-induced secretion of these cytokines also enhances endothelial 
tubule formation in angiogenesis. 
• The secretion of cytokines induced by galectins can be inhibited by the 
presence of lactose.  
• Intravenous injection of a pathological circulating concentration of galectin-2, 
-4, -8 separately or a combination of galectin-2, -4 and -8 together into nude mice 
resulted in increase of G-CSF, GM-CSF, IL-6 and sICAM-1 concentrations in the blood 
circulation within 24 or 48hr. 
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• Regression analysis showed significant correlation of G-CSF and IL-6 levels 
with each of galectins-2, -4 and -8 in the sera of breast and colon cancer patients. 
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CHAPTER 8 General discussion and implications for future 
studies 
8.1 Discussion 
The results presented in this thesis show that galectin-3, as well as galectins-2, -
4 and -8 induce secretion of various cytokines from blood vascular endothelial cells in 
vitro. The secretion of these cytokines enhances the endothelial expression of cell 
surface adhesion molecules, promoting increased adhesion of cancer cells to the 
blood vascular endothelium. The galectin-induced secretion of these cytokines also 
promotes endothelial cell migration and tubule formation in angiogenesis. These in 
vitro findings were strongly supported by the demonstration of increased 
concentrations of these cytokines in the sera of nude mice in response to 
intravenous injection of recombinant galectins and were further supported by 
demonstration of correlation between the levels of these circulating galectins and 
cytokines in the sera of human colon cancer and breast patients. A general model of 
the action of the galectin-endothelial interaction and subsequent cytokine secretion 
in metastasis promotion is shown in Fig 8.1. 
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Fig 8.1: The postulated role of interaction between circulating galectins and vascular 
endothelium and subsequent secretion of cytokines in metastasis promotion  
A: Galectin-endothelial interaction induces endothelial secretion of cytokines. B: the 
galectin-induced secretion of cytokines promotes angiogenesis and metastasis. Galectin-induced 
cytokines released from the endothelium induce increased expression of cell surface adhesion 
molecules by the endothelium and promote metastasis by increasing heterotypic adhesion and 
angiogenesis.  
A 
B 
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It is known that cytoplasmic galectin-3 functions as an apoptosis inhibitor by 
suppressing mitochondrial depolarization and preventing the release of cytochrome 
C (221), while nuclear galectin-3 acts as an mRNA splicing promoter (280), and in 
contrast to cytoplasmic galectin-3, has pro-apoptotic activity (240). Cell surface-
associated galectin-3 is involved in many cell-cell and cell-matrix interactions (306, 
438) and promotes cancer development and metastasis (439). Cancer cell-associated 
galectin-3 has been shown to contribute to tumor cell heterotypic adhesion to 
endothelium (315) and cancer cell invasion (262, 263) and the cytokine-mediated 
effects demonstrated in this thesis add to these findings.  
Galectin-3, the only chimeric galectin, is also unique in the galectin family for 
containing tandem repeats of short amino-acid stretches fused onto the CRD (440, 
441). However, all members of the galectin family are defined by their ability to 
recognize β-galactose and by their consensus amino-acid sequences (170). The 
carbohydrate binding sites of galectins can accommodate adjacent saccharides as 
well as galactose and different galectins are specific for different oligosaccharides 
(177, 178). The studies reported here show that galectin-2, -3, -4 and -8 at 
pathological concentrations seen in cancer patients induce secretion of several 
metastasis-promoting cytokines by interaction with the vascular endothelium. These 
cytokines then increase endothelial expression of several cell surface adhesion 
molecules that enhance cancer cell adhesion to the endothelium in metastasis. 
The patterns of cytokine secretion induced by each galectin member have been 
shown not to be the same. For example, galectin-3 induces a significant increase of 
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α5β1, but not α5β3 integrin. Integrin α5β3 is known to be recognized by  a wide range 
of ECM molecules, including fibronectin, fibrinogen, von Willebrand factor, 
vitronectin, and proteolysed forms of collagen and laminin, whereas integrin α5β1 is 
shown to be selectively bound by fibronectin (442). The different patterns of the 
changes of the cell surface adhesion molecules in response to different galectins may 
aid future identification of the exact molecular mechanism of the galectin-induced 
secretion of cytokines. 
Serum levels of cytokines are higher in various types of cancers than in healthy 
people and people with benign tumors (443-452). Cytokines released in response to 
infection, inflammation and immunity, can inhibit tumor development and 
progression. On other hand,  host-derived cytokines can promote cancer growth, 
attenuate apoptosis and facilitate tumor cell invasion and metastasis (96). Cytokines 
can have either pro- or anti- inflammatory activity and immunosuppressive activity, 
depending on the microenvironment. Immune cells are the major source of cytokines 
but many human cells are capable of producing them during cancerous conditions 
(453, 454). Efforts to understand cytokine function during tumor development and 
progression are complicated by the pleiotropy of the cytokine action and also by the 
ways in which the microenvironment influences the effects of individual cytokines 
(455). In some instances cytokine release has correlated with tumor suppressing 
effect. For example the historical administration of “Coley’s toxins”, bacterial extracts 
administered as cancer immunotherapy, was shown to result in marked increase in 
cytokine levels and tumor clearance in some of the treated patients (456, 457). 
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Subsequent studies about systemic infusion of individual cytokines were conducted 
to retain the therapeutic potential of Coley’s toxins as well as ameliorate the 
undesirable side effects (458-460) but with, at best, only modest therapeutic 
benefits. 
 
8.2 Future studies 
The endothelial cell surface ligands for each galectin that are responsible for 
subsequent stimulation of cytokine secretion remain unknown.  Although IL-6 is 
shown to be induced by each of these galectins, a different range of cytokines is 
induced by each galectin. This indicates that although these galectin members may 
share similar endothelial cell surface ligands in their induction of cytokines, each of 
them likely also has its own specific ligands. 
Furthermore, although the galectin-induced cytokine secretion is inhibitable by 
lactose and TF-expressing glycans, it remains to be tested whether the galectin-
endothelial interaction in galectin-induced cytokine secretion is mediated through 
protein-carbohydrate or protein-protein interactions.  And if galectin-induced 
cytokine secretion is indeed mediated by protein-carbohydrate interaction, what is 
the nature of the glycan ligands.  Future investigations in these areas will help greatly 
to clarify the molecular mechanisms of galectin-mediated cytokine secretion.    
 The studies reported here provide further evidence for the significance of the 
increased circulation of galectins in metastasis promotion. They also indicate that 
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targeting the action of these circulating galectins may represent a promising novel 
therapeutic strategy to reduce metastasis and improve cancer survival.  The design 
and development of galectin inhibitors may have great therapeutic potential.  
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